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“Imagination is more important than knowledge. For 
knowledge is limited to all we now know and 
understand, while imagination embraces the entire 
world, and all there ever will be to know and 
understand.” 
 

















© 2016 Leonne Elisabeth Philippen 
Cover Design: Nelleke Philippen-Odekerken  
Published by: Datawyse, Universitaire Pers Maastricht  











Non-coding RNAs in eccentric 








ter verkrijging van de graad van doctor 
aan de Universiteit Maastricht 
op gezag van de Rector Magnificus, 
Prof. dr. Rianne M. Letschert 
het besluit van het College van Decanen, 
in het openbaar te verdedigen 




Leonne Elisabeth Philippen 










Financial support by the Dutch Heart Foundation for the publication of this thesis is 
gratefully acknowledged.  
 
The research described in this thesis was supported by a grant of the Dutch Heart 









Dr. Paula A. Da Costa Martins  
Dr. Ellen Dirkx 
 
 
Assessment Committee  
 
Prof. Dr. Marc Vooijs (chairman)  
Prof. Dr. Ir. Erik Biessen  
Prof. Dr. Jan de Boer 
Prof. Dr. Thomas Thum, Hannover 





CHAPTER 1 General introduction 7 
CHAPTER 2 Non-coding RNAs in control of gene regulatory programs in 
cardiac development and disease 19 
CHAPTER 3 Antisense MicroRNA Therapeutics in Cardiovascular Disease: 
Quo Vadis? 39 
CHAPTER 4 miR-148a regulates gp130-coupled signaling dynamics in heart 
failure 59 
CHAPTER 5 A phenotypic, high-content screen to identify EccentriMIRS: 
microRNAs involved in eccentric cardiomyocyte hypertrophy 91 
CHAPTER 6 Long non-coding RNA Bigheart plays a direct role in regulating 
cardiomyocyte hypertrophic remodeling by affecting RNA 
splicing 109 
CHAPTER 7  Summary and General Discussion 145 
CHAPTER 8 Valorization 161 
Acknowledgements 169 
Curriculum Vitae 171 






















Pathological hypertrophy is a principal risk factor for the development of heart 
failure and lethal arrhythmias. This has been indicated by the Framingham Heart 
study that demonstrated that left ventricular hypertrophy is the strongest predictor 
of heart failure and cardiovascular morbidity.1 Left ventricular hypertrophy is 
caused by chronic pressure overload, as observed in long-standing systemic arterial 
hypertension or LV outflow tract obstruction. With time pressure overload causes 
exhaustion of the preload reserve and basal contractility becomes mismatched to 
the level of afterload, provoking a lower extent and speed of shortening of the LV 
chamber. The reduced systolic fractional shortening is associated with an 
inadequate cardiac output. Although the pathophysiology of pressure overload-
induced hypertrophy is well-recognized in heart failure patients, current treatment 
heart failure regimens fail to address the underlying genetic and molecular 
mechanisms of this pathological condition.  
 
Current pharmacological treatment strategies using e.g. β-blockers and ACE-
inhibitors primarily addresses the symptoms of heart failure, while the prognosis of 
affected individuals still remains poor. As such, there is a dire need for new 
diagnostic as well as therapeutic approaches for treatment of this disease. More 
molecular, mechanistic insights will lead to the development of tailored diagnostics 
as well as personalized therapeutics, which would decrease the morbidity and 
increase life quality of heart failure patients. 
 
 
Molecular mechanisms and signaling pathways underlying cardiac 
hypertrophy  
 
Pathological cardiac hypertrophy as a result of pathophysiological stress signals 
(such as neurohormonal activation, hypertension, aortic stenosis, inflammation or 
cardiac injury) may be initially compensatory in terms of decreasing ventricular wall 
stress and maintaining pump function, but can proceed to decompensation and 
heart failure. Pathological remodeling is associated with fibrotic remodeling, 
increased rates of cardiomyocyte death, and ventricular chamber dilatation. The 
defining features of maladaptive hypertrophy include increased cardiomyocyte size, 
enhanced protein synthesis, and a higher organization of the sarcomere. At the 
molecular level, these changes are characterized by the activation of the fetal gene 
program, so called since expression patterns resemble those observed during 
embryonic stage. Still, the molecular mechanisms responsible for long-standing 
hypertrophy eventually proceeding to overt heart failure are poorly understood.  
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Two distinct hypertrophic phenotypes can be distinguished based on the geometry 
of the heart and individual cardiomyocytes: concentric cardiac hypertrophy and 
eccentric cardiac growth. Concentric pathological hypertrophy is characterized by a 
decrease in left ventricular chamber dimension and thickening of the left ventricular 
free wall and septum. At the cellular level, individual cardiomyocytes typically 
increase in size in lateral direction by adding sarcomeres in parallel. Concentric 
pathological hypertrophy is usually due to pressure overload (hypertension, aortic 
stenosis). On the other hand, eccentric pathological hypertrophy (associated with 
myocardial infarction, dilated cardiomyopathy) is characterized by longitudinal 
growth of individual cardiomyocytes with sarcomeres added in series, and can lead 
to ventricular wall dilatation.2 Concentric hypertrophy can progress to eccentric 
hypertrophy and dilation with associated systolic heart failure, as observed in 
animal models with long-term pressure overload stress due to aortic banding. 
However, the underlying mechanisms of this transition remain poorly understood.  
Furthermore, whether left ventricular hypertrophy is adaptive or maladaptive 
remains highly controversial.3 
 
A growing number of signaling mechanisms have been characterized as important 
pathways in the development of pathological cardiac hypertrophy. The circulating 
peptides Angiotensin II, Endothelin-1 (ET-1) and several Cathecholamines are able 
to bind to myocardial G protein Coupled Receptors (GPCRs) and play a fundamental 
role in cardiac hypertrophy. GPCRs are coupled to and activate three principal 
classes of heterotrimeric GTP-binding proteins: Gαs, Gαi, and Gαq/Gα11. All G proteins 
consist of Gα and Gβγ subunits that dissociate upon receptor activation and 
independently modulate the activity of downstream signaling effectors, typically 
Adenyl Cyclase (AC) or Phospholipase-C (PLC). The cardiac β1-adrenergic receptors 
couple primarily to downstream effector Gαs and initially increase myocardial 
contractility and heart rate after epinephrine or nor-epinephrine stimulation, but 
eventually lead to cardiomyocyte hypertrophy, fibrosis and progressive impaired 
cardiac function.4  The cardiac cholinergic receptors are typically coupled to Gαi and 
are activated by acetylcholine. The third class of receptors coupled to Gαq/Gα11, 
include Angiotensin II receptor, Endothelin receptor type A, and alpha-adrenergic 
receptors. Activation of Gαq/Gα11 is also a potent inducer of MAPK signaling in 
cardiac myocytes.5 MAPK pathways are initiated in cardiomyocytes by GPCRs, 
Receptor Tyrosine Kinases (IGF-1 and fibroblast growth factor receptors), PKC, TGF-
β, Cardiotrophin-1 (gp130 receptor), and by stress stimuli such as ischemia or 
cytotoxic agents. Gαq/Gα11 signaling activates PLC. PLC then catalyzes the generation 
of diacylglycerol (DAG), which leads to PKC activation and synthesis of inositol 1,4,5-
triphosphate.6 Ins(1,4,5)P3 accumulation induces intracellular Ca
2+ release to then 
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activate calcineurin–NFAT or calmodulin- dependent protein kinase (CaMK), which 
mediate cardiomyocyte growth. Calcineurin is a calcium-dependent protein 
phosphatase that dephosphorylates transcription factors of the NFAT (nuclear 
factor of activated T cells) family. This leads to their translocation to the nucleus 
where NFAT forms complexes with cofactors such as GATA4 and MEF2 to activate 
hypertrophic target genes including ANF (Atrial Natriuretic Factor), Alpha-actinin, 
Beta-myosin, and TNF-α (Tumor Necrosis Factor-Alpha). The Calcineurin-NFAT 
pathway is one of the most well established pathways involved in pathological 
hypertrophy and heart failure.7  
 
IL-6 family cytokine signaling via the glycoprotein 130 (gp130) co-receptor is 
reported to involve at least four major pathways: the janus kinase/signal transducer 
and activator of transcription (JAK/STAT) pathway8, p42/44 MEK/ERK1/2 pathway9, 
MEK5/ERK510,11, and the phosphatidylinositol 3-OH kinase (PI3K)/Akt pathway12. All 
four pathways are involved in hypertrophic and/or protective signaling in the heart 
in vitro and in vivo. JNK and p38 are mainly activated by stress type stimuli.13 ERK1 
and ERK2 are directly activated by the MAPK kinases MEK1 and MEK2, whereas 
ERK5 is activated by MEK5. JNKs are directly activated by MKK4 and MKK7, and p38 
kinases are activated by MKK3 and MKK6. Cardiac-specific overexpression of MEK1 
in transgenic mice resulted in specific activation of ERK1/2 and concentric 
hypertrophy without signs of cardiomyopathy.14 Constitutively active MEK5 
specifically activated ERK5 and induced an elongated morphology in vitro where 
sarcomeres were assembled in series. Stimulation with the cytokine leukemia 
inhibitory factor (LIF), which activates MEK5, led to a similar response. Cardiac-
specific MEK5 transgenic mice showed eccentric cardiac hypertrophy that 
progressed to dilated cardiomyopathy and sudden death.10 Although different IL-6 
cytokines can exert similar cardioprotective effects, they induce distinct activation 
patterns of gp130 downstream signaling. The IL-6 family member Cardiotrophin-1 
(CT-1) can induce eccentric hypertrophy in cardiomyocytes via MEK/ERK signaling, 
whereas Leukemia Inhibitory Factor (LIF) induces hypertrophy and protection via 
gp130-mediated JAK/STAT activation. It is highly likely that IL-6 family cytokines 
achieve their effects via a combination of these downstream signaling pathways.  
Although a growing number of pathways have been unraveled, we still do not fully 
understand the molecular mechanisms underlying pathological hypertrophy leading 
to heart failure. The past decade it has become increasingly clear that not only 
protein-coding genes play an important role in the development of (pathological) 
cardiac hypertrophy, but that also non-coding RNAs (ncRNAs) are playing an 
interesting role in these phenomena.  
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The non-coding part of the genome 
 
Today, there is a myriad of publications showing that the actual list of RNAs 
encoded in the genome (the transcriptome) is more complex and widespread than 
previously thought.15 Up to 98% of the human genome encodes for RNA transcripts 
and the majority of those do not encode proteins.16 Among these RNAs are 
thousands of ncRNAs, which contain regulatory information. Classification of 
ncRNAs is based on their length, function, biogenesis, polarity (sense or antisense), 
and protein-binding partners.17  
 
Long ncRNAs or lncRNAs (>200 nucleotides) are relatively stable and do not undergo 
major processing before carrying out their normal functions.18 On the other hand, 




LncRNAs can interact with proteins, DNA and RNA. They can be expressed in the 
nucleus or cytoplasmic fraction of the cell. Nuclear lncRNAs can modulate 
chromatin architecture by interacting with chromatin remodeling complexes to 
regulate the expression of genes located on the same chromosome (cis-acting) or 
on a distant chromosome (trans-acting). LncRNAs can be classified into four 
categories based on their mechanism of action: guide, scaffold, decoy, and signal.20 
Guide lncRNAs bind proteins such as chromatin modifiers and direct 
ribonucleoprotein complexes to specific chromatin targets.21 This activity can cause 
changes in gene expression either in cis or in trans by lncRNA binding to target DNA 
as a RNA:DNA heteroduplex, as RNA:DNA:DNA triplex, or RNA recognition of 
complex surface of specific chromatin features, which cannot easily be predicted by 
just the lncRNA sequence itself.22 Scaffold lncRNAs serve as central platforms for 
assembly of complex protein components and bind multiple effector interaction 
partners that could each regulate transcription positively or negatively when acting 
alone and lead to either transcriptional repression or activation20. For example, the 
lncRNA HOTAIR binds the Polycomb Repressive Complex 2 (PRC2), which methylates 
histone H3 on K27 of HOXD locus to promote gene repression.23 This same lncRNA 
was later found to also bind to a second complex containing LSD1/CoREST/REST, 
indicating HOTAIR serves as a scaffold for at least two distinct histone modification 
complexes.24 Decoy lncRNAs can serve as RNA-binding decoys or competing 
endogenous RNAs (ceRNAs) for microRNA target sites.25 Signal lncRNAs are 
transcribed in a spatiotemporal manner to integrate developmental cues, cellular 
context and other diverse stimuli, thereby influencing downstream signaling in a 
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tissue-specific and stage-dependent manner. Several lncRNAs are able to exert 
more than one mechanism of action that all together are critical for their biological 
function. 
 
LncRNAs in cardiovascular disease 
 
A variety of lncRNAs have demonstrated to play a key role in cardiac development 
and disease (described in Chapter 2). The lncRNA Braveheart (Bvht) is a key 
regulator of cardiovascular lineage commitment and cardiac gene regulatory 
networks expression. Silencing of Bvht in mouse neonatal cardiomyocytes altered 
cardiac-specific gene expression and blocked their differentiation into mature 
cardiomyocytes. In cardiac progenitor cells, Bvht promotes expression of mesoderm 
progenitor 1 (Mesp1), a master gene of cardiovascular lineage commitment, by 
sequestering PRC2 (a writer of the repressive histone modification H3K27me3).26 
Another study showed that the lateral mesoderm-specific lncRNA Fendrr is also a 
regulator of heart development in the mouse. Loss of function of Fendrr caused 
embryonic lethality due to defective heart morphology and function. Fendrr, 
regulates its neighboring gene Foxf1 by interacting with the polycomb repressive 
complex 2 (PRC2) and the resulting complex binds to the promoter region of Foxf1 
and Paired-like homeodomain transcription factor 2 (Pitx2), thereby leading to the 
silencing of these two genes.27 The lncRNA MALAT1 was shown to regulate 
endothelial cell function and vessel growth, since silencing of MALAT1 reduces 
vessel growth in vivo and in vitro.28 The lncRNA cardiac hypertrophy related factor 
(CHRF) functions as a sponge for miR-489, which protects against heart failure 
development by targeting MYD88. The overexpression of CHRF resulted in the 
upregulation of Myd88 expression and the activation of NF-κB system, inducing 
hypertrophy with sarcomere organization and increase in cell surface area.29 
Furthermore, a cluster of lncRNAs transcribed from the myosin heavy chain 7 
(Myh7) locus was identified that showed transcriptional changes during cardiac 
development. These myosin heavy-chain-associated RNA transcripts (Myheart, or 
Mhrt) are abundant in the adult heart and specific to cardiac tissue.30 Mhrt binds to 
the helicase domain of Brg1, a domain that is crucial for tethering Brg1 to 
chromatinized DNA targets, thereby preventing the interaction of Brg1 with 
chromatin and impairing its ability to regulate chromatin remodeling and gene 
expression. The Brg1– HDAC–PARP complex is activated by pathological stress and 
cooperatively controls the change in the α/β- MHC ratio in failing hearts. Cardiac 
stress in mice induced by pressure overload lead to a progressive loss of Mhrt 
expression in cardiomyocytes along with the development of pathological 
hypertrophy. Restoring Mhrt expression to the prestress level attenuated 
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pathological hypertrophic responses and restored cardiac function, demonstrating 
the cardioprotective role of Mhrt in vivo. The Mhrt-Brg1 feedback circuit is thus 




Short ncRNAs regulate gene expression by playing crucial roles during mRNA 
transcription, translation, splicing, and export.31 Many different ncRNAs exhibit cell 
type specific expression32 and localize within specific subcellular domains.33,34 The 
fact that ncRNAs are regulated during development,35 and even associated with 
human diseases such as cancer, diabetes, neurodegenerative and cardiovascular 
diseases,36 underlines the biological relevance of these transcripts. The major 
classes of short ncRNAs are small interfering RNAs (siRNAs), Piwi-interacting RNAs 
(piRNAs), small nucleolar RNAs (snoRNAs), and microRNAs. Each class binds to 
proteins of the Argonaute family to regulate their targets,37 except for snoRNAs. The 
siRNAs and microRNAs are generated from dsRNA precursors by RNase III 
ribonuclease Dicer. SiRNAs (~21 nt) are named after their ability to efficiently 
reconstitute silencing complexes. It was shown that antisense RNA induced 
sequence-specific gene silencing by base pairing with complimentary mRNA species 
and preventing protein translation.38 Duplexes of siRNA are perfectly matched, 
unlike microRNA duplexes, which contain mismatches in the middle. In contrast, 
piRNAs (24-30 nt in length) are produced by a Dicer-independent mechanism and 
interact with a subset of Argonaute proteins related to Piwi.39 Another class of small 
ncRNAs are snoRNAs (60-300 nt), which reside in the nucleolus of the cell, were 
synthesis and processing of cytoplasmic ribosomal RNAs (rRNAs) occurs. The main 
function is to guide site-specific rRNA modification.40      
MicroRNAs are endogenous, single-stranded small RNA molecules consisting of 20-
23 nucleotides, generated from endogenous hairpin transcripts. MicroRNAs are 
transcribed as parts of longer molecules (primary microRNAs or pri-microRNAs) by 
RNA polymerase II or III. The pri-microRNA is processed in the nucleus by the RNase 
III endonuclease Drosha and its cofactor, DiGeorge syndrome critical region 8 
(DGCR8), to release an approximately 70 nucleotide long stem-loop intermediate 
known as precursor microRNA (pre-microRNA) (Fig 1).41,42 The pre-microRNA is 
subsequently exported to the cytoplasm by the protein exportin-5 (Exp5, member 
of the nuclear transport receptor family), where it is further cleaved by a second 
RNase III enzyme, Dicer, to produce a double-stranded RNA duplex comprising the 
microRNA and its antisense strand microRNA*.43 The miR maturation is completed 
by loading the microRNA strand of the duplex onto a protein of the Argonaute 
family (Ago), to generate the RNA-induced silencing complex (RISC). The microRNA 
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guide strand, which is complementary to the target, remains in Ago as the mature 
microRNA, whereas the passenger strand (microRNA*) is degraded.44 Subsequently, 
the microRNA directs the RISC complex to its target mRNA and inhibits target gene 
expression by imperfect base pairing with sequences mainly in the 3’ untranslated 
region (3’ UTR) of the mRNA.45 A key element in this recognition process is a perfect 
match in the seed sequence, nucleotides 2-8, at the 5’ end of the microRNA. 
Interaction of microRNA with mRNA usually leads to degradation or translational 
inhibition with subsequent protein expression downregulation.42 Many microRNAs 
are represented as families, defined by the conservation of their seed regions with 
many being highly conserved from nematodes to humans, whereas others are 
primate-specific (see miRBase).  
 
MicroRNAs in cardiovascular disease 
 
A number of reports have described a role for microRNAs in the developing, but also 
the diseased, cardiovascular system. MicroRNAs regulate embryogenesis and cell 
fate determination,46 play a role in cardiovascular structure and function,47 and are 
involved in cardiac development.48 Interestingly, a hallmark in cardiac failure, is the 
re-expression of the fetal gene program, with an upregulation of b-type natriuretic 
peptide (BNP), atrial natriuretic factor (ANF), skeletal α-actin and β-myosin heavy 
chain (βMyHC).49 Furthermore, microRNAs regulate genes that are important for 
ventricular hypertrophy and fibrosis and therefore, play a key role in congestive 
heart failure.50,51 Several microRNAs, including miR-1, miR-29, miR-30, miR-133, and 
miR-150 are often downregulated, while others (miR-21, miR-23a, miR-125, miR-
195, miR-199b, and miR-214) are upregulated in cardiac hypertrophy. This 
microRNA expression pattern dictates the disease state.50,52 Knockdown of miR-133 
alone is sufficient to induce significant cardiac hypertrophy, whereas miR-133 
overexpression inhibits experimentally-induced hypertrophy,53 suggesting an active 
role for this microRNA in inhibition of hypertrophy and making it a possible target 
for modulating this process.  
 Myocardial fibrosis leads to abnormal mechanical stiffness contributing to 
contractile dysfunction and progression to heart failure.54. MiR-21 is enriched in 
cardiac fibroblasts during later stages of heart failure.55 MiR-21 targets SPRY1, 
leading to increased MAPK signaling, and subsequent increased fibroblast 
proliferation and fibrosis.  
 Angiogenesis prevents the myocardium from becoming hypoxic and is essential 
for cardiac repair after a myocardial infarction. This process requires angiogenic 
growth factors, such as vascular endothelial growth factor (VEGF) and fibroblast 
growth factor (FGF).56 The endothelial cell-specific miR-126 regulates the response 
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of endothelial cells to VEGF, and plays an essential role in neoangiogenesis following 
myocardial infarction. This occurs through inhibition of SPRED1 and PIK3R2, which 
are negative regulators of the VEGF pathway.57  
 
 
Aim of thesis 
 
Heart failure is a complex disease, with different underlying molecular mechanisms 
and pathways that are not yet fully understood. NcRNAs are rapidly emerging as 
crucial regulators in all different kinds of disease, including heart failure. Focusing 
on ncRNAs in pathological cardiac hypertrophy, a well-established predictor of heart 
failure, the aim of this thesis is to identify novel molecular processes underlying 
heart failure. In this context, the aim is to identify cardiac molecular mechanisms 
responsible for the transition from pathological cardiac hypertrophy to heart failure.  
 
To this aim, Chapter 2 describes the role of ncRNAs in gene regulatory programs in 
cardiac development and disease. Chapter 3 gives an overview of the current state 
of microRNA antisense therapeutics in cardiovascular diseases. In Chapter 4 we 
describe an intriguing novel mechanism of a microRNA (miR-148a) that represents a 
switch between concentric and eccentric hypertrophic remodeling. In Chapter 5 we 
use high throughput screens of a whole genome microRNA LNA library to identify 
microRNAs involved in eccentric cardiac hypertrophic remodeling. Finally, Chapter 6 
focuses on the differential expression pattern of lncRNAs in heart failure that were 
identified by an array on healthy mouse heart tissue and heart tissue from two 
different mouse models of cardiac disease. All the results and concluding remarks 
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Abstract 
Organogenesis of the vertebrate heart is a highly specialized process involving 
progressive specification and differentiation of distinct embryonic cardiac 
progenitor cell populations driven by specialized gene programming events. 
Likewise, the onset of pathologies in the adult heart, including cardiac hypertrophy, 
involves the reactivation of embryonic gene programs. In both cases, these intricate 
genomic events are temporally and spatially regulated by complex signaling 
networks and gene regulatory networks. Apart from well-established transcriptional 
mechanisms, increasing evidence indicates that gene programming in both the 
developing and the dis- eased myocardium are under epigenetic control by non-
coding RNAs (ncRNAs). MicroRNAs regulate gene expression at the post-
transcriptional level, and numerous studies have now established critical roles for 
this species of tiny RNAs in a broad range of aspects from cardiogenesis towards 
adult heart failure. Recent reports now also implicate the larger family of long non-
coding RNAs (lncRNAs) in these processes as well. Here we discuss the involvement 
of these two ncRNA classes in proper cardiac development and hypertrophic 





























For decades, cardiovascular scientists have been studying the molecular processes 
involved in pathological hypertrophy and observed how these resemble the 
molecular changes during fetal cardiac development.1 During mammalian 
embryogenesis, the heart is the first organ to form, and it starts when a population 
of mesodermal stem cells commits to the cardiogenic fate. These mesodermal 
progenitors form the primary heart field in the anterior mesoderm and migrate 
ventromedially to shape a linear heart tube.2,3 A second population of mesodermal 
cardiac progenitors, known as the secondary heart field, is derived from the 
pharyngeal mesoderm located medial and anterior to the primary heart field. These 
cells migrate from behind the heart tube into the anterior and posterior poles of the 
heart tube as it begins to undergo rightward looping as a result of uneven growth 
and remodeling, leading to the formation of primitive ventricles and atria.2,3 
Maturation of the heart in higher organisms includes septation, leading to the 
formation of ventricles and atria, as well as valve formation and outflow vessel 
development. The cells in the primary heart field contribute to most of the left 
ventricle and part of the right and left atria. The secondary heart field contributes to 
the right ventricle, most of the outflow tract and part of the atria.2,3 Cardiac neural 
crest cells migrating from the dorsal neural tube into the outflow tract participate in 
separation of the outflow tract.4 Cardiogenesis in mammals requires exquisite 
control of gene expression as their distinct patterns define each region of the heart, 
including individual chambers and valves. Uninterrupted cardiac development is 
integral to organismal survival.  
Studies of cardiogenesis in the simple model organism Drosophila melanogaster 
have defined many of the essential regulators of cardiac specification and 
differentiation and revealed that the cardiac gene regulatory network shows a 
remarkable evolutionary conservation over hundreds of millions of years. These 
studies, combined with many studies in vertebrate systems, have shown that the 
gene regulatory events and cellular movements that control cardiogenesis are 
temporally and spatially regulated by complex signaling networks. The formation of 
the vertebrate heart is controlled by intrinsic and extrinsic signals, and crosstalk 
occurs between myogenic transcription factors, their down- stream target genes, 
and upstream signaling pathways that direct cardiac cell fate, myocyte 
differentiation, and cardiac morphogenesis in the primary heart field and secondary 
heart field. Inductive signals such as bone morphogenetic protein (BMP), Notch, 
WNT and sonic hedgehog (SHH) in vertebrates activate a set of genes encoding 
transcriptional activators that are expressed in the primary and secondary heart 
fields. Core groups of transcription factors required for cardiogenesis include NK 
class of homeodomain proteins, GATA zinc-finger transcription factors, the MADS 
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domain transcription factor MEF2, T-box and Forkhead transcription factors, and 
the Hand class of basic helix–loop– helix (bHLH) factors.5  Nkx2-5 plays a crucial role 
during embryonic heart development. Mice with a ventricular-restricted deletion of 
Nkx2-5 display no structural defects but have progressive complete heart block, and 
progressive cardiomyopathy.6 Also, the calcineurin-regulated NFATc1 transcription 
factor is expressed in the murine endocardium and second heart field during 
cardiogenesis and is required for proper valve elongation and semilunar valve 
development.7 
The molecular fingerprints observed during the process of heart failure resemble 
those observed during cardiogenesis, and therefore adult heart failure is often 
described as being accompanied by the reactivation of a “fetal gene program”.8 The 
results of the Encyclopedia of DNA Elements (ENCODE) project have widened our 
understanding of genomics at an unprecedented level and indicate that at least 80% 
of the genome is functional and is transcribed into the well-studied coding RNAs as 
well as a much larger quantity of non-coding, regulatory RNAs.9-11 Roughly speaking, 
non-coding RNAs (ncRNAs) can be classified according to their transcript length into 
either small or long ncRNAs (lncRNAs), with lncRNAs arbitrarily defined as being 
larger than 200 nucleotides in length. The discovery of the epigenetic control of 
gene regulatory processes by non-coding RNAs has added a new layer of complexity 
to our understanding of heart function both during embryonic development and 
disease. Especially, microRNAs and lncRNAs have been shown to play an essential 
role in normal heart development and as regulators of the stress response in the 
adult heart (Fig. 1).  
Here, we will provide an overview of ncRNA-mediated control of gene regulation of 
the cardiac fetal gene program in the developing embryo and how it is reiterated in 
the processes that contribute to hyper- trophic heart disease of the adult 
myocardium (Fig. 2).  
MicroRNAs as regulators of the cardiac regulatory network  
MicroRNAs are a class of evolutionary conserved small (18–24 nucleotide) single-
stranded RNAs, encoded by the genome and affect gene expression by repressing 
mRNA translation and/or stability. In re- cent years, around 1000 microRNAs have 
been identified and function- ally characterized to certain detail. The importance of 
microRNA gene regulation for normal heart development and function was first 
underscored by generating loss of function mutations of Dicer, Drosha, Ago2 and 
DGCR8, four enzymes essential for microRNA biogenesis.12-15 Cardiac specific deletion 
of Dicer, the enzyme required to process microRNAs into their active mature forms, 
resulted in embryonic lethality in mice due to cardiac failure at day E12.5. 
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Fig. 1. Non-coding RNAs having a functional role during embryonic development. Already at early 
developmental stages, lncRNA Braveheart (Bvt) becomes expressed in mouse embryonic stem cells. Bvht 
is required for expression of core gene regulatory networks involved in defining cardiovascular cell fate 
and acts upstream of mesoderm posterior (MesP1), a master gene of cardiovascular lineage 
commitment. After cardiac looping, the miR-1-2/miR-133a-1 cluster becomes expressed, which plays a 
role in ventricular cardiomyocyte expansion. MiR-1 di- rectly targets Hand2, a bHLH transcription factor 
involved in ventricular cardiomyocyte expansion, while miR-133 directly regulates expression of serum 
response factor (SRF) and cyclin D2. The miR-17~92 cluster is involved in myocardial differentiation of 
cardiac progenitors in the secondary heart field, which is required for normal cardiac outflow tract (OFT) 
formation by repressing the expression of cardiac progenitor genes Isl1 and Tbx1. Fendrr is specifically 
expressed in nascent lateral plate mesoderm and is required for proper development of the heart and 
body wall in the mouse. The lncRNA n413445 regulates Relb mRNA levels, a transcription factor that is an 
essential component in the NFκB pathway that is important during fetal cardiac growth. Also, increased 
expression of the lncRNA n411949-regulated mRNA Mccc1 is of importance during embryonic growth. 
After birth, the miR-15 family becomes important during the neonatal period governing cardiomyocyte 
cell cycle withdrawal and binucleation by directly targeting chek1.  
 
Embryos lacking Dicer in the developing heart showed pericardial edema and a 
poorly developed ventricular myocardium, indicating an essential role for microRNA 
function in cardiogenesis.16 DGCR8 inactivation in neural crest cells using a Wnt1-
Cre-mediated deletion of the floxed DGCR8 allele resulted in major cardiovascular 
defects at E18.5, including arteriosus, persistent truncus interrupted aortic arch, 
cervical aortic arch and aberrant origin of the right subclavian artery.17 Likewise, 
Dicer activity is also required for normal functioning of the postnatal heart, as 
targeted Dicer deletion in adult mice resulted in a high incidence of sudden 
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Fig. 2. The role of non-coding RNAs in adult heart disease. During processes leading to adult cardiac 
hypertrophy, the miR-1–133 cluster becomes downregulated. miR-1 directly targets Fibullin-2, while miR-
133 repressing leads to direct derepression of RhoA, a GDP-GTP exchange protein regulating cardiac 
hypertrophy, Cdc42, a signal transduction kinase implicated in hypertrophy, and Nelf-A/WHSC2, a 
nuclear factor involved in cardiogenesis. Also, repression of miR-25 by the calcineurin/NFAT pathway 
leads to derepression of the transcription factor Hand2, leading to pathological cardiac remodeling. In 
response to cardiac stress stimuli, miR-208a expression leads to the upregulation of β-MyHC expression, 
thereby inducing myosin isoform switching, which is at least in part due to direct inhibition of the thyroid 
receptor-associated protein THRAP1, a transcriptional coregulator of the thyroid receptor, leading to in- 
creased thyroid hormone signaling. The lncRNA cardiac hypertrophy related factor (CHRF) regulates 
cardiac hypertrophy by directly binding to miR-489, which on its turn targets myeloid differentiation 
primary response gene 88 (Myd88). Overexpression of CHRF results in the upregulation of Myd88 
expression and the activation of NF-κB signaling, leading to hypertrophy. Furthermore, variants in 
myocardial infarction associated transcript (MIAT, also known as Gomafu/RNCR2) and Novlinc6 were 
identified by GWAS as a risk factor for myocardial infarction and cardiac disease. Novlnc6 regulates 
expression of BMP10, a key signaling ligand for cardiogenesis, which maintains Nkx2.5 expression.  
 
death, pronounced cardiac hypertrophy, ventricular fibrosis and reactivation of the 
fetal cardiac gene program.18 Combined, these studies demonstrate that 
modification of microRNA biogenesis at specific developmental windows impacts 
embryonic and adult myocardial morphology and function (Table 1).  
Bicistronic miR-1/miR-133 families  
Among the most abundantly expressed microRNAs in the heart is miR-1. In 
vertebrates, members of the miR-1 (miR-1-1, miR1-2, miR- 206) and miR-133 (miR-
133a-1, miR-133a-2, miR-133b) families are co-transcribed from the same 
bicistronic transcripts. MiR-1-1/miR- 133a-2 are clustered in an intergenic region of  
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human chromosome 20, whereas the miR-1-2/miR-133a-1 cluster is located in the 
antisense orientation within an intron of the Mind bomb1 (Mib1) gene on human 
chromosome 18. The expression of miR-1 and miR-133a is cardiac and skeletal-
muscle specific, whereas the related miR-206 and miR-133b genes are restricted to 
skeletal muscle.19,20 Transcription of the miR-1/miR-133 bicistronic precursors is 
directly regulated by serum response factor (SRF) in cardiac muscle, and by 
MyoD/Mef2 in skeletal muscles. In cardiomyocytes, SRF binds the enhancer regions 
of the miR-1/miR-133 cluster and regulates microRNA expression.20 Gain- and loss-
of function studies revealed that miR-1/miR-133 family members play crucial roles 
in the developing heart. Overexpression of miR-1 specifically in the developing heart 
resulted in decreased ventricular cardiomyocyte proliferation, ventricular wall 
thinning, heart failure and subsequent embryonic lethality at E13.5.20 In line, 
introduction of miR-1 into developing Xenopus embryos interfered with heart 
development and injection of miR-133 in embryos resulted in highly disorganized 
cardiac tissue, absence of cardiac looping or chamber formation, revealing that 
correct temporal expression and amounts of both miR-1 and miR-133 are required 
for proper skeletal muscle and heart development.19  
One of the validated targets of miR-1 is Hand2, a bHLH transcription factor involved 
in ventricular cardiomyocyte expansion.20 Interestingly, targeted gene deletion of 
Hand2 in mouse embryos resulted in embryonic lethality at embryonic day 10.5 
from heart failure, similarly to miR-1 transgenic mice.21 Furthermore, targeted 
deletion of miR-1-2 revealed that miR-1-2 regulates cardiac morphogenesis, 
electrical conduction, and cardiac cell-cycle control.16 Mice lacking either miR-133a-
1 or miR- 133a-2 do not display any overt developmental phenotype, whereas 
deletion of both microRNAs causes lethal ventricular–septal defects in 
approximately half of double-mutant embryos or neonates. The miR-133a double-
mutant mice that survive to adulthood succumb to dilated cardio- myopathy by 5–6 
months of age and heart failure. The absence of miR- 133a expression is associated 
with aberrant cardiomyocyte proliferation and ectopic expression of smooth muscle 
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genes in the heart. These abnormalities were proposed to be due to direct targeting 
of SRF and cyclin D2, both of which contain functional binding sites for miR-133a in 
their 3′- UTRs. These findings have established critical and redundant roles for miR-
133a-1 and miR-133a-2 in orchestrating cardiac development, gene expression, and 
function.22  
Also in the adult heart, these microRNA clusters fulfill a critical role since altered 
expression of miR-1 and miR-133 is associated with heart failure both in rodents and 
humans.23 Sequestering endogenous miR-133 with a targeted 3′UTR decoy resulted 
in marked myocyte hyper- trophy, significantly increased protein synthesis, 
increased fetal gene expression, and perinuclear expression of atrial natriuretic 
factor. In cultured neonatal cardiomyocytes, overexpression of miR-1 or miR-133 
inhibited phenylephrine and endothelin-1-induced cardiomyocyte hypertrophy. In 
line, in vivo inhibition of miR-133, using an antagomir treatment, caused marked 
cardiac hypertrophy by means of derepressing RhoA, a GDP-GTP exchange protein 
regulating cardiac hypertrophy, Cdc42, a signal transduction kinase implicated in 
hypertrophy, and Nelf-A/WHSC2, a nuclear factor involved in cardiogenesis. This 
significant myocardial hypertrophy was associated with re-induction of the fetal 
gene program.23 Cardiac delivery of AAV9-miR-1 in male Sprague-Dawley rats 
subjected to aortic stenosis, reversed hypertrophic remodeling, reduced cardiac 
fibrosis and apoptosis and improved calcium handling. One of the validated targets 
in this study was Fibullin-2, a secreted protein implicated in extracellular matrix 
remodeling.24 In line, SERCA2a gene therapy, which improves cardiac function both 
in animals and humans with heart failure, was shown to restore cardiac miR-1 
expression via an Akt/Foxo3-dependent pathway, indicating that miR-1 expression 
is critical for proper cardiac function.25 Recently, miR-133 was shown to target 
multiple components of the β1AR-signaling cascade, thereby protecting 
cardiomyocytes from β1AR-induced apoptosis. Among the direct targets of miR-133 
are the β1-receptor itself and its downstream effectors adenylate cyclase VI (ACVI) 
and PKA C-β, a key modulator of the β1AR-mediated accumulation of the second 
messenger cAMP. Using a cardiac-specific TetON-miR-133 inducible transgenic 
mouse model, the authors showed that after pressure overload TetON-miR-133 
inducible transgenic mice maintained cardiac performance and displayed 
attenuated apoptosis and decreased fibrosis compared to control mice.26 Another 
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receptor pathway that is targeted by members of this cluster is the insulin-like 
growth factor 1 (IGF-1)/insulin-like growth factor 1 receptor signal transduction 
pathway, a key regulator of cardiac muscle tropism and function. Both IGF-1 and 
IGF-1 receptor are direct targets of miR-1. Moreover, Foxo3a, a component of the 
IGF-1 signaling pathway, transcriptionally regulates miR-1 expression levels, pro- 
viding a feedback loop between miR-1 expression and IGF-1 signaling. In line, miR-1 
expression levels in myocardial biopsies from acromegalic patients, where IGF-1 is 
overproduced after aberrant synthesis of growth hormone, are inversely correlated 
with cardiac mass and wall thickness.27  
MyomiRs: miR-208a, miR-208b and miR-499 In the rodent heart, α-
MyHC (encoded by the Myh6 gene), a fast  
ATPase, is highly expressed in adulthood, whereas β-MyHC (encoded by the adjacent 
Myh7 gene), a slow ATPase, is the predominant myosin isoform in cardiomyocytes in 
the embryonic stage.28 The relative expression of these two myosin isoforms is 
correlated with the contractile velocity of cardiac muscle. Several pathologic stimuli 
can cause a shift in the MyHC composition of the rodent ventricle from α-MyHC to β- 
MyHC. The opposite holds true in humans, where β-MyHC is the pre- dominant 
cardiac myosin isoform expressed.29 Interestingly, these muscle-specific myosin 
genes harbor a family of microRNAs, called myomiRs, within their introns. MyomiRs 
consist of miR-208a, miR- 208b, and miR-499, encoded within the introns of Myh6, 
Myh7 and Myh7b genes, respectively. The myomiRs are highly conserved and share 
similar sequence identity, and the expression of the myomiRs parallels the 
expression of their respective host genes during development.30 Targeted deletion of 
miR-208a resulted in ectopic activation of the fast skeletal muscle gene expression 
within the heart, and mice were protected against cardiac hypertrophy and 
myocardial fibrosis. Mice lacking miR-208a fail to upregulate β-MyHC expression in 
response to cardiac stress stimuli, at least in part due to direct inhibition of the 
thyroid receptor–associated protein THRAP1, a transcriptional coregulator of the 
thyroid receptor, leading to increased thyroid hormone signaling, thereby regulating 
myosin isoform switching. Given that miR-208a null mice are viable, it indicates that 
miR-208a is not required for development of the heart and embryogenesis.31 
Inhibition of miR-208a in adult mouse hearts by systemic administration of an 
antimir against miR-208a prevented pathological myosin switches and cardiac 
remodeling upon stress, resulting in improved cardiac function and survival.32 
Furthermore, miR-208a regulates the expression of the two slow myosins and their 
intronic microRNAs, Myh7/miR-208b and Myh7b/miR-499, as deletion of miR-208a 
abolishes the expression of miR-208b and miR-499. MiR-208b and miR-499 display 
functional redundancy, and have crucial roles in specifying muscle fiber identity by 
activating slow and repressing fast myofiber gene programs.30  
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The miR-17~92 cluster The miR-17~92 cluster consists of six 
microRNAs: miR-17, miR-18a,  
miR-19a, miR-20a, miR-19b, and miR-92a. These six microRNAs belong to four 
microRNA families and are generated from a common primary transcript. The miR-
17~92 cluster was initially reported as a human oncogene, named Oncomir-1 and is 
located on human chromosome 13. This microRNA cluster has two paralogs, the 
miR-106b~25 cluster and the miR-106a~363 cluster. The two paralogs are located at 
different genetic loci, which provide an extra layer of redundancy among the four 
microRNA families. The miR-106b~25 cluster consists of miR-106b, miR-93 and miR-
25 and is located in the 13th intron of the human MCM7 gene. On the other hand, 
the miR-106a~363 cluster maps to chromosome X in both humans and mice. The 
miR-106a~363 and miR-106b~25 clusters contain microRNAs that are highly similar, 
and in some cases even identical, to those encoded by the miR-17~92 cluster. This 
indicates that they probably have overlapping functions by regulating a similar set 
of direct downstream targets33 and most likely originated from a series of ancient 
evolutionary genetic duplication events. The broad conservation of sequence across 
species implies the importance of those microRNAs during vertebrate 
development.33  
 
Loss of function studies revealed a critical role for the miR-17~92 cluster in heart 
development. MiR-17~92 mutants die shortly after birth and display ventricular 
septal defects and lung hypoplasia. In contrast, loss of the paralogous miR-106a~93 
and miR-106b~25 clusters does not affect organismal viability and these mutants do 
not display an obvious phenotype. This is most likely due to functional redundancy 
with the miR-17~92 cluster. However, miR-17~92/miR-106b~25 double null 
embryos and miR-17~92/miR-106b~25/miR-106a~363 triple null embryos die at 
mid-gestation, before E15, and exhibit a much more severe phenotype compared to 
embryos lacking miR-17~92 alone. At E13.5 and E14.5 in the developing mouse 
embryo, miR-17~92/miR-106b~25 double null embryos showed edema and vascular 
congestion associated with severe cardiac developmental abnormalities including 
defective ventricular and atrial septation and thinning of the ventricles.33  
Furthermore, the miR-17~92 cluster is involved in myocardial differentiation of 
cardiac progenitors in the secondary heart field, which is required for normal 
cardiac outflow tract (OFT) formation. The cardiac OFT is a developmentally 
complex structure that is often defective in patients with congenital heart disease. 
The bone morphogenetic proteins Bmp2 and Bmp4, direct OFT myocardial 
differentiation via regulation of the miR-17~92 cluster. The miR-17~92 cluster in its 
turn represses the expression of cardiac progenitor genes Isl1 and Tbx1.34  
Gain-of-function studies have revealed a role for the miR-17~92 cluster in organ size 
regulation. Global miR-17 overexpression leads to organ growth retardation, 
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including the heart. In contrast, overexpression of the entire miR-17~92 cluster 
provokes cardiomyocyte hypertrophy and hyperplasia. Recently, transgenic 
overexpression of the miR-17~92 cluster in cardiomyocytes was shown to be 
sufficient to induce cardiomyocyte proliferation in embryonic, postnatal, and adult 
hearts. Moreover, miR-17~92 cluster overexpression in adult cardiomyocytes 
protects the heart from myocardial infarction-induced injury.35  
Inhibition of miR-25 in vivo by 4 weeks of antagomir treatment in adult mice 
induced cardiac dilatation accompanied by decreased cardiac function.36 This 
phenotype was even more severe in a pressure overload-induced heart failure 
model, due to the miR-25 mediated derepression of the transcription factor, Hand2. 
Hand2 is involved in the formation of the second heart field of the developing heart, 
and becomes re-activated in the adult failing heart by this microRNA mechanism. In 
line, Hand2 overexpression in mice leads to decreased cardiac function and 
dilatation, while conditional Hand2 gene deletion proved protective against 
pressure overload-induced heart failure.36 A contrasting publication found that 
inhibition of miR-25 by antagomir treatment in a five-month long pressure overload 
study in mice increased cardiac function by derepression of SERCA2a. Further 
research is needed to clarify this contradiction and obtain a more integrative 
understanding of the functional role of the miR-106b~25 and miR-106a~363 clusters 
in the adult heart.37  
The miR-15 family  
By comparing microRNA expression profiles in mouse cardiac ventricles at P1 and 
P10, multiple miR-15 family members were identified as regulators of postnatal 
cardiomyocyte mitotic arrest. The miR-15 family consists of miR-15a, miR-15b, miR-
16, miR-195, and miR-497. Family member miR-195 displayed a 6-fold increase in 
expression at P10 compared to P1. Overexpression of miR-195 in the developing 
heart using a transgenic mouse model caused congenital heart abnormalities 
associated with premature cell cycle arrest. The miR-15 family member miR-195 
directly targets cell cycle gene checkpoint kinase 1 (Chek1). Inhibition of the miR-15 
family in neonatal mice with locked nucleic acid-modified anti-microRNAs was 
associated with an increased number of mitotic cardiomyocytes and derepression of 
Chek1. These results suggest that the miR-15 family is important during the 
neonatal period governing cardiomyocyte cell cycle withdrawal and binucleation.38 
The neonatal mammalian heart still has regenerative capacity after myocardial 
infarction through proliferation of preexisting cardiomyocytes. The miR-15 family 
modulates neonatal heart regeneration by inhibiting postnatal cardiomyocyte 
proliferation. Inhibition of the miR-15 family from an early postnatal age until 
adulthood increased myocyte proliferation in the adult heart and improved left 
ventricular systolic function after adult myocardial infarction in mice.39  
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LncRNAs: adding layers of complexity to cardiac gene regulation  
Most lncRNAs are RNA polymerase II transcribed, 5′-capped, alternatively spliced 
and polyadenylated. They are less conserved than microRNAs and only a small 
subset show evolutionary conservation of the primary sequence. Yet, lncRNAs do 
show tissue and cell type-specific expression, indicating that their expression must 
be tightly controlled. LncRNAs are distinguished by a diversity of molecular 
functions derived from their ability to act as scaffolds for protein–protein 
interactions and/or chaperones that direct protein complexes to specific RNA or 
DNA sequences. One of the first identified mechanisms for lncRNA action is 
imprinting. For imprinted genes, the expression occurs from only one allele, instead 
of both parental alleles being expressed equally. Secondly, LncRNAs can act both as 
transcriptional activators and repressors by interacting with epigenetic modifying 
protein complexes, regulate expression of genes located in close proximity (cis-
acting) or target distant transcriptional activators or repressors (trans-acting). 
LncRNAs can also act as molecular decoys. In this case, the lncRNA can ‘sponge’ 
protein-based factors such as transcription factors away from chromatin or sponge 
tiny RNA species.40 Finally, lncRNAs can act as molecular guides by directing 
ribonucleoprotein complexes to specific chromatin targets.41 LncRNAs may serve as 
central platforms for assembly of complex protein components. Some lncRNAs 
possess distinct domains that bind different protein factors, bringing transcriptional 
activators or repressors together in both time and space (Table 2).  
Since many cardiac diseases are heritable, series of genome-wide association 
studies (GWAS) have been performed to identify new disease loci for cardiovascular 
diseases. Remarkably, 93% of the identified disease loci fall outside protein-coding 
regions and could influence the expression or function of non-coding RNAs. In line, 
single nucleotide polymorphisms (SNPs) associated with cardiac disease have been 
identified to locate within lncRNA encoding genes42, suggesting that lncRNAs may 
have more causal roles in disease, which justifies an in-depth analysis of individual 
lncRNA function.  
The more detailed characterization of individual lncRNAs in development and 
disease of the cardiovascular system is only starting to emerge. In 2013, a hallmark 
publication demonstrated that lncRNA Braveheart (Bvht, AK143260) is required for 
cardiovascular lineage commitment. Bvht is expressed at early developmental 
stages in mouse embryonic stem cells (mESCs) and is also highly expressed in the 
adult mouse heart. Depletion of Bvht in mESCs impaired formation of 
cardiomyocytes in multiple in vitro differentiation assays. Bvht depletion in primary 
murine neonatal ventricular cardiomyocyte cultures resulted in unevenly distributed 
and irregularly bundled myofibrils after 5 days in culture compared to control cells 
and significantly smaller overall cardiomyocyte cell surface area, indicating that 
neonatal cardiomyocyte structure is disrupted in Bvht-depleted cells. Bvht is 
required for expression of core gene regulatory networks involved in defining 
cardiovascular cell fate and acts upstream of mesoderm posterior (MesP1), a master 
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gene of cardiovascular lineage commitment.43 Furthermore, the authors show that 
also the downstream targets of MesP1 require upstream Bvht activation, including 
the core cardiac transcription factors Gata4, Gata6, Hand1, Hand2, Tbx2, and 
Nkx2.5, among others.  
Another lncRNA, Fendrr (Foxf1 adjacent non-coding developmental regulatory RNA; 
ENSMUSG00000097336), is specifically expressed in nascent lateral plate mesoderm 
and is required for proper development of the heart and body wall in the mouse. 
Fendrr-deficient mice die around E13.5 due to abnormal functioning of the heart. 
Fendrr acts by modifying the chromatin signatures of genes involved in the 
formation and differentiation of the lateral mesoderm lineage through binding to 
both the PRC2 and TrxG/MLL complexes.44 Expression of the transcription factors 
Nkx2.5 and Gata6 was increased upon cardiac Fendrr deletion, accompanied by 
corresponding H3K4me3 changes in their promoter regions, while expression of 
other core transcription factors, such as Gata4 or Tbx5 was not affected.  
A third example of lncRNAs involved in cardiac development is the lncRNA SRA. The 
steroid receptor RNA activator 1 (SRA1) gene generates both steroid receptor RNA 
activator protein (SRAP) as well as several non-coding SRA transcripts, depending on 
alternative transcription start site usage and alternative splicing.45 The lncRNA SRA 
binds to MyoD, which regulates skeletal myogenesis. In vitro and in vivo 
experiments showed that SRA is a coactivator of MyoD.46 SRA is present in a 600-kb 
region of linkage disequilibrium (LD) associated with human dilated cardiomyopathy 
on 5q31.2-3, harboring multiple genes, in three independent Caucasian populations. 
Knockdown of SRA1 by Morpholino antisense in zebrafish resulted in impaired 
cardiac function phenotypes, with impaired contractility predominantly in 
ventricular heart chambers at 72 h post fertilization.47  
Recently, a cluster of cardiac-specific lncRNA transcripts from Myh7 loci was 
identified and named myosin heavy-chain-associated RNA transcripts (Myheart, or 
Mhrt). Mhrt antagonizes the function of Brg1, a chromatin-remodeling factor that is 
activated by stress to trigger aberrant gene expression and cardiac myopathy.48 The 
ATP-dependent Brg1– HDAC–PARP complex cooperatively controls the change in the 
α/β- MHC ratio in failing hearts.49 These lncRNAs, which are splice isoforms of Mhrt, 
have a tight correlation with the Myh6/Myh7 ratio during cardiac development and 
in hypertrophic hearts. Cardiac stress in mice induced by pressure overload lead to a 
progressive loss of Mhrt expression in cardiomyocytes along with the development 
of pathological hypertrophy. Restoring Mhrt expression to the prestress level 
attenuated pathological hypertrophic responses and restored cardiac function, 
demonstrating the cardioprotective role of Mhrt in vivo. Mhrt directly binds to the 
helicase domain of Brg1, a domain that is crucial for tethering Brg1 to chromatinized 
DNA targets, enabling a competitive inhibition mechanism by which Mhrt sequesters 
Brg1 from its genomic DNA targets to prevent chromatin remodeling and gene 
regulation by Brg1. This negative feedback circuit between a lncRNA and the Brg1 
chromatin remodeling complex is thus crucial for heart function.48  
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Likewise, lncRNA profiling of the cardiac transcriptome after myocardial infarction 
was performed to identify novel heart-specific lncRNAs with potential roles in both 
cardiac development and pathological cardiac remodeling. These novel lncRNAs also 
have human orthologues, which are dysregulated during disease. The novel lncRNA 
Novlnc6 was significantly downregulated in human dilated cardiomyopathy. 
Novlnc6 is associated with a bonafide cardiac developmental enhancer and 
modulates the expression of Nkx2.5, a master cardiac transcription factor, critical 
for the modulation of gene programs involved in cardiogenic differentiation, 
maturation, and homeostasis. Furthermore, knockdown of Novlnc6 by GapmeRs in 
cardiomyocytes resulted in concomitant downregulation of BMP10, a key signaling 
ligand for cardiogenesis, which maintains Nkx2.5 expression.50  
Additionally, variants in myocardial infarction associated transcript (MIAT, also 
known as Gomafu/RNCR2) were identified by GWAS as a risk factor for myocardial 
infarction. Six single nucleotide polymorphisms (SNPs) in MIAT showed markedly 
significant association with myocardial infarction.51 To date, the molecular 
mechanism by which MIAT causes cardiac disease is still unknown.  
By RNA sequencing of embryonic (E14), normal adult and hypertrophied adult 
hearts, Matkovich et al. identified 157 lncRNAs that were differentially expressed in 
embryonic hearts compared with adults, but relatively few fetal lncRNAs that 
showed altered expression in adult-onset cardiac hypertrophy. Only 17 lncRNAs 
were differentially expressed in hypertrophied hearts, 13 of which observed in 
embryonic hearts. By analyzing neighboring mRNAs within 10 kb of dynamically 
expressed lncRNAs, the authors revealed that 22 mRNAs were concordantly and 11 
were reciprocally regulated. Using lncRNA knockdown in C2C12 myoblasts, the 
functional reciprocal interactions between mRNAs Mccc1 and Relb, and lncRNAs 
n411949 and n413445, respectively, were validated. LncRNA n413445 and n411949 
are highly expressed in the embryonic heart but show quite low expression in adult 
hearts, with no apparent change in the pressure overloaded heart. The lncRNA 
n413445 regulates Relb mRNA levels, a transcription factor that is an essential 
component in the NFκB pathway that is important during fetal cardiac growth. An 
increase of the lncRNA n411949-regulated mRNA Mccc1 during embryonic growth 
may be of key importance for sensing free leucine levels and thus the availability of 
branched-chain amino acids for anabolic signaling in muscle.52  
In order to determine the expression profile of myocardial lncRNAs and their 
potential role in early stage reperfusion, Liu and colleagues performed microarray 
analysis and validated the results using polymerase chain reaction (PCR). They 
identified 64 lncRNAs that were up-regulated and 87 that were down-regulated, 
while 50 mRNAs were up-regulated and 60 down-regulated in infarct region at all 
reperfusion sampled. Target gene-related pathway analysis showed significant 
changes in cytokine–cytokine receptor interaction, the chemokine signaling 
pathway and nucleotide oligomerization domain (NOD)-like receptor signaling 
pathway which have a close relationship with myocardial ischemia/reperfusion 
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injury (MI/RI). The co-expressed network of 10 highly-dysregulated lncRNAs showed 
that ENSMUST00000166777 and AK156124 are in closest relation with coding RNAs 
(mRNAs). However, ENSMUST00000170410 and uc007prv.1 have the slightest 
relevance to coding RNAs (mRNAs). Six mRNAs (CXCL1, CCL9, CXCL12, EDA, TNFAIP3 
and BIRC3) were targeted by corresponding lncRNAs, all of which have been linked 
to ischemia/reperfusion injury.53  
Deep sequencing of RNA isolated from paired nonischemic (NICM; n = 8) and 
ischemic (ICM; n = 8) human failing LV samples collected before and after LVAD and 
from nonfailing human LV (n = 8) revealed high abundance of mRNA (37%) and 
lncRNA (71%) of mitochondrial origin. The analysis identified 18,480 lncRNAs in 
human LV. Among the 679 (ICM) and 570 (NICM) lncRNAs differentially expressed 
with heart failure, ≈10% are improved or normalized with LVAD. Furthermore, the 
expression signature of lncRNAs, but not microRNAs or mRNAs, distinguished ICM 
from NICM in this study, suggesting a predominant role for lncRNAs in the 
pathogenesis of heart failure and in reverse remodeling by mechanical support.54  
Recently, it was shown that the lncRNA cardiac hypertrophy related factor (CHRF) 
regulates cardiac hypertrophy by directly binding to miR-489, acting as a functional 
sponge to regulate anti-hypertrophic miR-489 expression and activity. The 
responsible downstream target of miR-489 appeared to be myeloid differentiation 
primary response gene 88 (Myd88). The overexpression of CHRF resulted in the 
upregulation of Myd88 expression and the activation of NF-κB signaling, leading to 
hypertrophy.55  
 
Conclusions and perspectives  
 
Studies on two major species of ncRNAs, microRNAs and lncRNAs, have changed our 
understanding about the epigenetic control of gene regulatory programs and reveal 
a vast overlap between the regulation of gene programs in the developing heart and 
adult-onset heart disease. As such, the emerging picture also demonstrates that the 
heart seems sensitive to relatively subtle changes in gene modifier effects. The 
ability of microRNAs to fine-tune gene expression programs and act as powerful 
stress regulators suggests their central role in many facets of cardiac biology. Since 
one single microRNA could possibly modulate dozens of target genes at once, and 
one gene could be targeted by multiple microRNAs, methods aimed to better 
understand the integration of microRNA control within gene regulatory networks 
are clearly necessary for the field. Our collective understanding of how these tiny 
post-transcriptional gene regulators function in cellular networks provides new 
molecular horizons for cures or therapies to a variety of human heart diseases, and 
the first examples of microRNA-based proof-of-concept therapies in small and larger 
animal models are well underway. Manipulation of individual microRNAs by 
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chemically modified oligonucleotides or adeno-associated viral vectors have 
therapeutic potential in animal models for cardiovascular diseases. A major 
translational challenge will remain in understanding the pharmacology/toxicology 
aspects, correct dosing and correct delivery to the site of action of these 
fundamentally new therapeutic entities. As for lncRNAs, literally thousands of 
putative lncRNAs have been identified in mammalian species including humans, but 
only dozens have been experimentally studied in sufficient detail so far. The 
relatively poor evolutionary conservation of lncRNAs still poses a barrier to translate 
their function from animal models to humans. Likely, the identification of 
evolutionary conserved functional domains in lncRNAs will provide relief to latter 
obstacle and possibly allow therapeutic manipulation by antisense oligonucleotide- 
based cardiac therapy. Eventually, the detailed characterization of ncRNAs with 
essential roles in the developing or the diseased heart will undoubtedly lead to a 
richer understanding of the complex gene regulatory networks that drive proper 
cardiac development and maintain healthy myocardial function.  
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Heart failure (HF) is the end result of a diverse set of causes such as genetic 
cardiomyopathies, coronary artery disease, and hypertension and represents the 
primary cause of hospitalization in Europe. This serious clinical disorder is mostly 
associated with pathological remodeling of the myocardium, pump failure, and 
sudden death. While the survival of HF patients can be prolonged with conventional 
pharmacological therapies, the prognosis remains poor. New therapeutic modalities 
are thus needed that will target the underlying causes and not only the symptoms 
of the disease. Under chronic cardiac stress, small noncoding RNAs, in particular 
microRNAs, act as critical regulators of cardiac tissue remodeling and represent a 
new class of therapeutic targets in patients suffering from HF. Here, we focus on the 





MicroRNAs (miRs) are a family of small (19–25 nucleotide) single-stranded 
noncoding RNA molecules that regulate gene expression at the post-transcriptional 
level. Inhibition of gene expression occurs through complementary base pairing 
with sequences mainly located in the 3′ untranslated region (3′ UTR) of the target 
mRNA,1 leading to translational repression or mRNA degradation (Figure 1). Key 
recognition elements comprise nucleotides 2–8 at the 5′ end of the microRNA and 
are known as seed sequences.2 MicroRNAs can be represented as families, defined 
by conservation of their seed region, with conservation of sequences from 
nematodes through to humans, implying importance of function during evolution. 
Between 10–40% of human mRNAs are regulated by microRNAs whereby single 
microRNA species can regulate multiple mRNA targets and single microRNAs may 
contain several microRNA recognition sites in their 3′UTR.3 Such complex regulatory 
networks can control key biological functions and alterations in microRNA 
expression are associated with numerous human pathologies such as cancer,4, 5 
neurodegenerative,6, 7 metabolic,8, 9 and cardiovascular diseases.10, 11 In recent 
years, research has been aimed at targeting dysregulated microRNA expression as a 
novel way to modulate biological processes for benefit. Such modulation of 
microRNAs has proven successful in vivo through the use of antisense 
oligonucleotides (ASOs) or modified microRNA mimics such as plasmid or lentiviral 
vectors that carry microRNA sequences designed to deliver microRNAs to cells and 
tissues (Figure 1). Since available heart failure (HF) pharmacotherapy has only a 
marginal impact on long-term prognosis of the disease, there is both room and a 
need for the development of innovative bio-therapeutics. This review focuses on 
the current status of microRNA-based therapies in HF and highlights the potential 
use of ASOs as microRNA inhibitors for the treatment of cardiovascular diseases.  
 
MicroRNAs and cardiovascular diseases 
 
A distinct set of differentially expressed microRNAs exists in the failing as compared 
to normal heart. miR-1, miR-25, miR-29, miR-30, miR-133, and miR-150 show 
downregulated expression, while miR-21, miR-23a, miR-125, miR-195, miR-199a/b, 
and miR-214 show increased expression in experimental and human HF. This altered 
expression pattern is associated with underlying mechanisms that lead to the 
disease state.12-14  
A hallmark of HF development is pathological hypertrophy.15, 16 Several microRNAs 
are reported to regulate prohypertrophic genes, including hypertrophy-associated 
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calmodulin, NFAT, Mef2a, Gata4, and Hand2 and are thought to be key regulators in 
HF development.12, 17, 18 Therapeutic cardiac-targeted delivery of one such 
 
 
Figure 1 MicroRNA processing and modulation of activity by antisense oligonucleotides and microRNA 
mimics. MicroRNA maturation is a complex process where any step is subject to tight molecular 
regulation. MicroRNAs are initially transcribed by RNA polymerase II from intergenic, intronic, or 
polycistronic loci into long primary transcripts (pri-microRNAs) that can encode one or more miRNAs. 
Hereafter, multiple 60–100 bp long microRNA precursor hairpin-like structures (pre-microRNA) are 
released by the action of the Drosha-DGCR8 complex. Export of these precursor stem-loop structures 
from the nucleus occurs in a Ran/GTP/Exportin-5-dependent manner and once in the cytoplasm, pre-
miRNAs are cleaved by the Dicer-TRBP complex and processed to generate microRNA duplexes. These 
will be incorporated into the Argonaute-containing microRNA-induced silencing complex (RISC) and after 
unwinding of the duplex occurs the mature microRNA strand will be kept in the RISC while the 
complementary strand will be freed and degraded. The mature microRNA in the RISC will direct it to 
mRNAs with partially complementary sites and lead to translational repression and/or degradation. 
MicroRNA activity can be modulated either by restoring function via double stranded microRNA mimics 
or by inhibition using single-stranded antisense oligonucleotides.  
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microRNA, miR-1, reversed pressure over- load-induced cardiac hypertrophy and 
attenuated pathological remodeling.19 miR-133, clustered with miR-1, is also 
repressed during HF and its repression suffices to induce cardiac hyper- trophy and 
increase expression of target mRNAs such as RhoA (GDP-GTP exchange protein 
regulating cardiac hypertrophy), Cdc42 (kinase implicated in hypertrophy), and Nelf-
A/WHSC2 (nuclear factor involved in cardiogenesis).20 In line, miR-133 
overexpression inhibits experimentally induced hypertrophy. Likewise miR-199b, a 
direct target of the calcineurin/NFAT pathway, is increased in mouse and human HF, 
and in vivo inhibition of miR-199b with a specific antagomir reduced nuclear NFAT 
activity and caused marked inhibition of hypertrophy and fibrosis.21 
An important feature in the process of myocardial infarction (MI) and subsequent 
systolic HF is myocardial fibrosis leading to abnormal mechanical stiffness and 
contractile dysfunction.22 Members of the miR-29 family are implicated in this 
process as they show marked downregulation in the border zone surrounding the 
infarcted area.23 Downstream targets of miR-29 include proteins associated with the 
fibrotic response such as; extracellular matrix-related genes such as elastin (ELN), 
collagenase type 1 alpha 1–3 (COL1A1-3) and fibrillin 1 (FBN1). miR-21 is also 
related to a fibrogenic phenotype as it controls cardiac fibroblast proliferation by 
facilitating MAPK signaling through induction of Sprouty homolog 1 (SPRY1).24 
MicroRNAs also regulate the repair response after MI, another key aspect of HF. 
This process prevents hypoxic damage through the induction of angiogenesis driven 
by the cytokines vascular endothelial growth factor and fibroblast growth factor.25 
The endothelial cell-specific miR-126 can regulate this response following MI by 
inhibition of negative regulators of the vascular endothelial growth factor pathway 
such as SPRED1 and PIK3R226 and, therefore, positively impact neo-angiogenesis 
and counteract hypoxia.  
MicroRNAs also play a pathophysiological role during atherosclerotic plaque 
progression. In this context, downregulation of miR-24 induces plaque stability by 
promoting the invasion of macrophages with matrix metalloproteinase-14 
proteolytic activity.27 In contrast, miR-126-null mice have reduced endothelial cell 
proliferation and exacerbated atherosclerosis and reconstitution of miR-126-5p was 
able to rescue endothelial cell proliferation and limit atherosclerosis.28  
Together, these studies establish microRNAs as key regulators of cardiovascular 
disease and identify them as potential therapeutic targets to treat human disease.  
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MicroRNA activity modulation: therapeutic approaches 
 
To date, the regulatory role of specific microRNAs in cardiovascular disease has 
primarily been elucidated from loss- or gain-of- function studies in mouse models of 
disease.17 ASOs have been the main pharmacological tools used to inhibit microRNA 
function in mouse disease models. Here, we speculate on the potential use of 
antimirs and their therapeutic potential for cardiovascular disease.  
 
ASOs: mechanism of action  
 
ASOs were first discovered in 1987 and can be described as short, single-stranded 
chains of nucleotides that hybridize with complementary RNA sequences.29 In the 
last 10 years, ASOs have also been used as tools to inhibit microRNA function (anti-
microRNA oligonucleotides (AMOs)), based on Watson-Crick base pairing.30 AMOs 
exert their activity through several mechanisms including RNase H-mediated RNA 
degradation where recognition of the RNA-AMO duplex by RNase H leads to 
cleavage of the RNA strand31 or sterically blocking access to pre-mRNA and mRNA 
without degrading the RNA32 (Figure 1).  
Despite several publications analyzing decreased microRNA expression level as 
measure of effectiveness of AMO treatment, the question remains whether this is 
the most reliable evaluation method to determine efficacy of microRNA inhibition. 
For example, binding of an AMO to its target microRNA may interfere with its 
detection but, depending on the chemistry of the AMO used, be able to inhibit 
microRNA function without also inducing its degradation. An example of this is LNA 
and 2′-fluoro/2′-methoxyethyl modified AMOs, which can inhibit microRNA activity 
without decreasing mature microRNA expression levels.33  
In such cases, evaluating microRNA target derepression as a secondary endpoint 
may also provide a valuable measure of AMO efficacy.  
Chemical modifications  
Because AMOs must bind specific nucleotide sequences the rational design of high 
affinity antagonists is relatively straightforward. However, since several enzymes 
present in the organism rapidly recognize RNA-like structures, premature 
degradation of AMOs can limit their bioavailibility. In this context, chemical 
modifications of AMOs can be employed to alter their pharmacokinetic properties 
and enhance cellular uptake without loss of binding (Figure 2). Indeed, differently 
modified antisense microRNAs have been shown to directly inhibit microRNA 
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function in vivo and the examples detailed herein clearly show the potential of 
antisense microRNAs to treat cardiovascular diseases.  
2’-OMe modifications  
Theoretically, systemically delivered oligonucleotides are susceptible to enzymatic 
degradation by nucleases present in the bloodstream by the same mechanisms that 
regulate native RNA. Methylation of the hydroxyl group at the 2′ position of the 
ribose unit is a relatively simple and attractive approach to increase resistance to 
nuclease attack. The 2′-O-methyl (2′-OMe) AMOs have been increasingly used in the  
 
Figure 2 Chemical modifications of anti-microRNA oligonucleotides. Structures of the most commonly used 
chemical modifications in antisense oligonucleotides to modulate microRNA activity (AMOs). The 2’-O-
methyl (2’-OMe), 2’-O-methoxyethyl (2’-MOE), and the 2’-fluoro (2’-F) nucleo- tides are modified at the 2’ 
position of the ribose moiety. Locked nucleic acid (LNA) is a bicyclic RNA analogue in which the ribose is 
locked in a C3’- endo conformation by introduction of a 2’-O,4’-C methylene bridge. PNA oligomers are 
uncharged oligonucleotide analogues where a peptide-like backbone consisting of N-(2-aminoethyl)-glycine 
units replace the sugar-phosphate backbone. In the morpholino oligomers, the sugar moiety is replaced by a 
morpholine ring. In the ZEN modification, a (N,N-diethyl-4-((4-nitronaphtalen-1-yl) diazenyl) aniline) unit is 
placed at several locations in the phosphate backbone, reducing susceptibility to nuclease attack. The 
GalNac modifier includes a N-acetylgalactosamine (GalNAc) conjugate as a ligand to target delivery to the 
liver. Many microRNAs have been modulated with different AMOs, in different disease settings and different 
animal models (colored circles). MicroRNAs that were targeted by different chemically modified AMOs in the 
context of cardiovascular diseases are marked in red. PNA, peptide nucleic acid.  
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past decade and have proven in vivo efficacy. Besides enhanced resistance to 
nuclease attack, 2′-OMe ASOs show improved binding affinity to their 
corresponding microRNA sequence as compared to unmodified AMOs.28, 33, 34 Let-7 
was the first microRNA to be success- fully silenced using this method in the 
nematode C. elegans.35 To further enhance resistance to nuclease attack conferred 
by 2′-OMe modification, phosphorothioate moieties in the linking backbone have 
also been introduced. These sulphur analogues of phosphate can be incorporated 
near either the 5′ or 3′ and show, in combination with a 3′-cholesterol unit, 
enhanced AMO stability in cell cultures.36 Krützfeldt et al.37 explored the potential of 
2′-OMe modification to modulate microRNA in vivo using regulation of miR-122, a 
microRNA involved in cholesterol synthesis in the liver, as a model system. 
Unmodified single- stranded AMO-122 had no effect on miR-122 expression levels, 
whereas unconjugated chemically altered RNA analogues, partially or fully modified 
with a phosphorothioate backbone and 2′-OMe modifications, had a partial effect. 
37 Additional cholesterol-conjugation of the altered synthetic AMO (antagomir) was 
able to completely abolish endogenous miR-122 levels suggesting that the partial 
decrease in miR-122 expression by the unconjugated modified RNA analogues was 
due to microRNA- 122-RNA duplex formation, whereas silencing miR-122 by the 
antagomir was the result of complete microRNA degradation.37 High sequence 
specificity was demonstrated by introducing position specific mismatches. The use 
of fluorescently labeled antagomirs further showed that antagomir-microRNA 
interaction took place in the cytoplasmic compartment, upstream of the processing 
bodies (P-bodies),37 sites that act as scaffolding centers for microRNA function. 
Administration of a miR-122-specific antagomir at a dose of 80 mg/kg for 3 
consecutive days effectively reduced miR-122 expression levels in mice for a period 
of 23 days.37 Moreover, antagomirs successfully abolished microRNA expression in a 
few cardiovascular studies (Figure 2). Antagomirs exhibit a broad biodistribution 
and can efficiently silence their target microRNAs in all tissues tested. Although they 
cannot cross the placental and blood–brain barriers, injection of antagomirs directly 
into the cortex efficiently reduced microRNA levels in the brain.37  
 
2’(F)-MOE modifications  
Another approach to increase the stability of AMOs is the combination of 2′-MOE 
(2′-O-methoxyethyl) with phosphorothioate modifications in the linking backbone. 
This method is similar to 2′-OMe modifications albeit using CH2CH2OCH3 protective 
groups rather than a simple CH3. The use of a library of 2′-MOE AMOs to investigate 
the biological importance of microRNAs identified several microRNAs involved in 
adipocyte differentiation. Effective silencing of miR-143, a microRNA that is 
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upregulated in differentiating adipocytes,38 reversed adipocyte differentiation in the 
liver. The same group also showed that silencing miR-122 in mice with a specific 2′-
MOE RNA antagonist efficiently reduced plasma cholesterol levels, increased 
hepatic fatty-acid oxidation and decreased hepatic fatty acid and cholesterol 
synthesis rates.39 Interestingly, the results obtained by Esau et al.39 suggest that 
each AMO may have different affinity for their corresponding microRNA, with some 
specific targets being maximally affected at very low doses and others being less 
responsive. Besides the 2′OMe and 2′MOE variations of RNA analogues, other RNA 
analogues containing substitutions at the same location within the ribose unit have 
been described. One such example is the 2′Fluoro modification, which has proven to 
be a potent inhibitor of both miR-122 and miR-21 in mice.33, 40 However, ASOs 
containing 2′-fluoro modifications require further modification to make them 
resistant to nuclease attack by making single strand antagonists with a full 




The pharmacokinetics of AMOs can also be modified by locked nucleic acid (LNA) 
modifications where the 2′-hydroxyl group is linked to the 4′ carbon atom of the 
sugar ring thereby forming a bicyclic sugar moiety. The linkage is preferably a 
methylene [CH2]n group bridging the 2′ oxygen atom with the 4′ carbon atom 
wherein n is 1 or 2. LNA-protected antisense RNAs exhibit extremely high thermal 
stability when hybridized with their corresponding RNA target molecules. In 
addition, LNA oligonucleotides display low toxicity at low doses, are highly soluble42 
and show excellent activity in targeting microRNAs. An LNA targeting miR-122 was 
the first of its kind to be validated in nonhuman primates causing a meaningful 
reduction in plasma cholesterol. Systemic delivery of an LNA in a physiological 
buffer resulted in a dose-dependent long-lasting and reversible decrease in total 
plasma cholesterol levels in African green monkeys, without any observed toxicities 
or histopathological changes.43 Empirically, LNAs possess the thermodynamically 
strongest duplex formation with complementary target RNA of all the AMOs. As a 
result, biological activity is often obtained with very short (8–15 nt) LNA-protected 
RNA sequences. Another advantage of LNA-modified oligonucleotides is their high 
metabolic stability (partly explained by enhanced nuclease resistance), their small 
size, excellent mismatch discrimination, and lack of toxicity in nonhuman 
primates.43, 44 However, LNAs may also form tight double strand binding which can 
lead to off-target microRNA engagement with subsequent inhibition of nontargeted 
microRNAs or precursor microRNAs. Indeed, a large animal model study using an 
LNA against miR-92a also inhibited the very closely resembling miR-25,45 which has 
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been shown to be associated with adverse effects in animal models of HF.14 Direct 
hepatoxicity of LNA nucleotides has also been observed in vivo, where adverse 
effects have been related to the use of particular LNA-modified oligonucleotide 
sequences.46 Nevertheless, LNAs show promise as they are well tolerated in vivo 
and are currently being evaluated in human clinical trials.  
 
The ZEN modifier  
 
Recently, Lennox et al.47 introduced a different approach to microRNA inhibition by 
using the non-nucleotide modifier ZEN (N,N-diethyl-4-((4-nitronaphthalen-1-
yl)diazenyl) aniline unit) bound at various locations in the phosphate backbone of 
the RNA structure of oligonucleotide sequences. Using this ZEN modifier on both 
5′and 3′terminal ends of 2′OMe modified AMOs resulted in full resistance against 
enzymatic degradation in serum and cell extracts and using miR-21 as an example 
demonstrated that ZEN modification was able to reduce AMOs to a length as short 
as 15-mers.47 In vivo testing of ZEN-AMOs is currently in progress but preliminary 
data indicate no obvious toxicity after systemic administration in mice.47  
 
GalNac conjugation  
 
After successful subcutaneous delivery of RNAi therapeutics by conjugation to GalNAc 
(N-Acetylgalactosamine) sugar,48 a carbohydrate-based chemistry developed by 
Alnylam (www. alnylam.com) other commercial organizations have adopted this 
approach. In 2013, Regulus Therapeutics (www.regulusrx.com) reported the use of 
GalNAc conjugated nucleotides indicating that they showed a 20-fold enhanced 
potency on hepatocytes and decreased expression of miR-122 target mRNAs as 
compared to unconjugated oligonucleotides. The company has also described data 
evaluating the use of GalNAc-conjugated oligonucleotides for in vitro and in vivo 
potency, pharmacokinetic/pharmaco- dynamics, toxicology and safety pharmacology, 
and inhibition of hepatitis C virus (HCV) replication. Efficacy was tested in a mouse-
human chimeric liver model of HCV and showed up to a 2-log reduction in viral load 
titer after just a single dose. Phase 1 clinical trials are ongoing and so far no serious 




In addition to the various sugar modifications, steric blockers can be made from a 
neutral backbone that is entirely different from DNA or RNA sugar-phosphate 
backbones. Peptide nucleic acid (PNA) oligonucleotides contain bases linked by 
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amide bonds.49 Due to the neutral charge of the amide backbone, binding to 
complementary sequences is very stable and occurs with high hybridization rates.50 
PNAs complementary to miR-122 have been shown to inhibit of target microRNA 




A different type of (uncharged) DNA analogue is the phosphoro-diamidate 
morpholine oligomer also known as a morpholino. The sugar backbone of these 
oligonucleotides has the ribose (or desoxyribose) ring replaced by a morpholine 
ring, which is attached to the phosphate backbone through the nitrogen of the 
morpholine ring. In addition, it has one of the phosphate oxygen’s replaced by a 
dimethylamino group. Although binding to complementary RNA does not have as 
high affinity as PNA binding, morpholinos have been successfully used to silence 
miR-37553 and mIR-20654 in zebrafish, revealing the roles these microRNAs play in 
pancreatic islet development and angiogenesis, respectively. Furthermore, since the 
backbone of morpholinos is neutral in charge, nonselective interactions with 
proteins, is less likely. Finally, morpholinos can be manufactured at low cost making 
them attractive for large in vivo studies.  
 
Sponges, masks, and erasers  
 
Recently, several methods to increase microRNA target specificity have been 
developed. One example is the use of microRNA sponges, where perfectly or 
imperfectly paired binding sites for the target microRNA sequences are inserted into 
an expression cassette in the 3′ UTR of a reporter gene. Those binding sites 
competitively inhibit and occupy the native microRNA-programmed microRNA-
induced silencing complex, thereby decreasing microRNA-induced silencing complex 
concentrations available for binding, and reversing the microRNA inhibitory effect 
on its target mRNA.55 This method has been shown to be effective in vivo using 
lentiviral vectors that stably and specifically silence miR-223 and subsequently 
upregulate its target sequences.56  
Another way, in which microRNA binding to its target mRNA can be blocked, is to 
use an oligonucleotide with perfect complementarity to the microRNA target 
sequence in the 3′ UTR of the mRNA. In this case, the binding site is masked, which 
prevents microRNA combining with the target mRNA. A distinct advantage of this 
approach is the specific targeting of microRNA binding to one particular mRNA. The 
third indirect method of microRNA inhibition involves “erasers”, which are tandem 
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repeats of a specific microRNA antisense sequence that induce almost complete 
elimination of endogenous microRNA.57 This method is comparable to the 
microRNA sponges, however erasers use only two antisense copies with perfect 
complementarity to the microRNA, while sponges contain multiple antisense copies 
of a microRNA.58 
 
Efficiency of AMOs in cardiovascular disease  
 
Antisense microRNA inhibitors have been successfully used to knockdown 
microRNAs in small animals for nearly a decade. After the breakthrough study by 
Krützfeldt et al.,37 several publications reported efficient microRNA knockdown by 
AMOs in mammalian cardiac tissue (Figure 2). Carè et al.20 were the first to use an 
antagomir to silence a cardiac microRNA showing that miR-133 silencing was 
sufficient to induce significant cardiac hypertrophic growth in mice. Many other 
cardiovascular microRNAs have subsequently been targeted (Figure 2; Table 1). 
Delivery of a specific antagomir to miR-21 in a mouse model of pressure-overload- 
induced cardiac disease prevented cardiac fibrosis and attenuated cardiac 
dysfunction.24 In vivo inhibition of miRNA-199b, a dysregulated microRNA involved 
in NFAT signaling, caused marked inhibition and even reversal of cardiac 
hypertrophy and fibrosis in mouse models of HF.21 Antagomir-mediated silencing of 
miRNA-214, which plays a pivotal role in regulating cardiac mitochondrial substrate 
flux, resulted in restored fatty acid oxidation and sub- sequent improvement in 
cardiac function.59 In mouse models of limb ischemia and MI antagomir-mediated 
inhibition of miR-92a enhanced blood vessel growth and functional recovery of 
dam- aged tissue.60 Inhibition of miR-208a by systemic administration of a specific 
LNA, in rats, led to improvement of cardiac function and attenuated pathological 
remodeling, indicating the exciting potential for this class of drugs.61 Furthermore, 
delivery of an LNA targeting miR-92a via a catheter in a pig model of MI resulted in 
reduced infarct size and improved cardiac function. Intravenous administration of 
the same LNA did not result in decreased infarct size compared to control animals, 
suggesting local administration might be preferred over systemic delivery for some 
types of AMOs.45 In 2008, the first publication appeared testing LNA chemistry 
constructs in nonhuman primates. Systemic administration of three doses of 10 
mg/kg of unconjugated LNA oligonucleotide effectively silenced miR-122 in African 
green monkeys, without any signs of LNA-associated toxicities or histopathological 
alterations in the tissues examined.43 This LNA antagonist (miravirsen, SPC3649) 
proved to be an effective drug in treating hepatitis C viral infection in 
chimpanzees.62 More recently, two other studies in nonhuman primates, showed 
that inhibition of miR-33a and miR-33b by either a 2′F/MOE- or 8-mer LNA-modified 
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AMOs resulted in derepression of miR-33 target genes such as the ATP- binding 
cassette transporter ABCA1, essential for the biogenesis and transport of high-
density lipoprotein (HDL), and increased plasma HDL cholesterol levels.41 These 
findings indicate the potential of seed-targeting AMOs to pharmacologically inhibit 
microRNAs and microRNA families in nonhuman primates. This opens up the 
exciting possibility that inhibiting the miR-33 family may reverse dyslipidaemia and 
atherosclerosis, which are risk factors in cardiovascular disease.  
 
AMOs from bench to bedside: perspectives and challenges  
  
To date, no clinical trials using AMOs have been initiated for the treatment of 
cardiovascular diseases. However, two companies, Regulus Therapeutics and 
Santaris Pharma, are developing therapeutics aimed at inhibiting miR-122 for the 
treatment of HCV infection in humans. Regulus Therapeuthics is developing a 
GalNAC-conjugated AMO-122 (RG-101) which entered a phase 1 study on healthy 
volunteers (http://www.regulusrx.com). Santaris Pharma is developing another 
antisense microRNA-122 drug, (miravirsen),62, 63 for which phase 1 and phase 2 trials 
have been completed. Phase 1 studies confirmed preclinical findings in rodents and 
nonhuman primates,62, 64 which showed good tolerability of the compound. The 
phase 2 trial in 36 patients with chronic HCV infection showed that miravirsen dose-
dependently reduced HCV RNA levels with long-lasting (>18 weeks) antiviral activity. 
However, the 4-week monotherapy (at a weekly dose of 7 mg/kg) was not sufficient 
to achieve a sustained response,65 with some patients displaying viral rebound by 
the end of the study. The patients were randomly assigned to receive five weekly 
subcutaneous injections of miravirsen at doses of 3, 5, or 7 mg per kg of body 
weight or placebo over a 29-day period. They were followed until 18 weeks after 
randomization.  
Altogether, these studies indicate that pharmacological inhibition of microRNA 
expression and activity can be achieved in a clinical setting, representing a feasible 
therapeutic strategy for patients. Nevertheless, various challenges still remain in the 
clinical use of microRNA-targeting drugs. The main technical hurdles are delivery, 
specificity and duration of action. Efficient in vivo delivery of therapeutic 
oligonucleotides is crucial for developing successful microRNA-based treatment 
modalities. In order to enter the cell, the oligonucleotide must travel across the lipid 
bilayer of the cell membrane. Currently, two strategies for microRNA delivery into 
the cell have been tested: conjugation and formulation. Conjugation approaches 
include attachment of lipophilic ligands that bind specific cell surface receptors 
increasing the rate of internalization into the cell whilst also allowing cell subset 
specific targeting. For instance conjugation of oligonucleotides to cholesterol has 
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been demonstrated to greatly enhance cellular uptake.66 Formulation strategies are 
mostly used when localized delivery is not possible and utilize supramolecular nano-
carriers, such as liposomes or polymeric nanoparticles.67 
At the current time, organ-specific targeting of oligonucleotides has only shown to be 
successful in the liver.43 In order to become of greater utility, effective delivery 
methods to other organs, especially the heart, are absolutely required. While 
conventional drugs are usually designed to be specific for a single cellular target (i.e., 
an enzyme or receptor), the fact that micro- RNAs have numerous downstream 
targets, many still to be identified, can lead to undesired effects. Understanding such 
effects is of major importance in developing microRNA-based therapies. Targeting a 
single microRNA might be a balance between beneficial and pathogenic effects. In 
vivo animal experiments have shown that administration of synthetic 
oligonucleotides results in long-lasting but reversible effects in non-human primates 
and mice.43, 68 Most studies used multiple daily-dosing regimens to efficiently reduce 
the level of the microRNA of interest for an extended period of time (3 weeks in mice 
and 7 weeks in African green monkeys). However, the fact that multiple injections 
are necessary for sustained effects may mean there is a limited possibility for a 
physician to intervene in case of unexpected or unwanted side effects. In theory this 
problem could be overcome by administration of sense microRNAs that would 
compete and neutralize AMO binding compared with its cell-associated target.  
The problems encountered with the tolerability of oligonucleotides have received 
little attention so far. Intravenous administration of oligonucleotides to humans has 
been reported to be associated with flu-like symptoms that increase in severity 
upon repeated dosing.69, 70 This mode of administration has been largely abandoned 
and replaced by subcutaneous dosing even though injection site reactions have 
been reported for all classes of oligonucleotides currently in the clinic.65, 69, 71 These 
injection site reactions appear to be related to an immunological memory response 
as upon increased dosing lesions appear not only at the site of administration but 
also at sites of previous injections.72, 73 This may ultimately limit the use of current 
AMOs in settings that require repeat or chronic administration. Another unresolved 
issue is the accumulation of oligonucleotides in proximal tubule cells of the kidney.74 
Although this is generally not associated with adverse clinical events, a few case 
reports of serious kidney problems occurring after administration of 
oligonucleotides in patients with Duchenne’s muscular dystrophy showed dose-
related proteinuria, suggesting that the effects on the kidney in humans may differ 
as such effects were not seen in preclinical models.73, 75 Thus, adequate evaluation 
of the physiological impact of long-term microRNA inhibition in vivo is key to the 
development of successful microRNA therapeutics.  
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A final consideration in the future development of drugs in this area is their 
potential high cost. Large sums of money have been spent in the research phase of 
microRNA-based oligonucleotide drugs and such costs may have to be recouped if 
and when they become approved for use in humans. The area of synthetic 
microRNA-based oligonucleotides is still in its infancy and while large-scale 
production of microRNA mimics and AMOs will lower the fixed costs, likely making 
them more attractive for clinical use, it remains unclear to what extend the costs 




Antisense inhibition of microRNAs by chemically modified oligonucleotides has 
proven to be a promising field of therapy for the treatment of cardiovascular 
diseases. It is a widely used tool in rodents to silence microRNA expression and 
thereby improve cardiac function. The high potency and metabolic stability of AMO 
technology emphasizes its potential to target microRNAs. Absence of toxicity in 
rodents, large animals and nonhuman primates suggests that AMO-based 
therapeutics could be safe as well as efficacious although it has yet to be confirmed 
that this translates into humans. The recent data from the phase II trial in HCV 
infected patients treated with miravirsen, an LNA against miR-122, is a milestone in 
the development of microRNA therapeutics. Therefore, it might be expected that 
the cardiovascular field will follow soon, marking the way toward microRNAs as a 
new class of drug targets for the treatment of people suffering with cardiovascular 
disease.  
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Heart failure, a major cause of morbidity, is preceded by ventricular remodeling, 
changes in left ventricular mass and volume of the myocardium in response to 
alterations in loading conditions. Concentric hypertrophy arises in pressure overload 
situations, involves wall thickening and often forms a substrate for left ventricular 
diastolic dysfunction. Eccentric hypertrophy develops in conditions of volume 
overload, results in wall thinning and chamber dilation and reduces ejection 
fraction. The molecular events that underlie these distinct forms of cardiac 
remodeling still remain poorly understood. Here, we demonstrate that expression 
of miR-148a changes dynamically in distinct subtypes of human and mouse forms of 
heart failure, where in human and mouse forms of concentric hypertrophy miR-
148a expression is elevated, while forms of dilated cardiomyopathy are 
accompanied by profoundly decreased miR-148a myocardial expression. In line, 
antagomir mediated silencing of miR-148a in vivo resulted in spontaneous wall 
thinning, chamber dilation and an increased volume of the left ventricle associated 
with a reduced ejection fraction. Additionally, adeno-associated viral (AAV) delivery 
of miR-148a protected the mouse heart from pressure overload-induced systolic 
dysfunction by preventing the transition of concentric hypertrophic remodeling 
towards dilation. Mechanistically, miR-148a targets the cytokine co-receptor 
glycoprotein 130 (gp130) and connects the responsiveness of cardiomyocytes to 
extracellular cytokines to activation of Stat3 signaling by altering the abundance of 
gp130. These findings show the ability of miR-148a to prevent the transition of 
pressure-overload induced concentric hypertrophic remodeling towards eccentric 
hypertrophy and dilated cardiomyopathy and provide evidence for the existence of 





Heart failure is a major cause of morbidity and death with little recent progress to 
reduce its high mortality. This disease is preceded by ventricular remodeling, 
changes in left ventricular mass and volume of the myocardium in response to 
alterations in loading conditions, with two distinct outcomes. Concentric 
hypertrophy results from cardiac growth and wall thickening which arises from 
pressure overload situations on the heart, as observed in patients with chronic 
hypertension, aortic valve stenosis or inherited forms of hypertrophic 
cardiomyopathy, and often yields a substrate for left ventricular diastolic 
dysfunction.1,2 Contrary, eccentric hypertrophy often develops under conditions of 
volume overload of the myocardium, with mitral- and aortic regurgitation or familial 
dilated cardiomyopathy as clinical correlates, resulting in pronounced systolic 
dysfunction and a concomitant decrease in ejection fraction.2 Pathological forms of 
concentric hypertrophy in certain hypertensive or aortic stenosis patients in time 
eventually gradually transform to eccentric remodeling of the heart and a 
worsening of prognosis.3 Despite this spectrum of clinically relevant cardiac 
remodeling phenotypes, the molecular events that underlie these distinct forms of 
cardiac hypertrophy still remain poorly understood.4 Accordingly, the stimulatory 
circulatory agonists, membrane-bound receptors and intracellular signaling 
cascades that connect biomechanical forces and the activation of myocardial stress 
pathways are central to understanding the initiation and progression to concentric 
versus eccentric hypertrophy. 
Cardiotrophin-1 (CT-1), a member of the interleukin-6 cytokine superfamily, exerts 
its pleiotropic functions using a gp130 homodimer or gp130/leukemia inhibitory 
factor receptor-β (LIFRβ) heterodimer, induces eccentric hypertrophy in cultured 
primary cardiomyocytes in vitro5-7 and exerts cardioprotective proliferative and 
survival effects in cultured embryonic, neonatal or adult cardiomyocytes.8 9-11 In 
vivo, CT-1 treatment induces left ventricular dilation in rats.12 In humans, increased 
CT-1 serum levels are observed in patients with unstable angina13, acute myocardial 
infarction14, hypertension, valvular diseases or heart failure15, correlated with the 
degree of left ventricular systolic dysfunction16,17 and left ventricular mass index in 
patients with dilated cardiomyopathy.18 19  
Cytokines of the interleukin-6 superfamily couple to gp130 receptors and confer a 
level of cellular protection against cell death mechanisms in a variety of cardiac 
stress conditions, and genetic deletion strategies of gp130 or downstream signaling 
components render widespread cell death in the myocardium in response to 
biomechanical stress.20-22 On the other hand, unrestrained activation of 
cytokine/gp130 signaling transmits prohypertrophic cues that facilitate the 
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transition to eccentric hypertrophy and systolic dysfunction23, suggesting that the 
expression of gp130 is determinant in the balance between cellular survival 
pathways versus maladaptive hypertrophic remodeling in the myocardium.  
Here, we demonstrate that cardiac expression of miR-148a alters dynamically in 
distinct subtypes of human and mouse forms of heart failure. In human and mouse 
forms of concentric hypertrophy miR-148a expression is elevated, while forms of 
dilated cardiomyopathy are accompanied by profoundly decreased miR-148a 
myocardial expression. In the heart, miR-148a targets gp130 and determines the 
extracellular cytokines responsiveness and cardiac signaling strength of canonical 
STAT3 hypertrophic signaling by altering the abundance of gp130. These findings 
provide evidence that myocardial miR-148a functions to prevent the transition of 
pressure-overload induced concentric hypertrophic remodeling towards eccentric 
hypertrophy and are proof of the existence of separable molecular cues that 






miR-148a is dynamically expressed in heart failure subtypes 
From microRNA profiling studies in human cardiac biopsies and mouse cardiac 
disease models, miR-148a-3p displayed opposite expression patterns depending on 
the type of heart disease studied. miR-148a is an intergenic microRNA, located on 
chromosome 6 or 7 in the murine and human genome, respectively, and distantly 
flanked by lncRNA genes (Fig.1a). The major mature miR-148a form in the heart is 
miR-148a-3p, which is fully conserved from the mouse to human genome, indicating 
an evolutionary pressure to resist variations in this microRNA gene (Fig.1a). 
Northern blotting revealed that miR-148a is broadly expressed in various tissues, 
with a relatively high expression in kidney, spleen and lung, to a lesser extent in liver 
and heart, and with traces of expression in brain, muscle and fat tissue (Fig.1b).  
Most remarkable, miR-148a displayed an opposite direction of differential 
expression in human cardiac biopsies of end-stage heart failure, with a pronounced 
decrease of miR-148a in left ventricular biopsies of dilated cardiomyopathy 
compared to healthy controls (Fig.1c), compared to a pronounced four-fold 
increased expression of miR-148a in the left ventricular myocardium of patients 
with hypertrophic cardiomyopathy compared to the respective healthy controls 
(Fig.1d). Next, we compared cardiac miR-148a expression differences in mouse 
models of dilated or hypertrophic cardiac remodeling. Cysteine and glycine-rich 
protein 3 (Csrp3), also known as Muscle LIM Protein, is a Z disc protein involved in 
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cardiac mechanical stretch sensing and required for proper cardiac geometry, 
energy metabolism and function. Mice homozygous null for Csrp3 develop early 
onset dilated cardiomyopathy and have been extensively used to study the 
pathophysiology of this subtype of heart failure. Csrp3 null mice displayed a very 
strong reduction of miR-148a in left ventricular tissue (Fig.1e). In contrast, mice 
harboring a constitutively activated mutant of Calcineurin A (CnA) under control of 
the myosin heavy chain promoter (Myh6-CnA) develop severe hypertrophic 
concentric remodeling soon after birth. Hearts from young Myh6-CnA mice revealed 
an increase in miR-148a expression (Fig.1f). Taken together, cardiac miR-148a 
abundance is increased in human and mouse forms of concentric hypertrophic 
cardiac remodeling and decreased in human and mouse forms of eccentric 
remodeling or dilated cardiomyopathy. 
 
miR-148a silencing provokes severe dilated cardiac remodeling 
To begin to address the involvement of miR-148a in cardiac remodeling, we made 
use of an antagomir to specifically silence endogenous miR-148a expression in vivo, 
a situation that mimics cardiac miR-148a reduction as observed in hearts from 
human and mouse models of dilated cardiomyopathy (Fig.1c,e). To this end, we 
designed chemically modified antisense oligonucleotides to target either 
Caenorhabditis elegans miR-39-5p as control antagomir (antagomir-ctrl or 
antagomir-Cel-39) or mmu-miR-148a-3p (antagomir-148a). Antagomirs (80 
mg/kg/day) were delivered by IP injection on three consecutive days to wild-type 
mice randomized to receive sham or transverse aortic constriction (TAC) surgery for 
six weeks (Fig.2a). Cardiac miR-148a expression was efficiently and specifically 
silenced (Fig.2b).  
Remarkably, antagomir-148a treatment sufficed to provoke a form of dilated 
cardiomyopathy already in sham-operated mice as evidenced by increased cardiac 
geometry and mild fibrosis at six weeks after sham operation (Fig.2c). As expected, 
upon TAC surgery the heart weight to body weight ratio increased, however this 
was not further affected by the antagomir-148a treatment (Fig.2d). Analysis of 
cardiac function by Doppler/echocardiography revealed that antagomir-148a 
treated animals show a mildly reduced systolic contractile function (Fig.2e, Table1), 
provoked LV dilation accompanied by increased LV volumes (Fig.2f,g). As expected, 
TAC surgery in mice treated with a control antagomir provoked transient 
hypertrophic remodeling with relatively well-preserved cardiac function at three 
weeks (Table1). Six weeks of TAC surgery in mice treated with a control antagomir 
resulted in severe myocyte disarray, interstitial fibrosis, systolic and diastolic 
dysfunction, left ventricular dilation, increased heart weight as well as an induction 
of a “fetal” gene program (Fig.2c-h, Table1). Strikingly, cardiac histopathology, 
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cardiomyocyte hypertrophy, contractile function, the extent of left ventricular 
dilation and left ventricular volumes were exacerbated upon TAC surgery in the 
presence of miR-148a silencing (Fig.2c-h, Table1), without discernable differences 
between the level of activation of classical “fetal” gene programs in hearts from 
mice receiving TAC surgery and receiving a control antagomir versus hearts from 
mice receiving TAC surgery and receiving antagomir-148a (Fig.2h). Taken together, 
these data demonstrate that miR-148a silencing in vivo evokes mild cardiac dilation 
under baseline conditions in sham-operated mice and produced exacerbation of 
pressure overload-induced cardiac remodeling and dysfunction. 
 
miR-148a overexpression suppresses pressure overload-induced cardiac dilation 
Next, we mimicked the increased expression of miR-148a as observed in conditions 
of concentric cardiac remodeling in human hypertrophic cardiomyopathy (Fig.1d,f). 
To this end, we made use of the high cardiac tropism and prolonged expression of 
viral vectors based on adeno-associated virus (AAV) serotype 9 upon systemic 
delivery. AAV9 vectors expressing mmu-miR-148a or a control vector were 
administered intravenously via injection into the internal jugular vein of adult mice 
(Fig.3a). The hearts of AAV-148a injected animals displayed an induction of miR-
148a of 4 fold over control on average (Fig.3b) and appeared morphologically 
normal with no signs of cardiomyocyte hypertrophy, changes in collagen content or 
capillary density (Fig.3c and data not shown), indicating that increased miR-148a 
alone is not an active driver of cardiac hypertrophy in vivo in the absence of further 
stimuli.  
To analyze miR-148a cardiac function under forced stimulation, AAV9-148a and 
AAV9-MCS animals were randomized to receive sham or TAC surgery. Six weeks of 
TAC surgery in AAV9-MCS mice resulted in increased heart weight, severe myocyte 
disarray, interstitial fibrosis, increased cardiomyocyte size, systolic and diastolic 
dysfunction, left ventricular dilation, as well as an induction of the classical “fetal” 
gene program (Fig.3c-g, Table2). Strikingly, cardiac histopathology, cardiomyocyte 
hypertrophy, systolic function, the extent of left ventricular dilation and left 
ventricular volumes were clearly attenuated in AAV9-148a injected mice after TAC 
surgery (Fig.3c-g, Table2). AAV9-148a treated hearts only displayed an induction of 
the “fetal” gene Nppa at baseline compared to hearts from AAV9-MCS mice. A more 
pronounced induction of transcripts encoding Nppa or Myh7 as part of the “fetal” 
gene program was observed in hearts from AAV9-148a injected mice receiving TAC 
surgery, but no differences were observed in Nppb or Acta1 transcript abundance 
(Fig.3h). Taken together, these data demonstrate that elevation of cardiac miR-148a 
expression in vivo protects the myocardium from dilation and cardiac dysfunction 
following pressure overload. 
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miR-148a directly targets cardiac glycoprotein 130 (gp130)  
To understand the mechanistic role of miR-148a in suppressing cardiac dilatation, 
we analyzed bioinformatics databases to search for miR-148a binding sites in 
cardiac expressed transcripts. MicroRNAs exert their action by regulating gene 
expression at the post-transcriptional level by imperfect base pairing with protein-
coding transcripts. We identified an enrichment of three putative miR-148a seed 
regions in interleukin 6 signal transducer (Il6st), better known as glycoprotein 130 
(gp130). The more proximal miR-148a binding site in the ~2.5 kb gp130 3’UTR 
demonstrated a perfect match for the miR-148a heptametrical seed sequence and 
showed complete evolutionary conservation (Fig.4a). To more directly establish the 
regulation of gp130 by miR-148a in the myocardium, we generated series of 
luciferase reporters harboring either the complete or truncated forms of the gp130 
3’UTR, including a reporter with site-directed mutagenesis of key nucleotides in the 
miR-148a binding site (Fig.4b). Transient transfection of synthetic precursor miR-
148a in cultured Cos7 cells decreased gp130 3’UTR reporter activity when either the 
intact ~2.5 kb 3’UTR or a distal truncation was coupled to luciferase compared to 
co-transfection with scrambled precursor molecules (Fig.4c). In contrast, a proximal 
truncation of the gp130 3’UTR, harboring two putative miR-148a binding sites, as 
well as a site-directed mutant of the complete gp130 3’UTR, remained unresponsive 
to synthetic precursor miR-148a molecules (Fig.4c). In line, endogenous gp130 
protein expression in primary cardiomyocytes was derepressed by transfection of 
miR-148a antimir molecules, while pretreatment with miR-148a precursor 
molecules provoked significant downregulation of endogenous gp130 at the protein 
level (Fig.4d). 
The gp130 co-receptor couples the responsiveness of the heart to cytokines from 
the interleukin-6 (IL-6) family, including IL-6, leukaemia inhibitory factor (LIF), 
oncostatin M or cardiotrophin-1, and intracellular MAPK, PI3K or JAK/STAT signaling 
by homodimerisation or heterodimerisation with LIF receptors at the cell surface. 
Cardiotrophin 1 (CT-1)-mediated gp130 activation and signaling is well known to 
induce eccentric hypertrophic remodeling and chamber dilatation. Despite clinical 
and experimental evidence that CT-1 levels are elevated in plasma and myocardium 
of patient with heart failure, direct evidence that CT-1 is sufficient to promote 
aspects of cardiac disease in vivo is conspicuously lacking in literature. To address 
whether miR-148a expression attenuates eccentric cardiac remodeling by 
attenuating gp130 responsiveness to CT-1, we compared cardiac phenotypes of 
mice that were either left untreated, infused with 20 µg/kg/day of CT-112 or infused 
with 60 mg/kg/day isoproteronol24 for two weeks (Fig. 4e). The data demonstrate 
that isoproterenol exposure produced a classical cardiac hypertrophy response 
accompanied by increased cardiac mass and wall thickening, interstitial fibrosis, and 
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reduced ejection fraction (Fig.4f-i). Remarkably, sustained CT-1 exposure produced 
typical features of eccentric remodeling with mild cardiac enlargement, wall 
thinning and severe systolic dysfunction (Fig.4f-i). Having established that CT-1 is a 
direct stimulator of eccentric cardiac remodeling in vivo, we observed that primary 
cardiomyocytes responded to CT-1 with a mild hypertrophic response in vitro, which 
was clearly attenuated by transfection of synthetic precursor miR-148a molecules 
(Fig.4j,k). Taken together, these data provide evidence for miR-148a-based 
regulation of gp130 expression in the adult heart, influencing the responsiveness of 
the heart to the pro-hypertrophic agonist CT-1. 
 
miR-148a dynamically influences gp130 downstream signaling  
The CT-1/gp130 co-receptor axis has been reported to result in ERK1/2 or ERK5 
MAPK, PI3K/Akt or JAK/STAT3 downstream signaling activation in the heart 11. miR-
148a expression was found increased in forms of concentric hypertrophic cardiac 
remodeling, while its expression was downregulated in forms of eccentric cardiac 
remodeling (Fig.1). To mimic this dynamic expression pattern in vivo and study the 
ramifications of differential miR-148a expression on gp130 expression levels and 
downstream signaling events in the intact heart, we subjected cohorts of mice to 
pressure overload by TAC, serially assessed cardiac geometry and function and 
sacrificed mice at 0 weeks (sham) or 2, 4, 6 or 8 weeks of TAC to measure cardiac 
miR-148a expression and evaluate the activation status of signaling cascades (Fig.5a). 
In line with our previous observations25-27, concentric hypertrophic remodeling with 
sustained systolic function was evident in mice in the first four weeks following TAC 
surgery, which gradually transitioned to eccentric remodeling and loss of systolic 
contractile performance. First, miR-148a expression gradually increased up to ten 
fold in pressure-overloaded hearts following 2 or 4 weeks of TAC compared to hearts 
from sham-operated mice (Fig.5b). In this time period, pressure-overloaded hearts 
increased in heart mass but still displayed sustained systolic function and showed no 
signs of left ventricular dilation, consistent with concentric hypertrophic remodeling 
(Fig.5c-e). More prolonged periods of pressure overload induced a subsequent steep 
reduction of cardiac miR-148a expression, resulting in a significantly lower miR-148a 
expression at 8 weeks of pressure overload compared to sham-operated mice 
(Fig.5b). Interestingly, at 6 and 8 weeks following TAC, when miR-148a expression 
steeply reduced, left ventricular mass did not change further but systolic function 
was drastically reduced and hearts displayed substantial left ventricular dilation 
concordant with eccentric cardiac remodeling (Fig.5c-e). Conclusively, in sustained 
pressure overload, concentric cardiac remodeling in early phases correlated with 
high miR-148a expression, while eccentric cardiac remodeling in later phases 
correlated with low expression of miR-148a.  
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Using this model of transient elevation and reduction of miR-148a accompanied 
with a phenotypic switch from concentric to eccentric cardiac remodeling, we 
assessed expression and activation status of the CT-1/gp130 co-receptor axis. The 
data show that cardiac CT-1 levels gradually increases in time with the pressure 
overload stimulus (Fig.5f). Interestingly, the expression of the direct miR-148a 
target gene gp130 was reduced by ~50% at week 4 after TAC, a time point that 
coincides with the highest induction of cardiac miR-148a expression (Fig.5g). No 
changes in LIF receptor expression were evident during this time period 
(Suppl.Fig.1a), further lending support to the specificity of the interaction between 
miR-148a and gp130. A reduction in gp130 expression would be expected to result 
in ramifications in the activation status of downstream ERK1/2 or ER5 MAPK, 
PI3K/Akt or JAK/STAT3 signaling. Indeed, in this model of sustained pressure 
overloading, a reduction in both phosphorylated STAT3 (Fig.5h) and phosphorylated 
Akt (Suppl.Fig.1b), but not total STAT3 or Akt expression, was evident at early time 
points after TAC, which coincided with the highest induction of cardiac miR-148a 
expression and lowest expression of gp130 (Fig.5b,g). No changes in ERK5 or ERK1/2 
activation were evident at the time points analyzed (Suppl.Fig.1c,d). 
Next, we also verified gp130 expression levels and STAT3, Akt, ERK5 or ERK1/2 
MAPK activation status in hearts from mice that received antagomir to specifically 
silence endogenous miR-148a expression in vivo, a situation that mimics miR-148a 
reduction as observed in hearts from human and mouse models of dilated 
cardiomyopathy. In sham-operated mice receiving antagomir-148a, which 
spontaneously produced features of eccentric cardiac remodeling, gp130 protein 
expression as well as increased activation of STAT3 and ERK1/2 was evident (Fig.5i, 
Suppl.Fig.1e). No clear differences in downstream signaling of antagomir-148a on 
the pressure-overloaded myocardium were evident. Finally, we compared gp130 
expression levels and STAT3, Akt, ERK5 or ERK1/2 MAPK activation status in hearts 
from pressure-overloaded mice that AAV9-MCS or AAV9-148a to increase 
endogenous miR-148a expression in vivo, a situation that mimics the situation we 
observed in hearts from human and mouse models of concentric cardiac 
remodeling. Here, a clear reduction in gp130 expression and a reduction in the 
activation status of STAT3 were evident (Fig.5j, Suppl.Fig.1f). Combined, our data 
reveal that miR-148a expression regulates cardiac gp130 expression and alters the 
responsiveness of the heart to cardiotrophin-1 stimulation and downstream STAT3 
signaling strength, where relatively high miR-148a expression produces forms of 
concentric hypertrophic remodeling and dampens CT-1 overstimulation with 





Here, we demonstrate that cardiac expression of miR-148a alters dynamically in 
distinct subtypes of human and mouse forms of heart failure, with high miR-148a 
expression in human and mouse forms of concentric hypertrophy and decreased 
miR-148a expression in forms of dilated cardiomyopathy. Mechanistically, miR-148a 
targets an evolutionary conserved heptametrical seed region in gp130, a pivotal co-
receptor for cytokines of the interleukin 6 superfamily, and determines the coupling 
between extracellular cardiotrophin-1 and cardiac signaling strength of the 
canonical STAT3, Akt, Erk5 and Erk1/2 hypertrophic cascades by altering the 
abundance of gp130. Using complimentary gain- and loss-of-function studies for 
miR-148a in the mouse, we demonstrate that the abundance of miR-148a, and 
consequently gp130, connects sustained biomechanical forces to diverse forms 
myocardial remodeling, with an overall conclusion that miR-148a expression acts as 
a protective molecular driver that promotes wall thickening and concentric 
remodeling. Vice versa, lowering of cardiac miR-148a expression results in increased 
gp130 expression leading to enhanced gp130-coupled intracellular signaling, and 
incites wall thinning and chamber dilation with the associated increase in stress on 
the ventricular wall, representing the first irreversible steps towards overt heart 
failure in dilated cardiomyopathy. Our findings are proof of the existence of 
separable molecular programs primary to concentric hypertrophy versus eccentric 
hypertrophy, chamber narrowing versus chamber dilation and wall thickening 
versus wall thinning, all occurring within the venue of biomechanical driven 
pathways of cardiac growth and failure. 
Cardiac remodeling in patients with heart disease encompass all quantifiable 
changes in left ventricular mass and volume, with a wide variety in the ratio of left 
ventricular wall thickness to chamber radius, often referred to as relative wall 
thickness (RWT), and diagnosed by echocardiographic, and cardiac magnetic 
resonance imaging (MRI) data.3 A normal left ventricular chamber size refers to 
normal geometry; differences in RWT distinguish concentric from normal and from 
eccentric remodeling. Concentric hypertrophy tend to arise from pressure overload 
situations on the heart, as observed in patients with aortic valve stenosis or 
hypertensive heart diseases, often yielding a substrate for left ventricular diastolic 
dysfunction. In contrast, eccentric hypertrophy develops secondary to conditions of 
volume overload of the myocardium, clinically observed in mitral and aortic 
regurgitation, precipitating in a strong reduction of ejection fraction.3 Despite the 
existence of a relatively detailed clinical diagnosis and physiological underpinnings 
of this spectrum of clinically relevant remodeling phenotypes, the molecular events 
that underlie distinct forms of cardiac hypertrophy still remain poorly charted.28 
Accordingly, the stimulatory circulatory agonists, membrane-bound receptors and 
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intracellular signaling cascades that connect biomechanical forces and the activation 
of myocardial stress pathways are central to understanding the initiation and 
progression to concentric hypertrophy as clinically observed in hypertrophic 
cardiomyopathies versus eccentric hypertrophy as it occurs in forms of dilated 
cardiomyopathy. 
In the heart, cardiotrophin-1 signals through a gp130 homodimer or 
gp130/leukemia inhibitory factor receptor-β (LIFRβ) heterodimer in cultured 
cardiomyocytes and was reported to induce a peculiar form of hypertrophy with 
increased cardiomyocyte size that is characterized by an increase in cell length but 
no significant change in cell width due to the assembly of sarcomeric units in series 
rather than in parallel, as is more commonly observed following stimulation with 
the canonical pro-hypertrophic adrenergic agonists or endothelin-1.6,7 The 
involvement of ERK5 and STAT3 in cardiotrophin-1-induced longitudinal elongation 
has been reported in adult cardiomyocytes7, and it is further supported by the 
molecular observation that overexpression of activated ERK5 induces serial 
insertion of sarcomeres in neonatal cardiomyocytes in vitro.29 Interestingly, STAT3 
upregulates ERK5 in other cell types (Song H, Oncogene 2004). Thus, the possibility 
that STAT3 mediates the longitudinal elongation through the downstream activation 
of ERK5, which determines cardiomyocyte elongation, requires further 
investigations. These morphological differences find a basis in the activation of 
distinct signaling cascades and proteomic outcomes between cytokines from the 
interleukin-6 superfamily or endothelin-1.30 Elongated cardiomyocytes, myocardial 
dilation and decreased ejection fraction were also evident following 6 weeks of 
cardiotrophin-1 treatment in rats.7 In line, in the current study we developed and 
characterized a mouse model with continuous cardiotrophin-1 infusion at a clinically 
relevant concentration of 20 µg/kg/day, which displayed the hallmarks of eccentric 
hypertrophy after two weeks: wall thinning, severe chamber dilation and a stark 
reduction in ejection fraction, in line with LV chamber dilatation and decreases 
ejection fraction in rats following continuous infusion of cardiotrophin-1. The 
cardiotrophin-1 infusion rodent models may proof useful for future studies 
examining the biochemical, geometric or functional ramifications of distinct 
hypertrophic agonists on the myocardium. 
Genetic studies on the involvement of gp130 in cardiac remodeling reveal a 
requirement of gp130-dependent signaling for myocyte survival pathways, on the 
one hand, as well as transmitting prohypertrophic signals, on the other. Indeed, 
myocyte-restricted deletion of gp130 yields massive apoptotic cell death and rapid 
onset of dilated cardiomyopathy following biomechanical stress.20 Heart-restricted 
overexpression of a dominant negative form of gp130 suppressed many molecular 
and morphological features of pressure overload-induced concentric hypertrophic 
70 
remodeling.21 The molecular decision between survival and hypertrophy is 
regulated by the interplay between gp130-mediated JAK/STAT activation and 
suppressor of cytokine signaling 1/3 (SOCS1/3), intrinsic JAK inhibitors and negative 
feedback regulators for gp130 signaling. Adenovirus-mediated gene transfer of 
SOCS3 to ventricular cardiomyocytes completely suppressed both hypertrophy and 
antiapoptotic phenotypes in cultured cardiomyocytes induced by leukemia 
inhibitory factor (LIF).31 Adeno-associated viral transfer of SOCS1 dampened 
JAK/STAT activation and the transition of hypertrophy to failure in a pressure 
overload model in vivo.32 Cardiac-specific SOCS3 knockout mice demonstrated 
enhanced activation of the signaling targets STAT3, Akt, ERK1/2 - and p38 MAPK and 
spontaneous cardiac eccentric remodeling, occurrence of arrhythmias and signs of 
heart failure, all of which were dependent on the presence of gp130, since 
SOCS3/gp130 double knockout mice displayed suppression of the cardiomyopathic 
phenotype.33 Further downstream of gp130, a variety of signaling branches are 
differentially activated by IL-6 cytokines, including the ERK1/2, p38 and ERK5 MAPK 
terminal branches, JAK/STAT3, PI3K/Akt, Gab1/SHP2 and RhoA.11,34,35 In line, Mek5 
transgenic mice displayed a severe form of eccentric remodeling with wall thinning, 
chamber dilation and severe fibrosis29, a phenotype that was largely recapitulated 
by silencing endogenous miR-148a using an antagomir strategy in the current study. 
In contrast, STAT3-deficient mice spontaneously develop signs of injury, 
inflammation and cardiac dysfunction with advancing age and in response to cardiac 
stress. Accordingly, the prevailing message supports a model where IL-6 
cytokine/gp130 confers a level of protective signaling in a variety of cardiac stress 
conditions, and that complete (genetic) deletion of gp130 signaling components 
causes widespread cell death. On the other hand, unrestrained activation of 
cytokine/gp130 signaling also confers prohypertrophic cues that facilitate the 
transition to eccentric hypertrophy and systolic dysfunction in situations of 
biomechanical stress. This model of cytokine/gp130 signaling is in line with a 
regulatory function of cardiac miR-148a, where higher miR-148a expression, and 
concomitantly reduced gp130 expression, sustains the protective cell survival 
effects while dampens over-activation of downstream signaling cascades, yielding 
concentric forms of hypertrophy. With sustained periods of biomechanical stress, 
decreased miR-148a expression, and concomitant derepression of gp130, promotes 
over-activation of a variety of hypertrophic intracellular signals, yielding eccentric 
hypertrophic remodeling, dilated cardiomyopathy and systolic dysfunction. As such, 
the biphasic regulation of miR-148a provides a mechanistic explanation for the 
clinically observed transition from early phase “compensatory” forms of 
hypertrophy to later phase decompensation and overt heart failure in the setting of 
sustained biomechanical stress. 
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Materials and Methods 
Human heart samples. Approval for studies on human tissue samples was obtained 
from the Medical Ethics Committee of the University Medical Center Utrecht, The 
Netherlands. All patients or their relatives gave written informed consent before 
operation. In this study, we included tissue from the left ventricular free wall of 
patients with end-stage heart failure secondary to ischemic heart disease. Control 
tissue was taken from the left ventricular free wall of refused donor hearts. Failing 
hearts were also obtained from patients undergoing heart transplantation because 
of terminal heart failure. Non-failing donor hearts that could not be transplanted for 
technical reasons were used for comparison, where neither donor patient histories 
nor echocardiography revealed signs of heart disease. 
 
Mouse models. Mice used in this study were male and female B6CBAF1 wild-type 
mice (Charles River Laboratories) of 2–6 months of age. Other mice used in this 
study were male calcineurin transgenic mice in a B6CBAF1 background expressing 
an activated mutant of calcineurin in the postnatal heart under control of the 5.5 kb 
murine Myh6 promoter (Myh6-CnA36). Sample size was determined by a power 
calculation based on an echocardiographic effect size. Randomization of subjects to 
experimental groups was based on a single sequence of random assignments. 
Animal caretakers and investigators were blinded to group allocation during the 
experiment and/or when assessing the outcome. All protocols were performed 
according to institutional guidelines and approved by local Animal Care and Use 
Committees. All mice were housed were housed on a 12hr:12hr light:dark cycle in a 
temperature-controlled environment with ad libitum access to water and chow at 
Innoser Netherlands BV, a commercial mouse breeding company with a quarterly 
animal health monitoring system that complies with FELASA guidelines and 
recommendations. 
 
Aortic banding, CT-1 infusion and transthoracic echocardiography. Transverse 
aortic constriction (TAC) or sham surgery was performed in 2-month-old wildtype 
B6CBAF1 female and male mice by subjecting the aorta to a defined 27-gauge 
constriction between the first and second truncus of the aortic arch, as described 
previously.25,37 For Doppler-echocardiography, mice were shaved, lightly 
anaesthetized with isoflurane (mean 1% in oxygen) and allowed to breathe 
spontaneously through a nasal cone. Non-invasive, echocardiography was 
performed as describes previously in detail.26 Doppler was used to calculate the 
pressure gradient between the proximal and distal sites of the transverse aortic 
constriction and only mice with a pressure gradient >50 mm Hg were included. 
Chronic cardiotrophin 1 (20 µg/kg/day dissolved in phosphate-buffered saline), 
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isoproterenol (60 mg/kg/day dissolved in phosphate-buffered saline) or saline 
administration was performed using Alzet miniosmotic pumps (no. 2002; Alza) 
surgically inserted dorsally and s.c. in 2-month-old wild-type B6CBAF1 female and 
male mice under isoflurane anesthesia and left for an additional 2 weeks. All 
protocols were performed according to institutional guidelines and approved by 
local Animal Care and Use Committees. 
 
Antagomir studies. Chemically modified antisense oligonucleotides designed to 
target mmu-miR-148a-3p (5′-ACAAAGUUCUGUAGUGCAC-3′/3CholTEG-3′ or 
C.elegans miR-39-5p (5′-AAGGCAAGCUGACCCUGAAGUU-3′/3CholTEG-3′) with a 3′ 
cholesterol conjugation and 2 phosphorothioate bonds at the very first 5′ end and 4 
phosphorothioate bonds between the last 3′ bases 38 were synthesized at Integrated 
DNA Technologies (IDT). All antagomirs were HPLC purified and desalted before use. 
Female and male wild-type B6CBAF1 mice (8–10 weeks of age) were subjected to 
sham or TAC surgery. Following 3 days, mice were injected (intraperitoneally) with 
antagomir-148a (80 mg kg−1 body weight) or control antagomir (80 mg kg−1 body 
weight) for 3 consecutive days. Echo analysis was performed at 3 weeks and 6 
weeks after surgery.  
 
AAV Vectors. All of the AAV vectors used in this study were generated by the 
International Centre for Genetic Engineering and Biotechnology (ICGEB) AAV Vector 
Unit (AVU) (www.icgeb.org/avu-core-facility.html) using a dual/triple plasmid 
cotransfection procedure followed by PEG precipitation and purification through 
CsCl2 gradient centrifugations as described previously.39 Adult mice were 
intravenously injected with AAV9-MCS and AAV9-miR-148a via the jugular vein at a 
dose of 1x1012 viral genome particles per animal. 
 
Primary cardiomyocytes cultures and immunocytochemistry. Cardiomyocyte 
cultures were isolated by enzymatic dissociation of 1–2-day-old neonatal rat hearts 
and processed for immunofluorescence microscopy as described previously.40 
Neonatal cardiomyocytes were transfected with precursors (Ambion) and inhibitors 
(Exiqon) of microRNAs (10 nM) using Oligofectamine (Invitrogen). For visualization 
of cardiomyocyte size and sarcomeric organization, the cells were stained for α2-
actinin with mouse monoclonal anti-sarcomeric α-actinin antibody (Sigma-Aldrich, 
A7811 clone EA-53, 1:500) followed by rat anti-mouse phenylephrine–Texas red-
conjugated monoclonal antibody (Life Technologies, RM2817 clone M1/70.15, 
1:800). Nuclear staining was performed with VECTASHIELD Mounting Medium 
(Vector Laboratories) containing 4′,6-diamidino-2-phenylindole (DAPI). Myocyte 
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hypertrophy was induced by stimulation for 24 h with phenylephrine (10 μM) as 
described previously40 or with Cardiotrophin-1 (CT-1, 2nM).  
 
pMIR-reporter assays. Cos7 cells were purchased at the American Type Culture 
Collection (ATCC; CRL-1651) and cultured in DMEM supplemented with 10% FBS, 
100 units/ml penicillin/streptomycin and 2 mmol/liter L-glutamine (Thermo 
Fischer). Cos7 cells were screened for mycoplasma with the MycoAlert PLUS 
Mycoplasma Detection kiet (Lonza) upon receipt from ATCC and subsequently 
checked on a yearly basis. Cos7 cells were transfected with pMIR reporter plasmids 
harboring the entire 3′ UTR of mouse gp130, or with pMIR reporter plasmids 
harboring the first part of the 3′ UTR of mouse gp130, or with pMIR reporter 
plasmids harboring the latter section of the gp130 3′ UTR using X-tremeGENE 9 
(Roche) transfection reagent, followed by transfection with miR-148a or scrambled 
miR precursor molecules using Oligofectamine reagent (Thermo Fisher). Luciferase 
activity was measured 24 h after transfection with a dual luciferase assay kit 
(Promega) using Renilla luciferase as internal control to correct for transfection 
efficiency. 
 
Northern blot analysis. Northern blotting was performed as described previously26 
using 3′-digoxigenin-labelled locked nucleic acid oligonucleotides for miR-
148a and U6 small nuclear RNA (Rnu6-2). Detection was achieved with Fab 
fragments from polyclonal anti-digoxigenin antibodies, conjugated to alkaline 
phosphatase (Roche). 
 
Western blot analysis. SDS PAGE electrophoresis and blotting were performed as 
described previously.7 Primary antibodies that were used included anti-gp130 (Cell 
Signaling Technology; rabbit pAb cat. no. 3732), anti-LIFR (Santa Cruz Biotechnology; 
mouse mAb cat sc-515337), anti-CT-1 (Santa Cruz Biotechnology; mouse mAb cline 
AN-B3 cat. no. sc-9991), anti-GAPDH (Millipore; mouse mAb clone 6C5, cat. no. 
MAB374), anti-STAT3 (Cell Signaling Technology; mouse mAb clone 124H6, cat. no. 
9139), anti-phospho-STAT3 (p-Tyr705) (Cell Signaling Technology; mouse mAb clone 
M9C6 cat. no. 4113), anti-Akt (Cell Signaling Technology; mouse mAb clone 2H10 
cat. no. 2967), anti-phospho-Akt (pSer473) (Cell Signaling Technology; rabbit mAb 
clone D7F10 cat. no. 9018), anti-p44/42 MAPK (ERK1/2) (Cell Signaling Technology; 
rabbit mAb clone 137F5 cat. no. 4695), anti-phopsho-p44/42 MAPK (p-Thr202-204-
Erk1/2) (Cell Signaling Technology; rabbit mAb clone D13.14.4E cat. no. 4370), anti-
ERK5 (Cell Signaling Technology’ rabbit mAb clone D3I5V cat. no. 12950), anti-
phospho-ERK5 (p-Thr218/Tyr220) (Cell Signaling Technology; rabbit pAb cat. no. 
3371) followed by corresponding horseradish peroxidase (HRP)-conjugated 
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secondary antibodies and enhanced chemiluminescence ECL detection. Western 
Blots were performed with Stain Free gels for loading control. Signals were detected 
using the ECL system (Amersham Pharmacia Biotech; Piscataway, NJ, USA). Results 
are expressed as an n-fold increase over the values of the control group in 
densitometric arbitrary units.  
 
Quantitative real-time PCR. Total RNA (1 μg) was applied to either miR-based or 
mRNA-based reverse transcription. Real-time PCR was performed on a BioRad 
iCycler (Biorad) using SYBR Green. Transcript quantities were compared using the 
relative Ct method, where the amount of target normalized to the amount of 
endogenous control (L7) and relative to the control sample is given by 2–ΔΔCt. For 
microRNA real-time PCR, miRNAs were isolated with TRIzol reagent (Invitrogen) and 
cDNA was generated with the miScript Reverse Transcription Kit (Qiagen). For real-
time PCR detection of miRNAs, miScript Primer Assays and the miScript SYBR Green 
PCR Kit (Qiagen) were used.  
 
microRNA target prediction. Putative microRNA-148a target genes were identified 
using the microRNA databases and target prediction tools miRBase 
(http://microrna.sanger.ac.uk/), PicTar (http://pictar.mdc-berlin.de/) and 
TargetScan (http://targetscan.org/index.html). 
 
Histological analysis and (immunofluorescence) microscopy. Hearts were arrested 
in diastole, perfusion fixed with 4% paraformaldehyde/PBS solution, embedded in 
paraffin and sectioned at 4 μm. Paraffin sections were stained 
with haematoxylinand eosine for routine histological analysis; Sirius red for the 
detection of fibrillar collagen; and FITC-labelled wheat-germ-agglutinin (Sigma-
Aldrich, 1:100) to visualize and quantify myocyte cross-sectional area. Slides were 
visualized using a Zeiss Axioskop 2Plus with an AxioCamHRc. Cell surface areas were 
determined using ImageJ imaging software (http://rsb.info.nih.gov/ij/). 
 
Statistical analysis. The results are presented as mean ± standard error of the 
mean. Statistical analyses were performed using Prism software (GraphPad 
Software Inc.), and consisted of ANOVA followed by Bonferroni’s Multiple 
Comparison Test when group differences were detected at the 5% significance level, 
or Student’s t-test when comparing two experimental groups. For Western blots 
analysis, normality of distributions was verified by means of the Kolmogorov–
Smirnov test. Data were analyzed using a one-way analysis of variance, followed by 
a Newman-Keuls to assess specific differences among groups. Differences were 
considered significant when P<0.05. 
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THE PAPER EXPLAINED 
 
Problem  
The heart responds to stress situations by altering its mass, volume and geometry 
with two outcomes. In patients with chronic hypertension, aortic valve stenosis or 
inherited forms of hypertrophic cardiomyopathy, the heart walls typically thickens 
and displays abnormalities in relaxation in a process called concentric hypertrophic 
remodeling. In contrast, in patients with valvular disease or inherited forms of 
dilated cardiomyopathy, the heart walls typically become thinner, the chamber 
volume increases and systolic contraction force reduces in a process called eccentric 
hypertrophic remodeling. Although these subsets of myocardial remodeling have 
different clinical outcomes, virtually no information is available on the molecular 
events that distinguish concentric versus eccentric cardiac remodeling. 
Results  
Here, we demonstrate that the expression of a non-coding RNA gene, microRNA-
148a (miR-148a), alters in opposite fashion in these two distinct subtypes of human 
and mouse forms of cardiac remodeling. In concentric hypertrophy miR-148a 
expression is elevated, while in forms of dilated cardiomyopathy myocardial miR-
148a expression is strongly reduced. MicroRNAs target protein-coding messenger 
RNAs and control the translation of their protein. Mechanistically, we found that 
miR-148a is able to reduce the expression of the cytokine co-receptor glycoprotein 
130 (gp130). When miR-148a expression is relatively high, gp130 expression is 
reduced, rendering cardiac muscle cells less responsive to cytokine stimulation by 
cardiotrophin-1, which promotes eccentric cardiac remodeling. Conversely, reduced 
miR-148a expression allows increased expression of gp130, increased sensitivity to 
cardiotrophin-1 stimulation, increased intracellular Stat3 signaling and increased 
eccentric remodeling.  
Impact 
These results demonstrate that miR-148a can reduce the transition of concentric 
hypertrophic remodeling towards eccentric hypertrophy and molecular programs 
exist that distinguish between these two opposite forms of cardiac remodeling. 
Additionally, new therapeutic approaches aimed to maintain myocardial miR-148a 
expression elevated in cardiac stress may protect the heart from eccentric 
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Figure 1 | MicroRNA-148a is downregulated in heart failure. (a) Schematic 
representation of the genomic localization and precursor sequence of mmu-miR-
148a located on the opposite strand on chromosome 6 in the mouse genome. The 
mature miR-148a-3p strand is conserved among several species. (b) Northern blot 
analysis of miR-148a-3p expression in diverse mouse organs. (c) RT-PCR analysis of 
miR-148a-3p expression in non-failing and dilated cardiomyopathy human left 
ventricular myocardium. (d) RT-PCR analysis of miR-148a-3p expression in non-
failing and hypertrophic cardiomyopathy human left ventricular myocardium. (e) 
RT-PCR analysis of miR-148a-3p expression in hearts from wild-type and Csrp3 
knockout mice, the gene encoding muscle LIM protein (MLP). (f) RT-PCR analysis of 
miR-148a-3p expression in hearts from 3 week-old non-transgenic littermates and 
Myh6-CnA transgenic mice.  
Data information: Data are means ± SEM. Student’s paired 2-tailed t-test was used 
to compare groups. n, number of hearts; RT-PCR, real-time-polymerase chain 
reaction; NF, non failing; DCM, dilated cardiomyopathy; HCM, hypertrophic 
cardiomyopathy; Csrp3, cysteine and glycine-rich protein 3; Myh6, alpha myosin 
heavy chain; CnA, calcineurin. *P < 0.05 vs corresponding control group.  
 
Figure 2 | miR-148a silencing promotes spontaneous eccentric hypertrophic 
remodeling and dilated cardiomyopathy in vivo. (a) Design of the study. Two-
month-old wild-type mice were injected with a control antagomir targeting C. 
elegans miR-39 (antagomir-Cel-39) or and antagomir against mmu-miR-148a-3p and 
subjected to sham or TAC surgery. Cardiac geometry and function was determined 
by serial Doppler echocardiography at 3 weeks and 6 weeks after surgery. (b) RT-
PCR analysis of miR-148a and unrelated let-7b expression in hearts from mice 
receiving control antagomir (antagomir-Cel-39) or antagomir against miR-148a. (c) 
Representative images of whole hearts (top panels), H&E-stained sections of four-
chamber view (second panel), high-magnification H&E-stained sections (third 
panel), Sirius-red-stained sections (fourth panel) and WGA-stained (fifth panel) 
histological sections. (d) HW/BW ratio. (e) Quantification of EF by echocardiography 
in antagomir control and antagomir-148a treated mice after sham or TAC surgery. 
Measurements of (f) LVIDs, and (g) LV volumes in control and antagomir-148a 
treated mice after sham or TAC surgery. (h) RT-PCR analysis of transcript abundance 
of the hypertrophic stress marker genes Nppa, Nppb, Acta1 and Myh7 in hearts 
from control antagomir or antagomir-148a treated mice after sham or TAC surgery.  
Data information: Data are means ± SEM. One-way ANOVA with Bonferroni’s 
multiple comparison test was used to compare groups. n, number of hearts; C. 
elegans, Caenorhabditis elegans ; TAC, transverse aortic constriction; RT-PCR, real-
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time-polymerase chain reaction; H&E, hematoxylin & eosin; WGA, wheat germ 
agglutinin; HW/BW, heart weight to body weight ratio; EF, ejection fraction; LVIDs, 
left ventricular mass internal diameter in systole; LV, left ventricular; Nppa, 
natriuretic peptide type A; Nppb, natriuretic peptide type A ; Acta1, alpha skeletal 
actin ; Myh7, beta myosin heavy chain. *P < 0.05 vs corresponding control group; #P 
< 0.05 vs experimental group.  
  
Figure 3 | Cardiac AAV9-miR-148a overexpression protects the heart against 
eccentric hypertrophy, chamber dilation and systolic dysfunction. (a) Design of the 
study. Two-month-old mice were injected with control AAV9 (AAV9-CMV) or an 
AAV9 designed to overexpress mmu-miR-148a-3p (AAV9-148a) and subjected to 
sham or TAC surgery. Cardiac geometry and function was determined by serial 
Doppler echocardiography at 4 and 7 weeks after surgery. (b) RT- PCR analysis of 
miR-148a expression in hearts from mice receiving AAV9-CMV or AAV9-148a virus. 
(c) Representative images of whole hearts (top panels), H&E-stained sections of 
four-chamber view (second panel), high-magnification H&E-stained sections (third 
panel), Sirius-red-stained sections (fourth panel) and WGA-stained (fifth panel) 
histological sections. (d) HW/BW ratio. (e) Quantification of LVPWs, (f) EF and (g) LV 
volume by echocardiography in AAV9-CMV and AAV9-148a treated mice after sham 
or TAC surgery. (h) RT- PCR analysis of transcript abundance of hypertrophic stress 
marker genes Nppa, Nppb, Acta1 and Myh7 in hearts from AAV9-CMV and AAV9-
148a treated mice after sham or TAC surgery.  
Data information: Data are means ± SEM. One-way ANOVA with Bonferroni’s 
multiple comparison test was used to compare groups. n, number of hearts; AAV9, 
adeno-associated virus serotype 9; TAC, transverse aortic constriction; RT-PCR, real-
time-polymerase chain reaction; H&E, hematoxylin & eosin; WGA, wheat germ 
agglutinin; HW/BW, heart weight to body weight ratio; EF, ejection fraction; LVIDs, 
left ventricular mass internal diameter in systole; LV, left ventricular; Nppa, 
natriuretic peptide type A; Nppb, natriuretic peptide type A ; Acta1, alpha skeletal 
actin ; Myh7, beta myosin heavy chain.. *P < 0.05 vs corresponding control group; 
#P < 0.05 vs experimental group.  
 
Figure 4 | miR-148a targets glycoprotein 130 (gp130), co-receptor for IL-6 
superfamily cytokines. (a) Location and evolutionary conservation of the mmu-miR-
148a seed region on gp130. (b) Schematic representation of luciferase reporters. (c) 
Activity assay of luciferase reporter constructs in neonatal rat cardiomyocytes. (d) 
Western blot for endogenous gp130 in neonatal rat cardiomyocytes when 
transfected with scrambled control antimir (scr.anti-miR), antimir-148a (anti-miR-
148a), or precursor for miR-148a (pre-miR-148a) and quantification of GAPDH-
corrected gp130 western blot signals. (e) Study design of mice receiving continuous 
81 
infusion of CT-1 (20 µg/kg/day) or isoproterenol (60 mg/kg/day). (f) Representative 
image of whole hearts (top panels), H&E-stained sections of the left ventricular free 
walls (second panels), high magnification H&E-stained sections (third panels), or 
Sirius Red stained (lower panels) histological sections of hearts from saline, CT-1 
infused and isoproterenol-infused mice. Measurements of (g) LV mass, (h) EF (i) IVSs 
in saline, CT-1-treated or isoproterenol-treated mice. (j) Confocal microscopy 
images of neonatal rat cardiomyocytes treated with scrambled or precursor-148a 
miR-148a with or without CT-1 stimulation. (k) Cell surface measurements from 
conditions in (j).  
Data information: Data are means ± SEM. One-way ANOVA with Bonferroni’s 
multiple comparison test was used to compare groups. n, number of transfection 
experiments (c), number of transfected wells (d), number of mice (g-i) or number of 
cells quantified in each condition (j); AAV9, adeno-associated virus serotype 9; TAC, 
transverse aortic constriction; RT-PCR, real-time-polymerase chain reaction; GAPDH, 
glyceraldehyde 3-phosphate dehydrogenase; CT-1, cardiotrophin 1; H&E, 
hematoxylin & eosin; WGA, wheat germ agglutinin; LV, left ventricular; EF, ejection 
fraction; IVSs, intraventricular septal thickness in systole; LVIDs, left ventricular 
mass internal diameter in systole. *P < 0.05 vs corresponding control group; #P < 
0.05 vs experimental group.  
 
Figure 5 | miR-148a differentially regulates gp130 and STAT3 downstream 
signaling in concentric and eccentric cardiac remodeling. (a) Design of the study: 
two month-old mice were subjected to sham or TAC surgery for 2, 4, 6 or 8 weeks. 
Mice were subjected to echocardiographic evaluation and hearts harvested at 
indicated time points. (b) RT-PCR analysis of miR-148a-3p expression at indicated 
time points. (c-e) Echocardiographically determined LV mass, EF or LVIDs, 
respectively. (f) Western blot analysis of myocardial CT-1 expression and 
quantification at indicated time points. (g) Western blot analysis of myocardial 
gp130 expression and quantification at indicated time points. (h) Western blot 
analysis of myocardial phosphorylated and unphosphorylated forms of STAT3 and 
quantification at indicated time points. (i) Western blot analysis of myocardial 
gp130 or phosphorylated and unphosphorylated forms of STAT3 and quantification 
in hearts from mice subjected to sham or TAC surgery and receiving antagomir-148a 
or a control antagomir (antagomir-Cel-39). (j) Western blot analysis of myocardial 
gp130 or phosphorylated and unphosphorylated forms of STAT3 and quantification 
in hearts from mice receiving AAV9-148a or AAV9-MCS. (k) Model depicting the 
influence of miR-148a on CT-1 - gp130 – STAT3 signaling in cardiac stress situations, 
resulting in differential activation of STAT3 signaling and eccentric remodeling. 
Data information: Data are means ± SEM. One-way ANOVA with Newman-Keuls 
multiple comparison test was used to compare groups. n, number of mice (b-f), 
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number of independent WB experiments (g-i); AAV9, adeno-associated virus 
serotype 9; TAC, transverse aortic constriction; RT-PCR, real-time-polymerase chain 
reaction; CT-1, cardiotrophin 1; LV, left ventricular; EF, ejection fraction; LVIDs, left 
ventricular mass internal diameter in systole. *P < 0.05 vs corresponding control 
group; #P < 0.05 vs experimental group.  
 
Supplemental Figure 1 | miR-148a differentially regulates ERK5, ERK1/2, Akt 
downstream signaling in concentric and eccentric cardiac remodeling. (a) Western 
blot analysis of myocardial LIFR expression and quantification at indicated time 
points. (b) Western blot analysis of phosphorylated and unphosphorylated forms of 
Akt and quantification at indicated time points. (c) Western blot analysis of 
phosphorylated and unphosphorylated forms of Erk5 and quantification at indicated 
time points. (d) Western blot analysis of phosphorylated and unphosphorylated 
forms of Erk1/2 and quantification at indicated time points. (e) Western blot 
analysis of phosphorylated and unphosphorylated forms of Akt, Erk5, Erk1/2 and 
quantification in hearts from mice subjected to sham or TAC surgery and receiving 
antagomir-148a or a control antagomir (antagomir-Cel-39). (f) Western blot analysis 
of myocardial gp130 or phosphorylated and unphosphorylated forms of Akt, Erk5 or 
Erk1/2 and quantification in hearts from mice receiving AAV9-148a or AAV9-MCS. 
Data information: Data are means ± SEM. One-way ANOVA with Newman-Keuls 
multiple comparison test was used to compare groups. n, number of independent 
WB experiments; LIFR, leukemia inhibitory factor receptor; AAV9, adeno-associated 
virus serotype 9; TAC, transverse aortic constriction; CT-1, cardiotrophin 1. *P < 0.05 
vs corresponding control group; #P < 0.05 vs experimental group.  
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Table 1. Morphometric and echocardiographic characteristics of sham and TAC 
mice treated for 6 weeks with control antagomir or antagomir-148a.  
  











n 7 8 8 8 
BW (g) 22.5±1.6 25.6±1.6 25.6±1.2 24.0±1.6 
LV mass (mg) 84±3 102±10 123±12* 149±18* 
LV mass/BW 
(mg/g) 
3.8±0.3 4.0±0.2 4.8±0.4 6.1±0.5*# 
IVSd (mm) 0.87±0.03 0.94±0.08 0.86±0.05 1.00±0.04 
IVSs (mm) 1.39±0.04 1.31±0.11 1.13±0.04* 1.32±0.07 
LVIDd (mm) 3.44±0.07 4.07±0.18* 4.39±0.16* 4.55±0.32* 
LVIDs (mm) 2.07±0.11 2.93±0.25* 3.38±0.21* 3.62±0.35* 
LVPWd (mm) 0.89±0.04 0.74±0.08* 0.88±0.12 0.91±0.07 
LVPWs (mm) 1.28±0.06 0.91±0.09 1.13±0.13 1.08±0.09 
EF (%) 78±3 62±5* 55±4* 51±4* 
FS (%) 40±3 29±3* 24±2* 22±2* 
E/A (mm/s) 1.33±0.09 1.32±0.13 1.52±0.18 1.27±0.04 
 
Data are expressed as means ± SEM. BW, body weight; Ctrl, control; LV, left 
ventricular; IVSd, interventricular septal thickness at end-diastole; IVSs, 
interventricular septal thickness at end-systole; LVIDd, left ventricular internal 
dimension at end-diastole; LVIDs, left ventricular internal dimension at end-systole; 
LVPwd, left ventricular posterior wall thickness at end-diastole; LVPws, left 
ventricular posterior wall thickness at end-systole; EF, ejection fraction; FS, 
fractional shortening; E/A, Doppler E/A ratio; TAC, transverse aortic constriction. *, 
indicates P<0.05 vs sham group subjected to treatment with a control antagomir; #, 
indicates P<0.05 vs experimental group. 
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Table 2. Morphometric and echocardiographic characteristics of sham and TAC 
mice treated for 6 weeks with AAV-MCS or AAV9-miR-148a.  
  







n 11 10 10 14 
BW (g) 19.1±0.5 23.8±1.0 22.6±1.2 25.1±0.9 
LV mass (mg) 82±3 99±8 102±7* 116±5* 
LV mass/BW 
(mg/g) 
3.9±0.1 4.1±0.2 4.6±0.4* 4.6±0.2* 
IVSd (mm) 0.84±0.02 0.93±0.02* 0.85±0.02 0.91±0.02*# 
IVSs (mm) 1.21±0.05 1.39±0.03* 1.17±0.05 1.26±0.03 
LVIDd (mm) 3.57±0.07 3.58±0.08 4.06±0.14* 4.09±0.08* 
LVIDs (mm) 2.27±0.10 2.22±0.09 3.23±0.19* 3.08±0.11* 
LVPWd (mm) 0.82±0.02 0.95±0.10 0.79±0.03 0.92±0.02# 
LVPWs (mm) 1.23±0.03 1.38±0.09 1.00±0.04* 1.22±0.03# 
EF (%) 74±2 76±2 46±5* 57±3*# 
FS (%) 37±2 38±2 19±2* 26±2*# 
E/A (mm/s) 1.24±0.04 1.25±0.05 1.35±0.03 1.19±0.02 
 
Data are expressed as means ± SEM. AAV, adeno-associated virus; BW, body weight; 
LV, left ventricular; IVSd, interventricular septal thickness at end-diastole; IVSs, 
interventricular septal thickness at end-systole; LVIDd, left ventricular internal 
dimension at end-diastole; LVIDs, left ventricular internal dimension at end-systole; 
LVPwd, left ventricular posterior wall thickness at end-diastole; LVPws, left 
ventricular posterior wall thickness at end-systole; EF, ejection fraction; FS, 
fractional shortening; E/A, Doppler E/A ratio; TAC, transverse aortic constriction. *, 
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MicroRNAs are single-stranded, non-coding RNA molecules of about 22 nucleotides 
in length. Increasing evidence associates microRNAs to cardiac remodeling and 
heart failure. Distinct forms of cardiac remodeling (concentric or eccentric) can 
occur, yet current pharmacotherapy only follows a “one-size-fits-all” approach, 
regardless of underlying type of remodeling. One signaling cascade that is closely 
associated with the development of eccentric hypertrophy and dilation of the 
ventricular chambers involves cardiotrophin-1 (CT-1) activation and downstream 
signaling. Previously, we showed that CT-1 infusion provokes eccentric hypertrophy 
and dilatation without an initial concentric hypertrophy response. Here, we 
establish a high content phenotypic screening assay in neonatal rat cardiomyocytes 








Pathological left ventricular hypertrophy, often caused by chronic hypertension or 
formed in the remote zone after a myocardial infarct, represents the main risk 
factor for the development of heart failure and lethal arrhythmias.1 Although the 
underlying molecular mechanisms are still poorly understood, there now is 
compelling evidence that microRNA genes, employed in response to disease stimuli, 
are intimately involved in left ventricular hypertrophic enlargement and 
subsequently heart failure.2 MicroRNAs are small non-coding RNA stress-responsive 
genes that act by suppressing a variety of protein coding genes at the post-
transcriptional level. Various stress activated signaling cascades have the ability to 
increase the expression of series of microRNAs, which in turn suppress anti-
hypertrophic modulators, allowing pathological cardiac hypertrophy to ensue.3  
 
Cardiac hypertrophy has distinct morphological phenotypes at the organ level.4-7 On 
the one hand, a form of cardiac remodeling that consists of thickening of the 
ventricular walls is also defined as concentric hypertrophy. This form of hypertrophy 
is often observed secondary to aortic stenosis, hypertension and associated with 
metabolic disorders in heart failure with preserved ejection fraction (HFpEF).8 At the 
microscopic level, cardiomyocytes isolated from concentric hypertrophic hearts 
display an increase in size more in width than in length. In contrast, eccentric 
cardiac remodeling consists of thinning and dilation of the ventricular walls and an 
increase of the left ventricular cavity size. Clinically, eccentric hypertrophy is often 
observed with post-infarct healing and inherited forms of dilated cardiomyopathy.9 
At the microscopic level, cardiomyocytes isolated from eccentric remodeled hearts 
display a disproportional increase in length rather than width. 
Despite these phenotypically distinct causes of heart failure, current 
pharmacotherapy follows a “one-size-fits-all” approach, regardless of the underlying 
type of remodeling that eventually evoked heart failure. It still remains unclear how 
the heart is able to react by concentric hypertrophy in response to e.g. chronic beta-
adrenergic stimulation in early stages with near normal ejection fraction and in time 
gradually demonstrates eccentric remodeling with severe dilation and dramatically 
lowered ejection fraction.10 Understanding the precise molecular underpinnings 
that drive concentric versus eccentric cardiac remodeling is crucial in striving 
towards a therapeutic approach for sub-type specific forms of heart failure.  
 
To dissect these different types of remodeling, stimuli that specifically provoke one 
specific type of hypertrophy are the first step towards understanding phenotypically 
different forms of cardiac disease. In primary cultured cardiomyocytes, stimulation 
with the IL-6 cytokine family member cardiotrophin-1 (CT-1) causes a phenotype of 
cardiomyocyte hypertrophy with more pronounced increases in cell length and 
where sarcomeres are added in series (eccentric hypertrophy), rather than in 
parallel (concentric hypertrophy), as is often observed with α-adrenergic 
stimulation.11 12 
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To gain more insight in the signaling cascades and molecular mechanisms involved 
in eccentric remodeling and dilatation, we performed a high-content microscopy, 
high-throughput functional screening for microRNAs that influenced neonatal 
cardiomyocyte eccentric remodeling using a whole-genome miRNA library. We 
identified 26 microRNAs that decreased CT-1 induced cardiomyocyte hypertrophy 
compared to scrambled anti-miR treatment (control) with a z score < -2.0. We 
selected the LNA miRs based on the extent to which they had inhibited hypertrophy 
and the degree of conservation between mouse and human. Our top 4 microRNA 
candidates miR-125b-5p, miR-542-3p, miR-151-5p and miR-532-3p are specific 






Primary cardiomyocyte cultures 
 
Primary cardiomyocytes were isolated from 1-2 days old Sprague Dawley rats after 
decapitation, and cardiomyocytes were isolated by enzymatic dissociation as 
described previously13. Briefly, hearts were collected, atria were removed and 
ventricles cut into small pieces in salt buffer on ice. The ventricular tissue was 
subjected to multiple rounds of enzymatic digestion using pancreatin (Sigma) and 
collagenase (Gibco) as digestive enzymes at 37 degrees. Every 20 min supernatant 
was collected in FBS, and 9 mL fresh enzyme solution was added to the residual 
tissue. Cells were pelleted and resuspended in DMEM medium (Gibco) 
supplemented with 15% fetal bovine serum, gentamycin (0.1%), and L-glutamine (1 
mmol/liter). To separate the non-cardiomyocyte fraction from the cardiomyocytes, 
cells were pre-plated on uncoated T75 flasks for 1 h at 37 degrees. This allows 
fibroblasts to adhere to the culture flasks, while cardiomyocytes remain in 
suspension. Afterwards, the supernatant containing the cardiomyocytes was 
collected and cells were counted manually. The cardiomyocytes were plated on 
gelatinized 96-well plates (Ibidi) in a density of 2.5 x 104 cells per well. The following 
morning, neonatal rat cardiomyocytes (NRCM) were cultured in serum-free DMEM 
media containing M199 media (20%), gentamycin (0.1%) and 1 mmol/liter L-




Neonatal rat cardiomyocytes (NRCM) were transfected with the mouse miRCURY 
LNA microRNA inhibitor library (Exiqon,) corresponding to all mouse mature 
microRNAs (711 mouse microRNAs listed in miRBase v. 19.0). MiR inhibitors were 
transferred manually from stock library plates onto collagen-coated black clear-
bottom 96-well plates (Ibidi). MiR inhibitors were transfected into NRCM using 
Oligofectamine (Invitrogen) according to the manufacturer’s transfection protocol, 
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at a final concentration of 50 nM. Briefly, Oligofectamine was diluted in serum free 
medium and added to the miR inhibitors on the 96-well plates. Half an hour later, 
the NRCM previously seeded on black 96-well plates were transfected manually 
with the oligofectamine/ miR inhibitor mixtures. After 24h, culture medium was 
replaced by fresh medium and left unstimulated (serum free) or stimulated with a 
final concentration of 2nM cardiotrophin-1 (Peprotech) to induce eccentric 
cardiomyocyte hypertrophy. NRCM were fixed at 72 h after plating and processed 




NRCM were fixed with 4% paraformaldehyde for 5 min, permeabilized with 0.1% 
NP40 in phosphate buffered saline (PBS) at room temperature. NRCM were then 
stained overnight at room temperature with the following primary antibodies 
diluted in 1% BSA solution: rabbit antibody against sarcomeric α-actinin (Abcam), 
mouse antibody against prolyl-4-hydroxylase beta (P4HB, Acris), and nuclear 
staining was performed with 4′,6-diamidino-2-phenylindole (DAPI, Molecular 
Probes). The sarcomeric α-actinin was used to visualize sarcomeric organization and 
determine cardiomyocyte size. The P4HB antibody was used to visualize the 
fibroblasts. NRCM were incubated for 2 h with the respective secondary antibodies 
conjugated to Alexa Fluor-488 (green fluorescent, Life Technologies), and Alexa 
Fluor-647 (red fluorescent, Life Technologies). All antibody incubation steps were 
performed at room temperature and intermitted by three washing steps with PBS/ 
0.1% NP40. Finally, NRCM were covered with 50% glycerol and stored at 4 °C until 
microscopic analysis.  
 
Images and analysis 
 
Image acquisition and analysis were performed at the ICGEB High-Throughput 
Screening Facility (http://www.icgeb.org/high-throughput-screening.html) using an 
ImageXpress Micro automated high-content screening fluorescence microscope. Per 
well 16 images were taken for each wavelength, resulting in circa 2500 cells 
analysed per well. For the image analysis MetaXpress software (Molecular Devices) 
was used. NRCM were only included in the analysis if they stained positive for both  
sarcomeric α-actinin, and Dapi for nuclei. Cardiac fibroblasts express prolyl 4-
hydroxylase beta (P4HB) but do not express α-actinin, therefore those were 




All the data are expressed as mean ± standard error (SEM). Statistical analyses were 
performed using Prism software (GraphPad Software), and consisted Student’s t-
test when comparing two experimental groups. For all data, differences were 
considered significant with a p value < than 0.05.  
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MiR target prediction 
 
Putative miR targets were identified using miR target prediction tool software 
miRWalk (http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2/mirretsys.php 
version miRWalk 2.0). Targets were only included if predicted by 3 or all 4 
databases: miRWalk, miRanda, RNA22 and Targetscan. The top predicted target 
genes of all miRs were subjected to bioinformatics analysis using GeneCodis 
software (http://genecodis.cnb.csic.es/analysis). Over 6000 genes were included in 






High throughput screen experimental setup using a miR LNA inhibitor 
library  
 
Since CT-1 administration causes cardiac eccentric hypertrophy without an initial 
concentric hypertrophic remodeling process (Chapter 4), this creates the 
opportunity to identify microRNAs specifically involved in eccentric remodeling and, 
possibly, forms of dilated cardiomyopathy. To this end, we performed a phenotypic, 
fluorescence-microscopy-based high throughput screening using a library of 711 
microRNA LNA inhibitors. Assays that are based on cells require optimal cell plating 
density in order to achieve maximal resolution in the readout process. Cell seeding 
conditions were optimized in preliminary studies in our lab with culture duration of 
up to 72h (data not shown). As the seeding number increased, the cell area 
quantification accuracy decreased due to cells overgrowing each other in the 
limited plate area, making it difficult for the software to identify the accurate cell 
borders of each cell and quantify cell size accordingly. The optimum cell seeding 
conditions for this assay appeared to be a density of 2.5 x 104 cells per well.  
 
Neonatal rat cardiomyocytes were plated on 96 well plates at 2.5 x 104 cells per 
well. The next morning, cardiomyocytes were manually transfected with the antimir 
LNA library containing 711 mouse microRNA inhibitors. Another 24h later, CT-1 was 
added to the cells to induce eccentric hypertrophy in vitro. After 72h, cells were 
fixed and stained with specific antibodies for fluorescence-based microscopy in an 
automated setup (Fig. 1a). In order to distinguish mycocytes from non-myocytes, 
cardiomyocytes were stained for sarcomeric α-actinin, fibroblasts for prolyl 4-
hydroxylase beta (P4HB) and nuclei for Dapi (Fig. 1b). Cardiac fibroblasts do not 
express α-actinin, therefore we used this as a selection criterion for cells to be 
included in the analysis. Cells were only counted if they displayed both Dapi and α-
actinin staining. Although non-myocytes were still detected due to their nuclear 
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staining, they were excluded for cell size quantification (Fig. 1c). Upon stimulation 
with CT-1, cardiomyocytes typically exhibited a 1.5-fold increase of their cell area 







Figure 1. High throughput screen to identify microRNAs specifically involved in eccentric cardiomyocyte 
hypertrophy. (a) High-content screen workflow. (b) Representative microscopy images of 
cardiomyocytes (α-actinin) and fibroblasts (P4HB) in culture, treated with scrambled anti-miR. (c) 
Microscopy images and image reconstruction of NRCM treated with scrambled anti-miR (left) and 
quantification of NCRM cell size under indicated conditions using an automated system (right). P4HB, 
prolyl 4-hydroxylase beta.  
 
 
Phenotypic high throughput screening identified microRNAs as regulators 
of eccentric remodeling (EccentriMIRs) 
 
Since the majority of the LNA miR inhibitors only showed a significant effect on cell 
size after stimulation with CT-1, and our objective was to identify miRs involved in 
pathological eccentric remodeling, we focused on the hits acquired from this screen 
in CT-1-stimulated cardiomyocytes. Fig. 2 shows screen results as the z score of the 
cell size upon transfection of a specific LNA miR inhibitor compared to the mean of 
control scrambled-miR transfected cells included on each plate. In the z score 
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method, the mean score of all of the compounds on a plate are subtracted from the 
raw value of the compound of interest, and this difference is divided by the 
standard deviation of all of the values.14 In our screen we also included a full plate 
of anti-miR scrambled LNA as an additional control. The screen identified 26 
microRNAs that decreased CT-1 induced cardiomyocyte hypertrophy compared to 
scrambled anti-miR treatment (control) with a z score < -2.0 (Fig. 2). There were also 
LNA miRs in our library that increased cardiomyocyte size, but since the goal of this 
screen was to identify potential target miRs or potential target pathways for 
therapeutical purposes, we did not elaborate on the pro-hypertrophic subset of LNA 
miR inhibitors. Instead, we selected the LNA miRs based on the extent to which they 




Figure 2. Identification of eccentrimiRs. Z score of all LNA miR measurements, calculated as z = (xi – x)/sx, 
where xi is the raw measurement on the i
th compound (LNA), x and sx are the mean and the standard 
deviation, respectively, of all measurements including scrambled control within the plate. Shown in red 
are microRNAs that inhibit CT-1 induced hypertrophy when inhibited by indicated LNA molecules.  
 
Fig. 3 displays the fluorescent images of the candidates with the smallest z-score 
that had the strongest effect on inhibition of hypertrophy and are completely 
conserved in human. The larger the value of z, the less probable the experimental 
result is due to chance. Using miR inhibitor molecules that are designed to 
specifically inactivate endogenous miRs, increased the validity of the effects 
observed. Anti-miR-125b-5p, anti-miR-532-3p, anti-miR-542-3p, and anti-miR-151-
5p all showed significant inhibition of CT-1-induced eccentric hypertrophy. Since our 
goal was to identify miRs that are involved in eccentric hypertrophy specifically, we 
compared our results to the results of a previously published screen done in 
cardiomyocytes that were stimulated with phenylephrine (PE) to induce concentric 
hypertrophy.15 Comparing the results of that study with our data, we can conclude 
that our top 4 microRNA candidates; miR-125b-5p, miR-542-3p, miR-151-5p and 
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miR-532-3p are specific inducers of eccentric hypertrophy since those microRNAs 
did not significantly induce α-adrenergic-mediated hypertrophy and miR-151-5p 
stimulation even resulted in an anti-concentric hypertrophy phenotype.15  Thus, this 
suggests that our top candidates are specifically involved in eccentric remodeling 




Figure 3. EccentrimiR inhibition protects against CT-1-induced eccentric cardiomyocyte hypertrophy. 
Microscopy images (upper panel) and image reconstruction (lower panel) of NRCM after CT-1 stimulation 
treated with scrambled anti-miR or antimirs against indicated microRNAs.  
 
We systematically identified miRs essential for NRCM eccentric remodeling using a 
synthetic miR LNA library of mouse origin. Next, we set out to further explore the 
target genes of our 4 candidate miRs miR-125b-5p, miR-542-3p, miR-151-5p and 
miR-532-3p to check for involvement in common pathways and processes. 
Prediction of miR target genes is still a challenging process and these processes 
usually result in an excessive number of putative target genes.16 Since the 
algorithms for miR target prediction provide distinct targets, we used the input of 4 
different databases: miRWalk, miRanda, RNA22 and Targetscan and only included 
the target genes predicted by 3 out of 4 or all 4 algorithms. For each miR, the top  
putative target genes were analyzed using GeneCodis. This web-based application 
integrates different sources of information to finding groups of genes with similar 
biological meaning. The enrichment analysis is essential in the interpretation of 
high-throughput experiments and provides clues for common pathways that our top 
4 miRs are regulating in relation to CT-1-induced eccentric remodeling. When 
analyzing for Biological Processes (BP) the tool revealed the enrichment for genes 
involved in ‘regulation of transcription, DNA-dependent’, ‘transport’, ‘transcription, 









Figure 4. Singular Enrichment Analysis of GO Biological Process. Graphs showing results for all putative 
target genes predicted by 3 or all 4 databases used (miRWalk, miRanda, RNA22 and Targetscan). The pie 





Functional analysis of the gene involvement in the Kyoto Encyclopedia of Genes and 
Genomes (KEGG) pathways revealed enrichment for genes belonging to ‘Pathways 
in cancer’, MAPK-signaling pathway’, ‘Endocytosis’, and ‘Regulation of actin 







Figure 5. Singular Enrichment Analysis of KEGG pathways. Graphs showing results for all predicted 
target genes predicted by 3 or all 4 databases used (miRWalk, miRanda, RNA22 and Targetscan). The pie 





Different hypertrophic phenotypes can be distinguished based on the geometry of 
the heart and individual cardiomyocytes. Concentric pathological hypertrophy is 
considered to be initially compensatory and occurs usually secondary to pressure 
overload as in clinical conditions such as aortic stenosis or high blood pressure.17 
Concentric hypertrophy can progress to eccentric hypertrophy and dilation with 
associated systolic heart failure, as observed in animal models with long-term 
pressure overload stress due to aortic banding. However, the underlying 
mechanisms for this transition remain poorly understood.  
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After establishing that CT-1 leads specifically to dilatation of the heart (Chapter 4), 
we used CT-1 as the stimulating agent to induce hypertrophy and set out to 
determine the molecular mechanisms specifically underlying eccentric cardiac 
hypertrophy. To that end, microRNA inhibitors were used as tools in a high 
throughput screening approach to unravel specific molecular pathways involved in 
eccentric remodeling of the heart. CT-1 stimulation of neonatal cardiomyocytes 
resulted consistently in a 1.5 fold increase in cell size. The advantage of our 
automated setup is that a very large number of microRNAs could be screened 
simultaneously, and the automated microscopy-based analysis of cell size ruled out 
potential human bias in analyzing the screening results. This assay was perfectly 
able to discriminate between cardiomyocytes and non-cardiomyocytes and included 
a higher number of cells analyzed per condition (±800) as compared to conventional 
approaches that involve manual quantification.  
 
In total 711 LNA microRNA inhibitors were tested for their ability to alter CT-1-
induced eccentric hypertrophy in isolated primary neonatal cardiomyocytes. A 
similar massive phenotypic screening method to detect changes in cardiomyocyte 
cell size has been previously described for α-adrenergic-induced concentric 
hypertrophy.15 That study used automated microscopy and an edge detection 
algorithm in order to achieve a high reproducibility using cardiomyocyte size as a 
key parameter. Quantitative analysis of candidate microRNA expression levels in 
primary cardiomyocytes revealed a low correlation level of the phenotypic effects of 
individual candidates and their expression level, indicating that focusing on the 
most strongly expressed and deregulated microRNAs risks to neglect other disease-
relevant miRs. The presumption that high endogenous miR expression levels 
correlate with high activity was not true in regards to pro-hypertrophic potential.15 
In the present study, rather than using expression levels as a selection criterion, we 
used phenotypic cell size measurements as a read out.  
 
To circumvent artificial experimental-induced false positives, we utilized a library of 
LNA miR inhibitors that target the endogenous miR population rather than 
introducing overexpression of miRs that might normally not even be present in the 
cardiomyocyte. The top 4 miRs identified in our screen that that are specific 
inducers of eccentric hypertrophy are miR-542-3p, miR-151-5p, miR-532-3p and 
miR-125b-5p.  
 
To get more insight in what pathways these miRs could be involved, we used miR 
target prediction tool software databases to identify potential target genes and 
pathways. Main pathways ways predicted include pathways in cancer. Indeed, 
several reports implicate miR-542-3p in cancer progression. MiR-542-3p was shown 
to suppress tumor cell invasion via targeting the AKT pathway in human 
astrocytoma.18 MiR-542-3p directly targets integrin-linked kinase (ILK) thereby 
inhibiting colon cancer cell proliferation and invasion.19 Moreover, miR-542-3p 
directly targets surviving, and overexpression of miR-542-3p induced G1 and G2/M 
arrest in multiple cancer cell lines, including lung cancer, breast cancer, and cervical 
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cancer.20,21 The tumor-suppressive function of miR-542-3p largely results from its 
synergistic effect on simultaneous modulation of multiple targets. Besides its known 
role as a tumor repressor, miR-542-3p also directly targets bone morphogenetic 
protein 7 (BMP-7), suppressing osteoblast cell proliferation and differentiation and 
thereby inhibiting bone formation. Silencing of miR-542-3p led to increased bone 
formation, bone strength and improved trabecular microarchitecture in sham and 
ovariectomized (Ovx) mice.22  
MiR-151 is often co-expressed with its host gene focal adhesion kinase (FAK). Mir-
151-5p directly targets RhoGDIA, a putative metastasis suppressor in hepatocellular 
carcinoma, thereby enhancing cell motility and tumor spreading.23,24 MiR-151-5p 
can also directly bind to the 3'-UTR of FXYD1 (coding gene of phospholemman, PLM) 
and inhibit its expression, altering vulnerability to ventricular arrhythmias in 
response to acute myocardial ischemia in estrogen-deprived rats.25  
Another miR, miR-532-3p was shown to directly target apoptosis repressor with 
caspase recruitment domain (ARC), thereby regulating mitochondrial fission in 
doxorubicin (DOX) cardiotoxicity. MiR-532-3p was not involved in DOX-induced 
apoptosis in cancer cells.26  
The last microRNA, miR-125b-5p is known as a tumor suppressor and several 
reports show its role in cell proliferation, differentiation, and apoptosis in multiple 
cell types.27-31 MiR-125b promotes apoptosis by directly targeting Mcl-1, Bcl-w and 
interleukin (IL)-6R.32 MiR-125b can regulate cell differentiation through direct 
repression of the core binding factor β (CBFβ) in hematopoietic malignancies.33 MiR-
125b expression in breast cancer cells suppresses proliferation and induces G1 cell-
cycle arrest.34,35 In lens epithelial cell, miR-125b was shown to directly target p53.36 
Also, miR-125b-5p was found to directly target 5-Lipoxygenase (5-LO), the key 
enzyme in leukotriene biosynthesis.  Leukotrienes are mediators of the innate 
immune system and inflammatory processes.37  In relation to the heart, miR-125b 
was shown to regulate of human embryonic stem cell (hESC) differentiation in 
general, and the development of hESC-derived mesoderm and cardiac muscle in 
particular.38 Overexpression of miR-125b protected mice against myocardial 
ischemia/reperfusion injury via targeting of p53 and TRAF6.39 Furthermore, miR-
125b is necessary for the induction of fibroblast-to-myofibroblast transition by 
functionally targeting apelin, a critical repressor of fibrogenesis, and inhibits p53 to 
induce fibroblast proliferation.40 
 
Those miRs are hardly studied in relation to cardiovascular disease. Predicted 
involvement in MAPK-signaling pathways is no surprise, since the known 
downstream pathways of CT-1 signaling involve MAPK effectors. The predicted 
involvement in regulation of transcription could be related to activation of 
transcription factors involved in eccentric hypertrophy, as concentric hypertrophy 
does also require activation of transcription.  
 
Additional validation of this screen is required. There are no molecular markers 
known to be specific for eccentric remodeling, therefore we could not use qPCR to 
validate our screen in the way it is done for measuring concentric hypertrophy 
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response. In concentric hypertrophy, measuring “fetal” gene markers like atrial 
natriuretic factor gene expression, a hallmark of the hypertrophy-associated gene 
expression program, can be used to determine the induction of the pathological 
hypertrophy. To validate the effect on eccentric hypertrophy in vivo, mice receiving 
CT-1 by osmotic minipumps could be injected with antagomir against these miRs 
and the level of eccentric remodeling could be established by echocardiography and 
evaluation of histologic sections of the hearts. Since CT-1 induces an increase in 
cardiomyocyte cell length rather than an increase in width, measuring cell area 
might not be optimal. However, the MetaXpress software we used is not capable of 
measuring y/x ratio in individual cells in an automated setup. Furthermore, the 
amount of fibroblast in certain wells was so high, that we had to exclude half of the 
images per well for analysis. Although this is in line with literature, only 800 cells per 
condition could be analyzed due to abundant fibroblast proliferation.41 High intense 
fibroblast immunofluorescence staining interfered with the edge-detecting capacity 
of the algorithm, making the analysis process more labor intensive due to manually 
checking of all analyzed pictures.  
 
This assay led to the identification of microRNA candidates, specifically involved in 
eccentric hypertrophic pathways that do not play a role in processes leading to 
concentric hypertrophy. Further in vivo validation will remain crucial in order to 
establish more molecular insight into the pathways specifically involved in 
dilatation. Identifying the target genes of those miRs that are affected in eccentric 
hypertrophy will provide more insight in the pathways that are activated specifically 
in eccentric remodeling. In the future, this could help to accomplish better patient 
stratification and development of personalized therapies aimed to specifically 
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Long noncoding RNAs (lncRNAs) are an emerging class of epigenetic regulators with 
important functions in cardiac development and disease. Here, we sought to 
identify and functionally characterize lncRNAs implicated in murine heart failure 
development. 
Methods and Results  
We profiled lncRNAs in non-ischemic, failing hearts of two classical mouse models, a 
sustained transverse aortic constriction model and mice harboring a cardiac-specific 
calcineurin transgene, and discovered ~3.400 differentially expressed lncRNAs in the 
failing murine heart. RNA interference (RNAi) was employed to silence Bigheart and 
demonstrate its requirement for agonist-induced cardiomyocyte hypertrophy. One 
of the verified interaction partners of Bigheart is MOV10, a putative RNA helicase 
that is involved in pre-mRNA processing and RNA splicing. GO analysis implicated 
MOV10 in both diastolic and systolic blood pressure, hypertension and coronary 
artery calcification, linking it directly to pressure overload-induced heart diseases. 
Conclusions  
We have identified differentially expressed lncRNAs in the failing murine heart and 
characterized previously unexplored lncRNA Bigheart to be functionally involved in 
heart failure development. GO analysis suggest a central role for Bigheart in RNA 
splicing that shed new lights how modulation of the cardiac epigenetic landscape 






A variety of cardiovascular diseases, such as hypertension and myocardial infarction 
provoke pathological remodeling of the myocardium, vulnerability to sudden death 
and heart failure (HF), representing the primary cause of hospitalization and death 
in Europe.1 Whereas common acquired forms of HF have genomic disease 
mechanisms underlying the progressive adverse remodeling of the myocardium, 
inherited cardiomyopathies have defined monogenetic disease causing mutations in 
genes encoding various structural components of the heart muscle. Despite the 
wide variety in disease-causing insults, HF therapy still follows a generic, ‘one-size-
fits-all’ approach, ignoring the inter-individual differences caused by underlying 
genetic susceptibility, age, gender or stages of disease.2,3 While current 
pharmacotherapy (β-blockers, ACE-inhibitors) and device-based therapies show 
effectiveness in prolonging survival in subsets of HF patients,4 there is currently no 
therapy that directly treats the underlying molecular disease mechanism, rendering 
HF a prevalent unmet medical need that receives a largely palliative clinical 
treatment.  
At the cellular level, a complex signaling network of transcription factors, co-
regulators and various regulatory RNA species orchestrate the morphological 
changes of the cardiomyocytes as a response to biomechanical stress leading to 
pathological hypertrophy.5 Although combinatorial transcription factor binding at 
proximal promoters is important and well characterized, the discovery of regulatory 
long noncoding RNA species (lncRNAs) has added a new layer of complexity to our 
understanding of transcriptional processes in heart disease. LncRNAs are RNA 
transcripts arbitrarily determined to be longer than 200 nucleotides and exert 
diverse biological functions independent of protein translation, including epigenetic 
silencing, transcription, and post-transcriptional regulation.6 Over 9,000 genomic 
loci are predicted to code for these regulatory transcript subclasses in the human 
genome.7,8 They exert their function both in the cytoplasm and in the nucleus and 
have the ability to act as decoys, sponges, scaffolds or chaperones allowing protein 
complexes, genes and chromosomes to be directed to appropriate RNA or DNA 
sequences.6,9  
In recent years, lncRNAs have increasingly been implicated in cardiovascular 
development, physiology, and pathology. For example, Braveheart (Bvht, 
AK143260) is involved in cardiovascular lineage commitment10, TERMINATOR, ALIEN 
and PUNISHER provide differentiation cues for pluripotent stem cells, cardiovascular 
progenitors and differentiated endothelial cells,11 while Fendrr is necessary for 
proper development of the heart and body wall in the mouse.12 Endothelial cell 
function, migration, differentiation and vessel growth are regulated by lncRNAs 
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MALAT113 and SENCR.14 Cardiac-specific lncRNA Myhrt transcripts from the Myh7 
genomic locus protect the heart from hypertrophy and failure by antagonizing the 
function of Brg1, a chromatin-remodeling factor that is activated by stress to trigger 
aberrant gene expression and cardiac myopathy.15 The lncRNA CHRF regulates 
cardiac hypertrophy by directly binding to miR-489, acting as a functional sponge to 
regulate anti-hypertrophic miR-489 expression and activity.16 Moreover, genome-
wide profiling of the cardiac transcriptome after myocardial infarction identified 
novel heart-specific lncRNAs with potential roles in both cardiac development and 
pathological cardiac remodeling. One of these novel lncRNAs, Novlnc6, modulates 
the expression of Nkx2.5, regulating cardiogenic differentiation, maturation, and 
homeostasis.17 Additionally, GWAS identified variants in lncRNA MIAT as a risk 
factor for myocardial infarction18, and susceptibility loci at chromosome 5q31 and 
6p21 carrying the lncRNAs SRA1 and HCG22 have been significantly associated with 
dilated cardiomyopathy (DCM).19,20 And finally, RNA sequencing was used to 
compare embryonic, normal adult and hypertrophied adult hearts, yielding lncRNAs 
n411949 and n413445 differentially expressed in the embryonic heart compared to 
normal and diseased adult hearts. These lncRNAs were functionally validated to 
target Mccc1 and Relb, thereby regulating the NFκB pathway and availability of 
branched-chain amino acids for anabolic signaling in muscle respectively.21  
Despite a steadily increasing number of reports on the functional role of single 
lncRNAs in cardiac disease, there exists uncertainty on the precise number of 
differentially expressed lncRNAs in non-ischemic pathological cardiac remodeling, in 
part due to the relatively poor annotation of lncRNAs. Although the number of 
databases containing information on lncRNAs is steadily increasing22-27 as novel 
information on their functional properties and genomic location emerges, the 
annotation of the deposited lncRNAs has not yet reached the standards of mRNA 
variants. Here, we add new evidence of the existence of robust numbers of 
differentially expressed lncRNA species by simultaneously profiling both lncRNAs 
and mRNAs in hearts suffering from non-ischemic, pathological hypertrophic 
remodeling using two well-established mouse models of heart failure: a surgical 
model of transverse aorta constriction (TAC) to induce sustained cardiac pressure 
overload and mice with heart-restricted calcineurin overexpression. RNA 
interference (RNAi) was employed to silence the lncRNA Bigheart and demonstrate 
its requirement for agonist-induced cardiomyocyte hypertrophy. Furthermore, 
functional interaction analysis and gene ontology (GO) analysis of Bigheart was 
performed using the NPInter database, revealing Bigheart’s role in mRNA 
processing. Taken together, Bigheart is directly implicated in adverse cardiac 




Animal models and transthoracic echocardiography 
We used adult (8-10 week old) calcineurin transgenic mice in a B6CBAF1/J 
background expressing an activated mutant of calcineurin in the postnatal heart 
under control of the 5.5 kb murine Myh6 promoter (MHC-CnA),28 and corresponding 
B6CBAF1/J wildtype mice (Charles River Laboratories). Hearts were removed, rinsed 
in ice-cold phosphate buffered saline, atria removed, snap-frozen in liquid nitrogen 
and stored in liquid nitrogen until use. Adult BL6CBAF1 mice (12-16 week old) 
underwent transverse aortic constriction (TAC) by subjecting the aorta to a defined 
27 gauge constriction between the first and second truncus of the aortic arch as 
described previously in detail.29,30 At 4 weeks of TAC surgery, animals were 
sacrificed, hearts removed, rinsed in ice-cold phosphate buffered saline, atria 
removed, snap-frozen in liquid nitrogen and stored in liquid nitrogen until use. For 
Doppler-echocardiography, mice were shaved and lightly anaesthetized with 
isoflurane (mean 1% in oxygen) and allowed to breathe spontaneously via a nasal 
cone. Non-invasive, echocardiographic parameters were measured using a digital 
cardiac ultrasound platform (SONOS 5500, Philips) with a 15 MHz linear scanner (M- 
and B-mode), and a 12 MHz short focal length-phased array transducer (pw- and 
cw-Doppler) applied parasternally to the shaved chest wall. Doppler was used to 
calculate the pressure gradient between the proximal and distal sites of the 
transverse aortic constriction and only mice with a pressure gradient > 50 mm Hg 
were included. At 4 weeks post-banding, fractional shortening and ejection fraction 
were reduced to 50% of corresponding values of sham-operated, indicating severely 
reduced systolic cardiac function. All animal studies were performed in accordance 
with local institutional guidelines and regulations. 
 
Primary neonatal rat cardiomyocytes cultures and siRNA transfections 
Cardiomyocyte cultures were isolated by enzymatic dissociation of 1 day-old 
neonatal rat hearts as described previously in detail.31 Cells were seeded in 10-cm 
dishes for RNA isolation or in 6-well plates to perform immunocytochemistry. One 
day after plating the neonatal rat cardiomyocytes were transfected with inhibitors 
(Dicer Substrate Duplex RNAs, IDT) of specific lncRNA transcripts (10nM) using 
Oligofectamin (Invitrogen). After 24 hours, cardiomyocyte hypertrophy was induced 
by phenylephrine (PE, 10 μM) stimulation for an additional 24h, as described 
previously.32 For visualization of cardiomyocyte size and sarcomeric organization, 
cells were washed with ice cold PBS, fixed with 4% PFA (for 10 min) and stained for 
α2-actinin (ACTN2; 1:500; Sigma) followed by a phalloidin Texas Red- conjugated 
antibody (1:800; Molecular Probes). Nuclear staining was performed with 
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VECTASHIELD Mounting Medium containing 4’,6-diamidino-2-phenylindole (DAPI; 
Vector Laboratories).  
 
RNA isolation and quantitative real time-PCR 
Total (1μg) RNA from mouse cardiac tissues or rat cardiomyocyte cells was isolated 
using TRIzol reagent (Invitrogen) and cDNA was generated using M-MLV Reverse 
Transcriptase (Promega). For real time RT-PCR, fluorescence detection was 
performed using SYBR Green on a BioRad iCycler (Biorad). Transcript quantities 
were compared using the relative Ct method, and normalized to endogenous 
GAPDH levels. 
 
Histological analysis and (immunofluorescence) microscopy.  
Hearts were arrested in diastole, perfusion fixed with 4% paraformaldehyde/PBS 
solution, embedded in paraffin and sectioned at 4 μm. Paraffin sections were 
stained with hematoxylin and eosine (H&E) for routine histological analysis; Sirius 
Red for the detection of fibrillar collagen; and FITC-labelled antibody against wheat-
germ- agglutinin (WGA) to visualize and quantify the myocyte cross-sectional area 
(1:100 Sigma Aldrich). Slides were visualized using a Zeiss Axioskop 2Plus with an 
AxioCamHRc. Cell surface areas were determined using ImageJ - imaging software 
(http://rsb.info.nih.gov/ij/). 
 
Microarray analysis of lncRNA and mRNA expression 
Total RNA was isolated from three hearts of each condition (wildtype, MyHC-CnA, 
sham, TAC), quantified by a NanoDrop ND-1000 and RNA integrity was additionally 
assessed by standard denaturing agarose gel electrophoresis. For microarray 
analysis, an Arraystar Mouse LncRNA Expression Microarray V2.0 was used. The 
sample preparation and microarray hybridization were performed based on the 
manufacturer’s standard protocols with minor modifications. Briefly, mRNA was 
purified from total RNA after removal of rRNA (mRNA-ONLY™ Eukaryotic mRNA 
Isolation Kit, Epicentre). Then, each sample was amplified and transcribed into 
fluorescent cRNA along the entire length of the transcripts without 3’ bias utilizing a 
random priming method. The labeled cRNAs were hybridized onto the Mouse 
lncRNA Array v2.0 (8 x 60K, Arraystar). After having washed the slides, the arrays 
were scanned by an Agilent Scanner G2505C. Agilent Feature Extraction software 
(version 11.0.1.1) was used to analyze the acquired array images. Quantile 
normalization and subsequent data processing were performed using the 





Gene ontology (GO) analysis was performed for RP11-654A16.3 (human Bigheart, 
NONCODE ID NONHSAG018057.2) with NPInter software (www.bioinfo.org/NPInter).  
 
Statistical and bioinformatical analyses  
The expression values of lncRNAs and mRNAs are presented as mean ± standard 
error of the mean (SEM). Statistical analyses were performed using the R 
programming interface and consisted of ANOVA when group differences were 
detected, or Student’s t-test when comparing two experimental groups. Adjustment 
for multiple testing was performed by applying Bonferroni’s Multiple Comparison 
Test or controlling the false discovery rate (FDR), respectively. Differences were 
considered significant when P<0.05 and fold change between groups >= 2 or <= 0.5, 
respectively. Hierarchical clustering and heatmap illustrations were performed using 
the “gplots”-package to show the distinguishable expression patterns of lncRNA and 
mRNA subsets among samples. Correlation of expression values of lncRNAs and 
nearby mRNAs is calculated by Pearson correlation coefficient as implemented in R. 
P-values of correlation tests have been adjusted for multiple testing by FDR with 
respect to all 74134 possible pairs of lncRNAs and nearby mRNAs represented on 
the Mouse lncRNA Array v2.0 (8 x 60K, Arraystar). “Nearby” is defined as the 
genomic distance of < 300 kb. 
 
For the validation of lncRNA, results are presented as mean ± standard error of the 
mean.33 Statistical analyses were performed using Prism software (GraphPad 
Software Inc.), and consisted of ANOVA followed by Bonferroni’s Multiple 
Comparison Test when group differences were detected at the 5% significance level, 
or Student’s t-test when comparing two experimental groups. Differences were 





Identification of cardiac hypertrophy associated lncRNAs  
We performed a mouse combined lncRNA/mRNA array on total RNA isolated from 
hearts from two well-established models of pathological murine cardiac 
hypertrophy and failure. The first model is a transgenic mouse model 
overexpressing calcineurin driven by the heart-specific alpha-myosin heavy chain 
promotor (MHC-CnA). The second model consists of mice that underwent 
transverse aortic constriction (TAC) surgery resulting in sustained cardiac pressure 
overload, which evoked pathological hypertrophic remodeling after 4 weeks. Both 
histological and molecular biological analyses were performed to phenotypically 
characterize all animals used in this study. As expected, both hearts from mice that 
underwent TAC surgery and from MHC-CnA mice displayed pathological cardiac 
hypertrophic remodeling indicated by an increase in cardiomyocyte size, fibrosis, 
and re-activation of hypertrophic fetal genes encoding the natriuretic peptides atrial 
natriuretic factor (Nppa), brain natriuretic factor (Nppb) and β-myosin heavy chain 
(Myh7) (Suppl Figure 1a, b). 
Hierarchical clustering was employed to differentiate the lncRNA expression 
patterns in wild-type (WT) or MHC-CnA murine hearts, and sham-operated and TAC-
operated murine hearts. Among the 19.704 lncRNAs probed on this microarray, 
1.325 lncRNAs were differentially expressed specifically in the group which received 
TAC surgery, graphically represented in a heat map representation (Figure 1a). 
Furthermore, 581 lncRNAs were exclusively differentially expressed in the MHC-CnA 
mice (Figure 1b,e). A total of 2.003 lncRNAs were significantly upregulated and 
1.410 lncRNAs were significantly downregulated in both pathological hypertrophy 
models compared to the control (WT) group (Figure 1c). Volcano plot analyses of 
the microarray data used a cut-off value of 2.0 fold up- or downregulation 
compared to WT hearts (x-axis) and an indication of p-value of 0.05 (y-axis). 
Statistically significant, differentially expressed lncRNAs with more than 2.0 fold 
change are indicated by the red dots (Figure 1d, e).  
Visualization of the data in a Venn diagram demonstrated that a total of 1.619 
lncRNAs were upregulated in TAC hearts, 1.139 lncRNAs showed an increased 
expression in MHC-CnA hearts, while 755 lncRNAs were commonly increased in 
expression in both models for pathological hypertrophy compared to the WT group 
(Figure 2a). Among the lncRNAs that were significantly decreased in hypertrophic 
hearts, 461 were specifically downregulated in TAC hearts, 197 lncRNAs showed 
decreased expression levels only in MHC-CnA hearts and 752 lncRNAs were 
commonly downregulated in both TAC and MHC-CnA hearts compared to WT hearts 
(Figure 2a). The top-hundred most severely upregulated or downregulated lncRNAs  
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Figure 1. Profiling of long noncoding RNAs in two animal models of heart failure. (a) Heat map 
representation of differentially expressed LncRNAs from the microarray data between hearts from 
specifically WT and TAC groups. Genes significantly (p < 0.05) up- or downregulated in the TAC group are 
marked in red and green, respectively. (b) Heat map representation of differentially expressed LncRNAs 
from the microarray data between hearts from specifically WT and MHC-CnA groups. Genes significantly 
(p < 0.05) up- or downregulated in MHC-CnA mice are marked in red and green, respectively. (c) Heat 
map representation of all differentially expressed LncRNAs from the microarray data between WT, TAC 
and MHC-CnA hearts. (d) Volcano plot analysis of the microarray data on the differentially expressed 
lncRNAs between WT and TAC groups. The vertical lines correspond to a 2.0 fold up and down regulation 
while the horizontal line represents a p-value of 0.05. The red dots to the left and to the right of the 
vertical lines indicate more than 2.0 fold change and represent the differentially expressed LncRNAs with 
statistical significance. Statistical significance was defined as fold change ≥ 2.0 and p-value ≤ 0.05 
between WT and TAC groups. (e) Volcano plot analysis of the microarray data on the differentially 
expressed lncRNAs between WT and MHC-CnA groups. The vertical lines correspond to a 2.0 fold up and 
down regulation while the horizontal line represents a p-value of 0.05. The red dots to the left and to the 
right of the vertical lines indicate more than 2.0 fold change and represent the differentially expressed 
LncRNAs with statistical significance. Statistical significance was defined as fold change ≥ 2.0 and p-value 
≤ 0.05 between WT and MHC-CnA groups.  
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Figure 2. Experimental validation of microarray analysis. (a) Venn diagram presentation of the amount 
of lncRNAs differentially expressed in WT, TAC and MHC-CnA hearts. (b) Heat map presentation of a 
selection of the top candidates similarly expressed in both TAC and MHC-CnA hearts versus WT hearts. 
(c) Scatter plot of the top candidates presented in (b) in WT versus TAC hearts. (d) Real-time PCR analysis 
of relative abundance of Bigheart (uc009hiz.1;ak014683;Bigheart) in hearts from WT, MHC-CnA and mice 
subjected to TAC *p < 0.05, **p < 0.005, ***p < 0.0005, #p < 0.0001 vs wild type group (error bars are 
s.e.m.). 
 
in WT versus TAC and WT versus MHC-CnA are presented in tabular format (Table 1-
4). 
Next, we focused on the 755 lncRNAs that showed common increased expression in 
both hypertrophic models. Among the 30 most strongly increased lncRNA 
transcripts, Braveheart (Bvht) and MALAT1 appeared (Figure 2b). We then selected 
lncRNA candidates that showed a similar differential expression pattern in both 
hypertrophy models and were not studied in this context before. Among these 
cardiac hypertrophy associated long noncoding transcripts, AK014683 (Ensembl ID 
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4833412C05Rik, or Bigheart) was selected because it showed 5-15 fold differences 
with WT hearts (Figure 2b, c). The expression levels of Bigheart were validated by 
RT-qPCR in WT, TAC and MHC-CnA hearts, confirming its dramatic differentially 
expression patterns originally detected by the microarray platform (Figure 2d). 
Interestingly, a recent publication by Ye et al. showed that the expression levels of 
Bigheart in the cardiac muscle were increased after both TAC-induced hypertrophic 
remodeling as after induction of myocardial infarction in mice.34  
Taken together, these data demonstrate that nearly two thousand lncRNAs display 
differential expression upon pressure overload-induced cardiac remodeling and 
dysfunction. Also, a large number of differentially expressed lncRNAs showed 
common aberrant expression in two established mouse models of non-ischemic 
forms of heart failure. Expression levels of lncRNA Bigheart were significantly 
increased in TAC and MHC-CnA mouse hearts. 
 
A functional role of Bigheart in cardiomyocyte hypertrophy 
Despite a steady increase in reports on the functional involvement of single 
lncRNAs, the functional implication of the vast majority of dysregulated lncRNAs in 
the heart remains virtually unexplored territory. Bigheart has been first described 
by Ye et al. showing that Bigheart levels were increased after TAC surgery in mice, 
as well as in mouse hearts after myocardial infarction. Interestingly, in their hnRNP 
U knockout mouse hearts, which develop lethal dilated cardiomyopathy and 
multiple defects in cardiac mRNA splicing, Bigheart was persistently expressed. 
hnRNP U deletion in the heart lead to accumulation of an alternatively spliced 
Bigheart isoform with an internal exon 2 skipped. The aberrant splicing of Bigheart 
pre-mRNA only occurred in the mutant mouse hearts.34 However, the functional 
role of Bigheart in the diseased myocardium is still unknown. To evaluate whether 
Bigheart is directly able to influence cardiomyocyte hypertrophy, an obvious 
functional alteration in pressure overload-induced remodeling, neonatal rat 
cardiomyocytes were transfected with specific siRNA species to silence Bigheart 
specifically in the rat genome. RNAi against Bigheart resulted in a pronounced 
downregulation of 90% of Bigheart levels compared to cells transfected with a 
scrambled siRNA control (Figure 3a). Next, neonatal rat cardiomyocytes, transfected 
with either scrambled siRNA or a Bigheart-specific siRNA, were treated with the 
prohypertrophic agonist α1-adrenergic agonist phenylephrine.35 To monitor 
changes in cell size, cardiomyocytes were stained for sarcomeric α-actinin and cell 
surface areas were determined. Repression of the Bigheart, which showed 
increased expression in TAC or MHC-CnA hearts compared to WT hearts (Figure 2d), 
resulted in a clear and significant reduction of PE-induced cardiomyocyte 
hypertrophy (Figure 3a, b).  
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Figure 3. RNAi-mediated silencing reveals selected lncRNAs as necessary mediators of cardiac 
remodeling. (a) Confocal microscopy images of neonatal rat cardiomyocytes untreated or treated with 
PE, and transfected with siRNA against Bigheart or scrambled control. Nuclei were visualized with DAPI 




Taken together, these results indicate that Bigheart is responsive to RNAi silencing, 
and has endogenous pro-hypertrophic properties in neonatal cardiomyocytes.  
 
Bigheart DNA sequence is partly conserved between mouse and human  
Next, used bioinformatics tools to get a better understanding of the mechanism by 
which Bigheart regulates cardiac hypertrophy. Mouse Bigheart has 2 transcripts: 
4833412C05Rik-001 of 1083bp long and 4833412C05Rik-003 of 850 bp in length 
(Figure 4a) located on chromosome 7: 67,784,538-67,803,496, reverse strand. Its 
human orthologue consist of one transcript, RP11-654A16.3-001, that is 588 bp in 
length.  Sequence alignment between human Bigheart and the mouse counterpart 
revealed that large parts of the sequence are completely conserved among those 
species (Figure 4b).  Many lncRNAs do not show the same pattern of high 
interspecies conservation as protein-coding genes. When they do, it’s often an 
indication of functionality. On the other hand, conservation could be found in 
functional interactions with proteins or other RNAs, as opposed to the conservation 












Figure 4. Location of Bigheart. (a) Image of chromosomal location with different transcripts for mouse 
Bigheart (b) Alignment image of human Bigheart 20 and mouse Bigheart (lower). Orange regions are 




Bigheart targets MOV10, a RISC complex RNA helicase 
Here we performed gene ontology (GO) analysis for RP11-654A16.3 (human 
Bigheart, NONCODE ID NONHSAG018057.2) with NPInter software 
(www.bioinfo.org/NPInter). This analysis revealed that human Bigheart was 
significantly associated with 10 biological processes (Tabel 5). Interestingly, many of 
these pathways indicate that Bigheart plays a role in mRNA processing events, 
which is consistent with the earlier publication of Ye et al. showing hnRNP U, an 
upstream regulator of Bigheart, is required for normal cardiac mRNA splicing.34  
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Tabel 5. GO pathway analysis of RP11-654A16.3 (NPInter software). 
#ncName GO term The description of GO term 
NONHSAG018057 GO:0006397 mRNA processing  
NONHSAG018057 GO:0006366 transcription from RNA polymerase II promoter  
NONHSAG018057 GO:0060011 Sertoli cell proliferation  
NONHSAG018057 GO:0006369 termination of RNA polymerase II transcription  
NONHSAG018057 GO:0006378 mRNA polyadenylation  
NONHSAG018057 GO:0006379 mRNA cleavage  
NONHSAG018057 GO:0031124 mRNA 3'-end processing  
NONHSAG018057 GO:0090305 nucleic acid phosphodiester bond hydrolysis  
NONHSAG018057 GO:0019054 modulation by virus of host cellular process  
NONHSAG018057 GO:0046778 modification by virus of host mRNA processing 
 
 
Moreover, interaction analysis with NPInter software revealed several interacting 
partners of Bigheart (Tabel 6). NPInter documents functional interactions (primarily 
physical interactions) between noncoding RNAs (except tRNAs and rRNAs) and 
proteins, RNAs and DNAs, which are experimentally verified. Among those genes, 
MOV10 is involved in pre-mRNA processing (Tabel 6). Further experimentally 
verified analysis revealed that MOV10 plays a significant role in both diastolic and 
systolic blood pressure, hypertension and coronary artery calcification, linking it 
directly to pressure overload-induced heart diseases.  
 
 
Tabel 6. Functional interaction between RP11-654A16.3 and other molecules (NPInter software). 
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We performed PAR-CLIP experiments for 3'
end processing factors;CLIPseq data were
analysed by CLIPdb PAR-CLIP 22813749 
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Tabel 7. Functional interaction between RP11-654A16.3 and other molecules (NPInter software). 
REPORTED 
GENE(S) CHR_ID CHR_POS DISEASE/TRAIT SNPS P-VALUE PUBMEDID 
MOV10 1 112673921 Blood pressure rs2932538 0.000008 21909110 
MOV10 1 112673921 Diastolic blood pressure rs2932538 1E-09 21909115 
MOV10 1 112673921 Hypertension rs2932538 0.0000003 21909115 
MOV10 1 112673921 Systolic blood pressure rs2932538 1E-09 21909115 
MOV10 1 112646431 Systolic blood pressure rs10745332 3E-09 25249183 
MOV10 1 112646431 Diastolic blood pressure rs10745332 0.00000008 25249183 
MOV10 1 112646431 Hypertension rs10745332 3E-09 25249183 
WDR33 2 127745011 Coronary artery calcification rs17015535 0.000006 23870195 
 
Taken together, bioinformatics analyses of interaction partners and GO pathways 
aid in the identification of mechanisms by which lncRNAs can influence adverse 
cardiac remodeling. Here we revealed new mechanistic insights in the role of 






The Encyclopedia of DNA Elements project revealed that more than 97% of genomic 
DNA is actively transcribed in various species of RNA, with only a very small 
proportion of mammalian genomes encoding protein-coding genes that yield 
messenger RNA transcripts.7,8 Small ncRNAs, most notably microRNAs (18-22 
nucleotides long), have been extensively studied and implicated as key players in 
several human pathologies, including cardiovascular diseases.37 However, much less 
is known about the biology and functions of lncRNAs in the cardiovascular system. 
Despite a steady increase in reports on the involvement of single lncRNAs, the 
functional implication of the vast majority of dysregulated lncRNAs in heart remains 
virtually unexplored territory. Although recent studies performed lncRNA profiling 
in models of cardiac differentiation, cardiac disease and cardiac 
angiogenesis,17,21,38,39 the discipline covering lncRNAs in cardiovascular diseases 
remains preliminary in nature and often address different diseases entities.  
In the current study, we profiled lncRNAs in non-ischemic, failing hearts of two 
classical mouse models, a sustained transverse aortic constriction model and mice 
harboring a cardiac-specific calcineurin transgene, and discovered ~3.400 
differentially expressed lncRNAs in the failing murine heart. We chose the Arraystar 
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platform for lncRNA and mRNA profiling since it provided the most reliable resource 
for lncRNA and mRNA profiling in a single experiment. Furthermore, next 
generation sequencing 7 applications and bioinformatics routines are not equally 
well established, and annotation of novel, putative lncRNAs remains a challenge. 
Among identified lncRNAs, we detected Braveheart, a critical regulator of cardiac 
cell fate,10 and MALAT1, a regulator of endothelial cell function and vessel growth.13  
Apart from these known lncRNAs, we identified the differentially expressed lncRNA 
Bigheart that was previously shown to be upregulated in heart disease models, but 
it’s function in the context of heart disease or downstream mechanism has not been 
described before. In the current study, we explored the functional role of Bigheart. 
Bigheart was significantly upregulated in cardiac hypertrophic remodeling. In line, 
RNAi-mediated knockdown of Bigheart transcripts remarkably decreased agonist-
induced hypertrophic effects, suggesting its direct functional requirement in this 
process.  
To obtain mechanistic insight in the potential lncRNA-mediated molecular 
mechanisms underlying cardiac remodeling, we took advantage of the NPInter 
database that documents functional interactions between noncoding RNAs and 
proteins, RNAs and DNAs based on experimentally verified results. GO-analysis-
based bioinformatics revealed that Bigheart in involved in mRNA processing (Tabel 
5). Indeed, one of the verified interaction partners of Bigheart is MOV10, a putative 
RNA helicase that is involved in pre-mRNA processing (Tabel 6). GO analysis 
implicated MOV10 in both diastolic and systolic blood pressure, hypertension and 
coronary artery calcification, linking it directly to pressure overload-induced heart 
diseases. A genome-wide association study of systolic and diastolic blood pressure, 
shows that MOV10 is associated with blood pressure and hypertension.40,41 Bigheart 
was previously implicated in a cardiac-specific heterogeneous nuclear 
ribonucleoprotein U (hnRNP U) knockout model of cardiac disease. Loss of hnRNP U 
expression in cardiomyocytes results in impaired sarcomere contractility and cardiac 
function, and mice deficient in hnRNP U expression in the heart develop a severe 
DCM phenotype. HnRNP U protein is required for normal pre-mRNA splicing and 
postnatal heart development and function. RNA sequencing of hnRNP U-deficient 
hearts showed activation of lncRNA Bigheart. Loss of hnRNP U resulted in context-
dependent splicing defects, since mixed splicing activities (skipping and inclusion) 
were observed. HnRNP U mutant hearts showed increased Bigheart levels. In 
addition, Bigheart is expressed as two alternatively spliced isoforms in hnRNP U 
mutant cells. Deletion of hnRNP U resulted in persistent expression of Bigheart in 
the heart, and the accumulation of an alternatively spliced Bigheart isoform with an 
internal exon 2 skipped.34  HnRNP U has binds specifically to lncRNAs and plays a 
role in chromosome organization.34 Moreover, hnRNP U protein is required for 
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chromosomal localization of Xist RNA in normal X chromosome inactivation42 and 
interacts with lncRNA Firre that is located on the X chromosome and is essential for 
maintaining or establishing higher-order nuclear architecture.43 Since hnRNP U acts 
upstream of Bigheart and is involved in cardiac pre-mRNA splicing events, it is likely 
that Bigheart also plays a direct role in the RNA splicing process, presumably via 
interaction with the RNA helicase MOV10. Introns are spliced from pre-mRNAs by 
the spliceosome of eukaryotic cells. RNA helicases are key regulators of splicing. 
They are involved in promoting conformational rearrangements and ensure that 
only appropriate substrates proceed through the splicing reactions.  
 
RNA helicases are key regulators of gene expression that act by remodeling RNA 
secondary structures and RNA-protein interactions. MOV10 has an ATP-dependent 
5' to 3' in vitro RNA unwinding activity. Moreover, MOV10 interacts directly with 
UPF1, the key component of the nonsense-mediated mRNA decay pathway. 
Knockdown of MOV10 resulted in increased mRNA half-lives of MOV10-bound as 
well as UPF1-regulated transcripts, indicating that MOV10 helicase activity 
promotes mRNA degradation of its target mRNAs and UPF1-regulated transcripts.44  
 
Accumulating evidence shows that alternative mRNA splicing affects a broad 
spectrum of cardiac genes during normal development as well as pathological 
progress of heart diseases.45-48 In patients with myotonic dystrophy type 1 abnormal 
splicing of SCN5A (the gene encoding the Na+ channel subunit expressed in the 
human heart) lead to the life-threatening heart rhythm disorder Brugada 
syndrome.49 Another study used the Affymetrix Exon array to evaluate mRNA 
splicing in left ventricular myocardial RNA from controls and patients with ischemic 
cardiomyopathy. They observed that mRNA splicing is broadly altered in human 
heart disease and that patterns of aberrant RNA splicing in four sarcomeric genes 
accurately assign samples to control or disease classes, suggesting distinct changes 
in mRNA splicing between groups. The ratio of minor to major splice variants of 
TNNT2, MYH7, and FLNC classified independent test samples as control or disease 
with >98% accuracy.50 Another example is the central fructose-metabolizing enzyme 
ketohexokinase, which is shown to be regulated during pathological cardiac 
hypertrophy through the splicing factor SF3B1.51 Although RNA splicing is a major 
contributor to total transcriptome complexity, the functional role and regulation of 
splicing in heart failure remain poorly understood. The discovery of pro-
hypertrophic lncRNA Bigheart that is implicated in cardiac splicing, might shed a 
new light on the regulation of splicing in heart disease. Further validation to confirm 
that MOV10 is responsible for the Bigheart-mediated effect on cardiac hypertrophy 
is still required.  
127 
Although lncRNA research is a relatively new field, approaches to therapeutically 
target dysregulated lncRNA transcripts are already being pursued by in vivo 
inhibition with small interfering RNAs or GapmeRs, a therapeutics field inspired by 
the success of microRNA therapeutics.52 Indeed, MALAT1 inhibition produced a 
promigratory response and increased basal sprouting and migration, whereas 
proliferation of endothelial cells was inhibited, reducing blood flow recovery and 
capillary density after hindlimb ischemia.13 Further functional characterization of 
lncRNAs will enhance our understanding of the molecular mechanisms underlying 
pathological cardiac remodeling and could open a new field for therapeutic 
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Supplemental Figure 1. Profiling of long non coding RNAs in two animal models of heart failure. (a) 
Representative images of whole hearts (top panels), haematoxylin & eosin (H&E)- stained sections of 
four-chamber view (second panel), high magnification H&E-stained sections (third panel), Sirius Red 
stained sections (fourth panel) and wheat germ agglutinin (WGA)-stained (fifth panel) histological 
sections of hearts from wild type (WT), calcineurin transgenic mice (MHC-CnA) and transverse aortic 
constriction (TAC) pressure overloaded. (b) Real-time PCR analysis of relative transcript abundance for 
the fetal marker genes Myh7, Nppa, and Acta1 in hearts from wild type (WT), calcineurin transgenic mice 
(MHC-CnA) and mice subjected to transverse aortic constriction (TAC) *P < 0.05, **P < 0.005 vs wild type 
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Table 1. WT versus TAC 
Gene Symbol logFC p value  -log10Pval 
AK003532 4.936 1.03E-07 6.987 
AK155809 4.832 1.64E-03 2.786 
AK030587 4.812 5.28E-07 6.278 
AK020360 4.675 2.43E-06 5.614 
AK156805 4.654 2.81E-03 2.552 
CRLM3 4.284 1.15E-05 4.939 
Lrp8 4.192 3.51E-07 6.455 
humanlincRNA1389 4.161 2.22E-04 3.653 
Sprr2g 4.140 2.09E-04 3.680 
AK036610 4.063 7.10E-05 4.149 
AK029663 3.995 7.76E-04 3.110 
AK086534 3.986 7.13E-05 4.147 
AK148952 3.897 3.43E-03 2.464 
AK145301 3.741 3.32E-05 4.479 
Gm16192 3.657 6.62E-07 6.179 
AK011682 3.566 3.40E-03 2.469 
Rcn2 3.506 3.43E-05 4.465 
Gm12301 3.489 1.50E-03 2.823 
AK136698 3.482 3.08E-04 3.512 
AJ409479 3.472 2.08E-04 3.682 
AK047313 3.422 3.98E-02 1.401 
AK006109 3.342 1.80E-05 4.746 
4732487G21Rik 3.315 2.42E-04 3.616 
Vmn2r29 3.257 6.07E-06 5.217 
AK016489 3.248 5.22E-05 4.282 
AK041310 3.188 3.28E-03 2.484 
AK143464 3.175 1.29E-06 5.889 
MM9LINCRNAEXON11713- 3.156 8.83E-04 3.054 
Gm12092 3.148 3.04E-04 3.517 
AK005183 3.142 8.63E-07 6.064 
BC030398 3.134 2.43E-04 3.614 
uc.451 3.118 1.94E-02 1.713 
AK015101 3.111 3.62E-04 3.442 
MM9LINCRNAEXON12060+ 3.091 1.28E-03 2.891 
AJ409495 3.067 3.31E-04 3.480 
AK042604 3.065 5.81E-07 6.236 
AK002748 3.057 3.52E-03 2.454 
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Gene Symbol logFC p value  -log10Pval 
AK086591 3.031 1.91E-05 4.719 
AK192563 3.027 2.59E-04 3.587 
AK082921 2.985 1.64E-05 4.786 
AK048000 2.985 1.73E-04 3.762 
AK078752 2.980 2.59E-06 5.586 
AK131851 2.958 1.56E-03 2.807 
AK052076 2.952 3.72E-02 1.429 
D430040D24Rik 2.950 4.07E-04 3.391 
4930570G19Rik 2.923 8.36E-04 3.078 
GDNFR-alpha 2.912 9.54E-02 1.021 
AK016944 2.886 2.16E-04 3.665 
AK033935 2.881 4.32E-03 2.364 
AK007126 2.874 5.69E-05 4.245 
Zfp82 2.873 6.79E-04 3.168 
AK137188 2.862 2.30E-06 5.637 
mouselincRNA0569 2.854 1.22E-03 2.914 
AK052417 2.849 1.30E-05 4.885 
AK013700 2.841 2.66E-05 4.575 
AK019332 2.761 6.57E-03 2.182 
AK172237 2.743 1.19E-05 4.923 
AK079804 2.730 7.25E-03 2.140 
AK044126 2.728 5.35E-03 2.272 
Sfrs14 2.706 1.90E-04 3.720 
AK006677 2.705 2.75E-04 3.560 
LOC100270707 2.700 8.18E-03 2.087 
AK008891 2.675 1.44E-04 3.842 
humanlincRNA1768 2.668 8.16E-04 3.088 
Telomerase-vert.2 2.668 4.73E-05 4.325 
Gm11164 2.664 3.76E-07 6.425 
BC028801 2.660 2.61E-06 5.583 
C030013C21Rik 2.659 2.92E-05 4.535 
AK035076 2.657 2.13E-04 3.671 
Gm15310 2.655 1.05E-04 3.979 
AK039307 2.652 2.48E-03 2.606 
AK089363 2.649 2.89E-04 3.539 
BM942986 2.631 5.88E-05 4.230 
AK006093 2.630 9.94E-03 2.003 
AK139621 2.617 1.55E-02 1.810 
134 
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humanlincRNA2047 2.613 2.85E-01 0.545 
Gm16118 2.612 1.33E-03 2.877 
AK163739 2.606 1.57E-04 3.803 
Aoah 2.594 2.82E-04 3.550 
Gm13334 2.593 2.75E-05 4.561 
AK017368 2.588 1.65E-02 1.783 
AK076843 2.583 3.75E-02 1.426 
AK046653 2.583 3.28E-04 3.485 
Gm15297 2.577 1.35E-02 1.869 
AK034419 2.571 3.67E-05 4.436 
Cdcp1 2.566 1.21E-04 3.918 
AK141773 2.562 2.14E-05 4.670 
AK082265 2.557 2.21E-07 6.655 
BB497033 2.547 2.40E-06 5.621 
Gm15541 2.544 1.25E-04 3.903 
BC134356 2.543 1.35E-04 3.868 
Ptn 2.542 1.83E-03 2.738 
Gm16990 2.539 6.46E-05 4.190 
AK033223 2.536 3.78E-05 4.423 
AK076245 2.528 2.27E-04 3.643 
AK084834 2.523 1.25E-03 2.903 
AK081202 2.519 2.80E-04 3.552 




Table 2. WT versus TAC 
Gene Symbol logFC p value  -log10Pval 
MM9LINCRNAEXON11101- -3.923 3.12E-04 3.506 
Gm12620 -3.927 1.02E-04 3.991 
Gm13232 -3.936 9.02E-05 4.045 
Gm6733 -3.937 1.14E-03 2.942 
Gm8979 -3.956 1.75E-05 4.758 
AK136146 -3.959 4.14E-05 4.383 
AK036276 -3.959 9.73E-04 3.012 
Gm8822 -3.959 3.68E-04 3.434 
AK161725 -3.980 2.85E-02 1.546 
uc.203 -3.982 1.87E-04 3.729 
Kars-ps1 -3.987 1.03E-05 4.989 
Gm11841 -3.989 2.18E-05 4.661 
Gm5466 -4.005 1.35E-05 4.871 
Gm13237 -4.016 5.49E-05 4.260 
AK171173 -4.025 1.95E-04 3.710 
Gm14937 -4.027 1.09E-05 4.963 
Gm14269 -4.032 2.69E-05 4.571 
Gm15331 -4.045 1.08E-05 4.967 
Gm11839 -4.073 2.38E-04 3.624 
Gm13167 -4.086 6.57E-05 4.183 
Gm7308 -4.092 1.06E-05 4.973 
Gm12626 -4.095 8.76E-06 5.058 
AC138228.1 -4.104 6.48E-06 5.188 
Gm3608 -4.104 6.99E-03 2.155 
Gm13082 -4.110 2.21E-04 3.655 
AK017799 -4.119 2.03E-06 5.692 
Ankrd16 -4.125 7.93E-05 4.101 
AK033485 -4.128 5.35E-04 3.272 
Gm12623 -4.129 9.81E-06 5.009 
Gm14670 -4.152 9.47E-04 3.023 
mKIAA0031 -4.169 5.42E-05 4.266 
Gm11448 -4.176 2.49E-05 4.604 
Anp32-ps -4.177 1.19E-03 2.924 
Timm44 -4.180 3.08E-05 4.511 
Gm8410 -4.183 4.20E-04 3.377 
Gm6563 -4.195 4.03E-06 5.394 
Gm5383 -4.196 3.54E-04 3.451 
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Rpl3l -4.201 7.65E-06 5.117 
BC030682 -4.212 2.38E-04 3.623 
Gm15754 -4.260 1.67E-06 5.778 
Nsun2 -4.261 2.83E-03 2.549 
BC080792 -4.292 1.06E-02 1.977 
Maf1 -4.303 3.24E-04 3.490 
Gm15861 -4.328 1.11E-03 2.954 
Gm13378 -4.331 1.70E-04 3.769 
AK142657 -4.389 6.73E-04 3.172 
Gm15285 -4.396 1.63E-04 3.789 
Gm9308 -4.417 1.00E-06 5.999 
AK142426 -4.442 5.69E-03 2.245 
Gm12097 -4.461 3.58E-04 3.446 
Hnrph1 -4.482 1.34E-04 3.872 
RP23-273I12.2 -4.497 4.06E-04 3.391 
Gm11893 -4.505 1.33E-02 1.877 
Ywhae -4.506 2.92E-03 2.535 
Gm13140 -4.509 8.41E-05 4.075 
Gm12647 -4.523 2.30E-03 2.639 
Gm13498 -4.550 4.03E-05 4.395 
RP23-147O14.4 -4.551 3.64E-07 6.439 
Gm10254 -4.560 8.62E-05 4.065 
humanlincRNA2192 -4.630 8.75E-04 3.058 
AK166453 -4.680 7.06E-06 5.151 
AK051369 -4.687 9.63E-05 4.016 
AK020577 -4.712 8.26E-05 4.083 
Itgb1 -4.762 8.31E-04 3.080 
Gm9826 -4.802 4.21E-05 4.376 
Nrbp1 -4.862 2.72E-03 2.566 
uc.420 -4.920 1.82E-05 4.740 
Gm15502 -4.943 2.76E-03 2.558 
Ivns1abp -4.991 1.25E-04 3.904 
Scs -4.991 1.30E-04 3.887 
Gm15899 -5.067 1.17E-03 2.932 
Got1 -5.101 2.95E-04 3.530 
RP23-34J4.1 -5.179 2.33E-05 4.632 
Aph1a -5.207 2.18E-04 3.662 
Vdac3 -5.313 3.23E-04 3.491 
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Gene Symbol logFC p value  -log10Pval 
Gm15790 -5.326 2.60E-04 3.585 
AK014252 -5.331 6.13E-04 3.213 
Neat1 -5.340 3.10E-04 3.509 
AK009593 -5.378 2.87E-04 3.543 
Gm11235 -5.486 2.62E-05 4.582 
Got2-ps1 -5.499 1.13E-03 2.946 
Gm11838 -5.536 7.73E-06 5.112 
Eif5al3-ps -5.557 1.40E-05 4.854 
Gm4913 -5.591 2.41E-04 3.618 
AK142855 -5.617 1.21E-04 3.918 
AK050743 -5.646 1.45E-03 2.840 
uc.185 -5.709 9.35E-06 5.029 
Gm6706 -5.787 2.07E-05 4.684 
Gm9825 -5.788 7.58E-05 4.121 
Gm14037 -5.825 3.46E-06 5.461 
Gm14078 -5.889 1.63E-04 3.787 
Gm12504 -6.022 4.07E-05 4.390 
Qk -6.194 7.49E-05 4.125 
Gm14016 -6.346 2.49E-05 4.604 
AK013372 -6.354 7.58E-06 5.120 
uc.366 -6.567 9.78E-05 4.010 
AK020213 -6.658 2.14E-02 1.670 




Table 3. WT versus MHC-CnA 
Gene Symbol logFC p value  -log10Pval 
AK014683 5.777 2.47E-06 5.607 
AK020360 5.524 1.52E-06 5.819 
AK021043 5.367 7.67E-07 6.115 
AK156805 5.357 1.76E-03 2.754 
CRLM3 5.143 6.26E-06 5.203 
AK006317 5.059 8.80E-07 6.056 
AK036610 4.901 4.94E-05 4.306 
AK013557 4.726 2.95E-07 6.531 
humanlincRNA1389 4.705 1.07E-04 3.969 
AK003532 4.688 6.69E-08 7.174 
Gm12092 4.612 7.31E-05 4.136 
Gm12295 4.503 6.17E-06 5.210 
AK029663 4.272 5.41E-04 3.267 
MM9LINCRNAEXON12060+ 4.153 7.40E-04 3.131 
AK145301 4.002 2.54E-05 4.596 
AK144299 3.909 8.17E-05 4.088 
Gm11476 3.886 3.44E-04 3.463 
AK143464 3.819 6.35E-07 6.197 
Lrp8 3.788 8.77E-07 6.057 
AK079801 3.764 9.97E-02 1.001 
AK042604 3.751 2.54E-04 3.595 
AK030587 3.745 1.11E-06 5.956 
AJ409479 3.663 1.71E-04 3.768 
4930512H18Rik 3.660 1.27E-05 4.895 
AK135766 3.585 1.86E-01 0.731 
AK035076 3.563 1.82E-04 3.740 
MM9LINCRNAEXON10137- 3.526 2.17E-05 4.663 
AK016489 3.499 6.96E-05 4.157 
AK007126 3.497 1.60E-05 4.795 
AK137188 3.492 1.74E-06 5.759 
AK136902 3.439 2.22E-04 3.653 
AK084560 3.426 7.50E-07 6.125 
AK016944 3.412 1.82E-04 3.740 
Ppp1r1c 3.381 1.63E-05 4.788 
Gm15247 3.331 6.60E-05 4.180 
AK010197 3.330 3.87E-05 4.412 
Gm6277 3.328 1.24E-04 3.907 
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AK031202 3.298 6.99E-07 6.156 
Gm15810 3.236 1.57E-04 3.803 
AK149258 3.227 1.20E-04 3.922 
BC028532 3.207 7.37E-05 4.132 
AK048037 3.203 2.93E-04 3.534 
Gm15297 3.168 5.89E-03 2.230 
AK085787 3.127 7.38E-07 6.132 
A430093F15Rik 3.116 6.37E-06 5.196 
B130046B21Rik 3.102 1.19E-03 2.923 
Gm9962 3.100 1.58E-01 0.802 
AK136666 3.083 6.49E-04 3.188 
4930570G19Rik 3.058 6.68E-04 3.175 
BC028660 3.027 7.29E-05 4.137 
AK052417 3.013 5.47E-06 5.262 
AK007034 3.000 3.71E-03 2.431 
AK041310 2.997 4.34E-03 2.363 
Gm12542 2.995 4.79E-03 2.320 
A830039N20Rik 2.964 3.21E-06 5.493 
Fxy 2.962 1.49E-04 3.828 
AK084753 2.943 6.97E-07 6.156 
Gm13334 2.940 2.05E-05 4.688 
Gm15934 2.939 4.64E-04 3.334 
AK082921 2.928 1.24E-05 4.907 
AK166127 2.906 4.36E-06 5.361 
AK076775 2.905 2.33E-04 3.633 
AK166199 2.888 1.13E-05 4.947 
AK039307 2.882 2.60E-03 2.585 
Gm15079 2.867 1.42E-06 5.847 
AK034630 2.857 5.27E-05 4.278 
AK089560 2.846 5.28E-04 3.277 
AK027968 2.846 2.89E-08 7.539 
AK048000 2.840 1.87E-04 3.728 
AK134233 2.835 1.11E-04 3.956 
AK089171 2.824 1.93E-04 3.715 
AK140174 2.817 4.14E-06 5.383 
AK076843 2.809 2.63E-02 1.580 
AK006109 2.802 5.94E-07 6.226 
BC094434 2.796 9.70E-02 1.013 
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AK015101 2.792 5.19E-04 3.285 
AK034309 2.790 2.16E-03 2.666 
AK139146 2.778 3.96E-04 3.402 
AK086534 2.726 3.32E-04 3.479 
BC125002 2.720 1.08E-03 2.967 
AK006973 2.719 8.60E-04 3.066 
BB497033 2.714 5.97E-07 6.224 
AK015703 2.713 9.13E-03 2.040 
Gm12454 2.710 6.93E-05 4.159 
AK131851 2.702 6.32E-04 3.199 
AK006677 2.700 1.84E-02 1.736 
AK165889 2.685 5.06E-03 2.296 
AK134400 2.665 1.53E-03 2.815 
AK084476 2.648 1.51E-03 2.820 
AK005614 2.647 2.94E-04 3.532 
AK083645 2.639 3.06E-05 4.515 
Zfp82 2.635 1.56E-03 2.807 
AK018131 2.630 4.63E-06 5.334 
Rint1 2.627 2.99E-04 3.525 
AK089363 2.622 3.07E-04 3.513 
AK139402 2.619 3.31E-06 5.480 
AK139621 2.617 1.58E-02 1.803 
AK041628 2.603 9.62E-06 5.017 
AK089956 2.599 1.71E-03 2.766 




Table 4. WT versus MHC-CnA 
Gene Symbol logFC p value  -log10Pval 
AK048881 -2.962 6.87E-04 3.163 
Gm7834 -2.967 1.24E-05 4.907 
AK039595 -2.972 3.09E-05 4.511 
CU041236.1 -2.982 2.16E-04 3.665 
Plekhj1 -2.983 4.75E-04 3.323 
Gm13082 -2.984 8.92E-04 3.049 
Son -2.986 2.32E-03 2.634 
1110005A23Rik -2.989 1.25E-04 3.902 
Got1 -2.997 2.22E-03 2.653 
Gm11581 -2.999 2.63E-03 2.580 
AK077785 -3.010 6.54E-03 2.185 
Gm9826 -3.020 3.51E-05 4.454 
Gm3531 -3.023 3.55E-05 4.450 
Gm15808 -3.033 2.38E-05 4.623 
Gm6563 -3.036 1.09E-05 4.963 
Gm5513 -3.037 1.91E-07 6.718 
Gm8383 -3.046 9.07E-07 6.042 
Gm7327 -3.058 1.13E-03 2.948 
mKIAA0031 -3.078 2.71E-04 3.567 
Gm9800 -3.087 3.08E-03 2.512 
mouselincRNA0143 -3.088 1.55E-05 4.808 
Gm15660 -3.091 5.23E-04 3.281 
MM9LINCRNAEXON11754- -3.094 1.67E-04 3.776 
AK014252 -3.108 9.06E-04 3.043 
Gm8402 -3.110 8.15E-05 4.089 
Gm4913 -3.127 1.92E-04 3.716 
Gm15790 -3.135 1.62E-03 2.790 
Gm8682 -3.140 1.95E-03 2.711 
BC024571 -3.161 5.29E-04 3.276 
AK042131 -3.174 1.12E-04 3.950 
Gm6762 -3.183 2.35E-03 2.629 
Gm14269 -3.203 1.29E-04 3.890 
Gm12820 -3.221 1.27E-03 2.897 
AK034318 -3.228 3.97E-04 3.402 
Gm16480 -3.245 4.20E-03 2.377 
Gm15163 -3.247 7.89E-04 3.103 
AK004273 -3.264 1.43E-05 4.844 
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AK156302 -3.267 2.59E-05 4.586 
Gm13378 -3.296 4.68E-04 3.330 
Gm15754 -3.307 4.14E-06 5.383 
AK140265 -3.311 4.03E-07 6.395 
Rshl2a -3.316 1.53E-04 3.817 
Gm13232 -3.341 1.66E-04 3.779 
AK017799 -3.359 3.53E-06 5.452 
Gm13237 -3.378 1.11E-04 3.953 
uc.366 -3.390 1.17E-04 3.932 
Gm13167 -3.393 1.54E-04 3.812 
Gm9308 -3.412 5.85E-06 5.233 
uc.420 -3.424 8.76E-05 4.057 
uc.203 -3.434 3.06E-04 3.515 
Rpl3l -3.434 1.44E-05 4.842 
AK018095 -3.465 1.20E-03 2.920 
AK047372 -3.533 1.16E-04 3.934 
Eif4a-ps4 -3.567 8.82E-06 5.054 
Gm40 -3.572 3.55E-01 0.449 
RP23-147O14.4 -3.574 1.51E-05 4.822 
Gm15332 -3.585 7.81E-06 5.107 
Gm15153 -3.653 4.07E-04 3.390 
Kars-ps1 -3.660 1.00E-04 3.998 
Maf1 -3.685 1.00E-05 4.998 
Gm9386 -3.685 3.55E-05 4.449 
Itgb1 -3.725 2.04E-03 2.690 
Ywhae -3.753 5.61E-03 2.251 
Ivns1abp -3.768 3.29E-04 3.483 
Hnrph1 -3.776 3.80E-04 3.420 
Gm12620 -3.817 1.15E-04 3.939 
Aph1a -3.826 3.67E-04 3.435 
AK142426 -3.862 9.37E-03 2.028 
AC138228.1 -3.890 1.09E-05 4.961 
Gm12623 -3.901 1.68E-05 4.774 
Gm12626 -3.902 1.21E-05 4.919 
Gm11839 -3.904 2.78E-04 3.556 
Gm13758 -3.918 3.05E-03 2.516 
Gm11838 -3.954 1.29E-05 4.888 
Gm5466 -3.965 1.11E-05 4.953 
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Got2-ps1 -3.967 3.79E-03 2.422 
Gm11841 -3.970 2.05E-05 4.687 
Gm15331 -3.980 9.84E-06 5.007 
Gm5379 -4.040 2.11E-03 2.675 
Gm11235 -4.051 3.31E-05 4.481 
Gm8459 -4.139 2.28E-03 2.643 
AK050743 -4.158 3.98E-03 2.400 
AK033935 -4.168 1.47E-03 2.832 
Scs -4.220 1.31E-04 3.882 
Vdac3 -4.286 7.80E-04 3.108 
Gm14078 -4.487 2.31E-04 3.636 
AK051369 -4.568 3.26E-05 4.486 
Gm8979 -4.619 3.48E-06 5.459 
AK013372 -4.784 3.37E-07 6.472 
humanlincRNA2192 -4.787 5.07E-03 2.295 
Gm15502 -4.945 2.73E-03 2.563 
AK166453 -5.014 8.45E-06 5.073 
BC030682 -5.187 2.30E-04 3.637 
Eif5al3-ps -5.245 1.93E-05 4.714 
Qk -5.514 1.11E-04 3.954 
Gm12504 -5.641 6.51E-05 4.187 
Gm6706 -5.695 1.93E-04 3.715 
Gm14016 -5.990 3.47E-05 4.460 
Gm14037 -6.006 4.23E-05 4.373 
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State of the art of heart failure  
Heart failure (HF) is a deadly and costly disease affecting 5.7 million people in the 
US alone, and a leading cause of hospitalization for those >65 years of age.1 It is the 
leading cause of death in industrialized nations and represents an enormous 
economic burden to society.  Pathological hypertrophy of the heart muscle is a 
common process among numerous types of heart diseases, including ischemic 
diseases, hypertension and several genetic forms of cardiomyopathies.2 Therefore, 
sustained hypertrophic remodeling represents one of the major clinical predictors 
of heart failure in humans. Hypertrophy of the left ventricle is caused by chronic 
pressure overload (hypertension, aortic stenosis).3 This can lead to decreased 
cardiac output due to reduced systolic fractional shortening. As described in 
Chapter 1, distinct phenotypes of hypertrophy can be distinguished based on the 
geometry of the heart and individual cardiomyocytes. Concentric cardiac 
hypertrophy displays a reduced left ventricular chamber dimension and thickening 
of the left ventricular free wall and septum. Eccentric hypertrophy is characterized 
by ventricular wall dilatation and can occur after myocardial infarction. Concentric 
hypertrophy can progress to eccentric hypertrophy and dilation leading to systolic 
heart failure.  
 
Current standard pharmacological therapy includes the use of inhibitors of 
angiotensin II, β-AR antagonists, aldosterone antagonists, and diuretics.4-6 Other 
modern therapies are interventional therapy (intracoronary stent implantation, 
balloon angioplasty, percutaneous valve repair),7 electrophysiological therapy 
(implantation of cardioverter defibrillator, cardiac resynchronization treatment, 
ablating arrhythmic foci),8 and surgical treatment (ventricular assist device 
implantation, heart transplantation).9 Current HF therapy is primarily focused on 
treating symptoms and fails to directly address the key underlying intracellular 
signal transduction abnormalities. Despite these different forms of treatments, HF-
related mortality remains high. It should be noted that so far there are no 
pharmacological HF drugs that target intracellular targets, as those compounds are 
difficult to create due to biochemical challenges (cell permeability issues etc.). 
Furthermore, our understanding of the deranged signaling pathways inside the cell 
that lead to the progress of the disease is far from complete. A better 
understanding of molecular mechanisms of the change in cardiac remodeling is 






The non-coding genome 
 
The genome is the carrier of hereditary information that defines an organism. 
Results from the Encyclopedia of DNA Elements (ENCODE) project indicates that at 
least 80% of the human genome can be transcribed, yet only less than 2% of our 
genome encodes proteins.10 Accumulating evidence shows that there is a clear 
correlation between the functional complexity of a certain organism and the 
diversity of its non-coding genome. The main output of the genomes of complex 
organisms is genetically active but non-coding RNA (ncRNA).11 These ncRNAs act as 
integral components of the molecular networks in development and disease.12 
Classification of ncRNAs is based on their length, function, biogenesis, polarity 
(sense or antisense), and protein-binding partners.13 According to their size, ncRNAs 
are subdivided into two groups: small ncRNAs (< 200 nt) and long ncRNAs. Long 
ncRNAs (>200 nucleotides) are relatively stable and do not undergo major 
processing before carrying out their normal functions.14 On the other hand, short 
ncRNAs (<200 nucleotides) are processed from longer precursors.15   
 
One of the most studied short ncRNAs are microRNAs (miRs), single-stranded small 
RNA molecules consisting of 20-23 nucleotides that are generated from endogenous 
hairpin transcripts.16 Numerous studies have identified alterations in expression 
levels of ncRNAs as a feature of heart failure, especially microRNAs (miRs). 
Therefore, considerable attention is focused on chemically targeting miR expression 
as a therapeutic solution for HF. In general, there are two approaches to developing 
miR-based therapeutics: miR antagonists and miR mimics. A new mechanism of 
action, the ability to function as master regulators of entire pathways and an 
apparent lack of adverse events in normal tissue make miR antisense inhibitors and 
miR mimics promising technologies for current and future therapeutics 
development. Ways to inhibit miR expression by antisense oligonucleotides are 
outlined in Chapter 3. For example, Regulus’ drug RG-101 is a GalNAc-conjugated 
anti-miR targeting miR-122 for the treatment of Hepatitis C virus (HCV). Their Phase 
I study is successfully completed, and the first Phase II clinical data are expected to 
be reported by the end of 2016 (http://www.regulusrx.com). Santaris Pharma, 
based in Copenhagen, Denmark has miravirsen (another antisense microRNA-122 
drug), in Phase II clinical trials.17,18 Phase I studies confirmed preclinical findings 
results in rodents and nonhuman primates,17,19 which showed good tolerability of 
the drug. A complete overview of preclinical studies applying anti-microRNA 
oligonucleotides to inhibit specific miRs in relevant models of HF is provided in 
Chapter 3, Table 1 (page 57).  
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Besides inhibiting miR expression, it is possible to induce miR expression using 
adeno-associated virus (AAV) vectors. Although AAV9 is not widely used for miR 
overexpression yet, in various cases it has proven to be beneficial to stimulate 
expression of a particular miR, as also described for miR-148a by AAV9 in Chapter 4. 
Intraventricular delivery of AAV vectors induced long-term (18 months) 
overexpression of miR-669a and improved survival of β-sarcoglycan (Sgcb)-null 
mice, a model for muscular dystrophy. Treated dystrophic mice displayed reduced 
pathological remodeling, enhanced sarcomere organization and increased systolic 
fractional shortening of the left ventricle.20 Furthermore, AAV-mediated 
overexpression of hsa-miR-590 and hsa-miR-199a in mice, after myocardial 
infarction, reduced infarct size and significantly improved cardiac function because 
they trigger cardiomyocyte proliferation and cardiac regeneration after myocardial 
infarction.21 Other reports indicate that AAV9–miR-378 attenuates cardiac 
hypertrophy after pressure overload because of thoracic aortic constriction.22 In 
rats, AAV-mediated overexpression of miR-1 lead to a marked reduction of 
myocardial fibrosis, improved calcium handling, inhibition of apoptosis, and 
inactivation of the mitogen-activated protein kinase signaling pathways, indicating 
prevention of maladaptive ventricular remodeling.23 AAV-mediated miR-
overexpression studies in relevant heart failure models are summarized in Table 1.  
 
Although there are no clinical trials yet for AAV-mediated overexpression of miRs, 
companies are developing miR mimics for therapy. Mirna Therapeutics developed a 
miR-34 mimic, called MRX34. MRX34 is a double-stranded RNA mimic of the tumor 
suppressor miR-34, which is delivered by liposome to inhibit multiple oncogenic 
pathways as well as to stimulate anti-tumor immune response to induce cancer cell 
death (www.mirnarx.com). MRX34 is currently in a Phase I clinical trial in patients 
with unresectable primary liver cancer, and advanced or metastatic cancer with 
liver involvement (ClinicalTrials.gov identifier: NCT01829971).24 If MRX34 proves to 












Table 1 Overview of preclinical studies using AAV to overexpress certain miRs in relevant models of 
heart failure 
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miR-148a as a regulator of cardiac hypertrophy 
 
In Chapter 4 we showed that miR-148a is differentially and dynamically expressed in 
distinct subtypes of human and mouse forms of heart failure. Concentric 
hypertrophy in both human and mouse hearts correlates with increased miR-148a 
expression, whereas dilated cardiomyopathy is accompanied by a profound 
decrease in miR-148a myocardial expression levels. In the heart, miR-148a directly 
targets glycoprotein 130 (gp130). Gp130 is a shared receptor utilized by several 
related cytokines, including IL-6, IL-11, IL-27, Leukemia Inhibitory Factor (LIF), 
Oncostatin M (OSM), and Cardiotrophin 1 (CT-1). CT-1 is a member of the IL-6 
family, and CT-1-mediated gp130 activation is well known to induce eccentric 
hypertrophic remodeling in cardiac myocytes. In vitro experiments demonstrated 
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that overexpression of miR-148a, by delivery of precursor molecules, inhibits 
eccentric cardiomyocyte hypertrophy after CT-1 stimulation in neonatal rat 
cardiomyocytes. In line, silencing of endogenous miR-148a results in spontaneous 
eccentric cardiomyocyte hypertrophy. In vivo inhibition of miR-148a, by using a 
specific antagomir, caused marked impairment in cardiac function and increased 
fibrosis, which was associated with an increase in gp130 expression.  In addition, 
AAV9-mediated overexpression of miR-148a provoked a resistance to pressure-
overload induced cardiac contractile dysfunction and dilatation.  
 
In recent years, many efforts have been done to unravel the different mechanisms 
between concentric and eccentric cardiac remodeling. How molecular dysfunction 
evokes different patterns of cardiac remodeling is unclear. Our results demonstrate 
that miR-148a can prevent the transition from concentric hypertrophy induced by 
pressure-overload towards eccentric hypertrophic remodeling and dilation of the 
left ventricle. This indicates that the different forms of hypertrophic remodeling are 
induced by distinct molecular programs.  
 
A recent study from the Molkentin lab describes a tension-based model, the force-
time integral of cardiomyocyte function, that distinguishes between hypertrophic 
versus dilated cardiomyopathy. They used an array of genetically altered mice that 
permit the systemic tuning of sarcomeric tension generation to assess 
consequences on cardiac remodeling and disease. This study focused on hereditary 
conditions affecting cardiac sarcomeric proteins. Well-characterized functionally 
opposite mutations of the calcium-sensing thin filament sarcomeric protein, cardiac 
troponin C (cTnC) were used that quantitatively shift calcium-binding and tension-
producing features of the myofilaments at a fixed amount on either side of normal 
to correlate with hypertrophic remodeling of the heart. The computational model of 
the integral of myofilament tension development predicted HCM and DCM in mice 
associated with essentially any sarcomeric gene mutations. They were also able to 
accurately predict human cardiac phenotypes from data generated in induced-
pluripotent-stem-cell-derived myocytes from familial cardiomyopathy patients.25 
Whether miR-148a is directly activated by changes in tension of the heart muscle 




Phenotypic screening to identify microRNAs involved in CT-1-mediated cardiac 
hypertrophy 
 
CT-1 is known for many years for its ability to induce eccentric hypertrophy in 
neonatal cardiomyocytes.  However, few articles report whether chronic CT-1 
administration leads to eccentric cardiac remodeling and altered cardiac function in 
vivo. López-Andrés and colleagues showed that CT-1 treatment increased left 
ventricular volumes, reduced fractional shortening and ejection fraction, and 
induced myocardial dilatation and myocardial fibrosis in Wistar rats treated with 20 
μg /kg per day during 6 weeks.26 To the best of our knowledge, our study is the first 
demonstration that chronic CT-1 administration leads specifically to dilation without 
an initial concentric hypertrophic response in mice. The finding that microRNA miR-
148a directly targets Gp130, a key component of this CT-1 pathway, identifies a 
possible additional site of therapeutic intervention for heart failure by the class of 
RNA therapeutics.  
 
Since we found that a specific miR can control the CT-1 pathway, we wanted to 
know if there are additional miRs that exert a similar effect. To this end, we 
performed a phenotypic high-throughput screen in neonatal rat cardiomyocytes 
stimulated with CT-1. CT-1 is a 201 amino acid protein member of the IL-6 family, 
that signals through a unique receptor system, consisting of leukemia inhibitory 
factor receptor beta (LIFRb) and a common signal transducer, the glycoprotein 130 
(gp130).27 Signal transduction via gp130 involves at least three major downstream 
pathways: the janus kinase/signal transducer and activator of transcription 
(JAK/STAT) pathway, the Ras-Raf mitogen- activated protein kinase (MAPK, 
MEK/ERK) signaling cascade, and the phosphatidylinositol 3-OH kinase (PI3K)/Akt 
pathway.27 Multiple studies have shown that CT-1 plays a dual role in the 
biophysiology of the myocardium, providing protective effects on the one hand, but 
predisposing the heart to pathological conditions on the other hand. It was shown 
that CT-1 promotes neonatal cardiac myocyte survival and proliferation and is 
required for cardiac myocyte maturation.28 Treatment of cardiac cells with CT-1 
induced heat shock protein (hsp) 70 and hsp90 synthesis and protected these cells 
against subsequent exposure to severe thermal or ischaemic stress.29 Another study 
showed that CT-1 can exert a protective effect against the damaging effects of 
simulated ischaemia/reoxygenation both when added after the simulated ischaemia 
at reoxygenation or when added prior to the simulated ischaemia. These protective 




Aside from its protective effects, CT-1 activation is also implicated in pathological 
cardiac remodeling. CT-1 was originally isolated for it’s capacity to induce 
hypertrophy in neonatal cardiac myocytes, causing eccentric hypertrophy with an 
increase in cell length without a significant change in cell width. Sarcomeric units 
were assembled in series rather than in parallel as is observed in concentric 
hypertrophy.31 In humans, increased CT-1 serum levels have been observed in 
patients with hypertensive heart disease. CT1 is more elevated in hypertensive 
patients with left ventricular hypertrophy than in patients that have normal 
ventricular thickening.32 Cardiac CT-1 secretion is stimulated by ventricular stretch 
in perfused rat hearts.33 Also in patients with aortic stenosis plasma levels of 
proBNP and CT-1 were elevated and both N-terminal proBNP and CT-1 levels 
correlated to the maximum trans-valvular aortic pressure gradient. CT-1 was the 
most significant predictor of the severity of aortic stenosis.34 Furthermore, 
expression levels of CT-1 were significantly increased in the failing left ventricular 
myocardium of patients with end-stage heart failure compared with non-failing 
donor hearts.35 Plasma CT-1 levels are increased in patients with dilated 
cardiomyopathy (DCM) and significantly correlated with the LVmass index, 
indicating that CT-1 plays an important role in structural left ventricular remodeling 
in patients with DCM.36 Also after myocardial infarction, CT-1 plasma levels are 
elevated in humans and correlate with the degree of left ventricular systolic 
dysfunction.37  
 
CT-1 has multiple functions that can result in opposite outcomes. CT-1 can promote 
proliferation and survival of cardiomyocytes but also can cause cardiac hypertrophy 
and ventricular remodeling. Also, it is able to regulate several organ systems besides 
the cardiovascular system, and it activates different signaling pathways. These facts 
make it difficult to target CT-1 for therapeutic purposes. Directing CT-1 therapeutics 
to the target organ is a key challenge that requires further investigation. The 
different activities of CT-1 reflect the different signaling pathways that are activated 
by CT-1. Thus targeting a microRNA that is involved in one specific downstream 
pathway could tackle the dual activity issues of CT-1. Since expression of particular 
miRs is in most cases not organ-specific, delivery to the target organ is again key in 
developing a therapeutic strategy.  
 
In Chapter 5, we used CT-1 as a hypertrophic stimulus on neonatal rat 
cardiomyocytes, and performed a high-content microscopy, high-throughput 
functional screen for miRs that influenced neonatal cardiomyocyte eccentric 
remodeling using a whole-genome miRNA library. The goal of this approach was to 
gain more insight in the signaling cascades and molecular mechanisms involved in 
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eccentric remodeling and dilatation. From our screen we identified miR-125b-5p, 
miR-542-3p, miR-151-5p and miR-532-3p as specific inducers of eccentric 
hypertrophy. None of those miRs has been studied in relation to eccentric 
hypertrophy and cardiovascular disease. Functional analysis of the gene 
involvement in the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways 
revealed enrichment for genes belonging to ‘Pathways in cancer’, MAPK-signaling 
pathway’, ‘Endocytosis’, and ‘Regulation of actin cytoskeleton’ as top categories. 
Further experimental validation implicating these miRs in directly targeting genes in 
those pathways is still needed.  
 
Other screens performed in cardiomyocytes have focused on identifying miRs in 
proliferation21, and miRs in concentric hypertrophy38. As expected, our top 
candidates were not among the candidate miRs in aforementioned 2 screens. An 
alternative approach, not including miRs, to differentiate hypertrophic signaling 
pathways was done by quantifying the contribution of individual pathways to 
specific changes in shape and transcript abundance. Cardiac myocytes were 
stimulated with 15 hypertrophic agonists and subsequently quantified for 
differential regulation of 5 shape features using high-throughput microscopy and 
transcript levels of 12 genes using qPCR. While hypertrophy pathways are highly 
connected, the agonist screen revealed distinct hypertrophy phenotypic signatures 
for the 15 receptor agonists they tested. They reported strong correlations between 
Bax and connective tissue growth factor (CTGF) mRNA abundance in response to 
angiotensin II and between myocyte elongation and CITED4 mRNA abundance in 
response to Nrg1. In their model, Nrg1 stimulates myocyte elongation and CITED4 
expression, LIF stimulates myocyte elongation, and CITED4 expression negatively 
regulates myocyte elongation.  Overexpression of CITED4 does not affect elongation 
of unstimulated cardiac myocytes. However, overexpression of CITED4 increased 
cell size and induces myocyte proliferation. Increased CITED4 may therefore be 
beneficial to the heart by preventing high levels of myocyte elongation.39 Although 
they also used CT-1 as one of the hypertrophic stimulants, no results on those 
experiments are described in their main report. In the supplemental data it is 
showed that CT-1 stimulation is followed by a significant increase in mRNA levels of 
IkB and VEGF, but in none of the other genes tested.  
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Bigheart: a key lncRNA in the heart 
 
It has become increasingly evident that besides miRs, another class of ncRNA, 
lncRNAs, plays a key role in cardiac physiology and pathology. An overview of 
lncRNAs involved in control of gene regulatory programs in cardiac development 
and disease is provided in Chapter 2. In Chapter 6, we profiled lncRNAs in hearts 
suffering from non-ischemic, pathological hypertrophic remodeling using two well-
established mouse models of heart failure: a surgical model of transverse aorta 
constriction (TAC) to induce sustained cardiac pressure overload and mice with 
heart-restricted calcineurin overexpression. We then selected lncRNA candidates 
that showed a similar differential expression pattern in both hypertrophy models 
and were not studied in this context before. We selected AK014683 (Ensembl ID 
4833412C05Rik, or Bigheart) because it showed 5-15 fold differences with WT 
hearts. Bigheart was previously described to be upregulated in heart disease 
models40, but its function was still unknown. We used RNA interference (RNAi) to 
silence the lncRNA Bigheart and demonstrate its functional requirement for agonist-
induced cardiomyocyte hypertrophy. GO-analysis-based bioinformatics using the 
NPInter database that documents experimentally verified functional interactions 
between noncoding RNAs and biomolecules revealed that Bigheart in involved in 
mRNA processing. It was previously shown that Bigheart expression is increased in a 
cardiac-specific heterogeneous nuclear ribonucleoprotein U (hnRNP U) knockout 
model of cardiac disease. Loss of hnRNP U resulted in context-dependent splicing 
defects, since mixed splicing activities (skipping and inclusion) were observed.40 
Indeed, our analysis using the NPInter database revealed that one of the verified 
interaction partners of Bigheart is MOV10, which is involved in pre-mRNA 
processing. Further validation to confirm that MOV10 is responsible for the 
Bigheart-mediated effect on cardiac hypertrophy is still required. Besides this new 
lncRNA Bigheart, our array also identified previously verified lncRNAs in heart 
failure. We detected Braveheart, a critical regulator of cardiac cell fate,41 and 
MALAT1, a regulator of endothelial cell function and vessel growth,42 confirming the 
accuracy of our results.  
 
 
Not all lncRNAs are lncRNAs 
 
Many non-coding RNA transcripts (including lncRNAs) contain multiple putative 
small open reading frames (ORFs) that can potentially be translated and have a 
coding function.18 There is increasing evidence that short ORFs present in some 
ncRNAs (including lncRNAs) are actually translated into small bioactive peptides, the 
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abundance of which is probably greatly underestimated. The polished rice (pri) or 
tarsal-less (tal) gene in Drosophila was originally annotated as a lncRNA, but 
demonstrated to encode a series of 11– to 32– amino acid peptides that orchestrate 
epidermal differentiation through the control of Shavenbaby transcriptional 
activity.43 Shavenbaby is a transcription factor and it was found that multiple 
genetic changes in the cis-regulatory region of shavenbaby caused the loss of dorsal 
cuticular hairs (quaternary trichomes) in larvae of Drosophila sechellia.44 
 
Recently, it was discovered that a skeletal muscle-specific lncRNA encodes a 
conserved micropeptide.  Bioinformatic analysis revealed a short 138 nucleotide 
ORF with the potential to encode a highly conserved 46 amino acid micropeptide, 
named myoregulin (MLN).45 The MLN micropeptide is highly conserved across 
mammals and shows a strong structural resemblance to phospholamban (PLN) and 
sarcolipin (SLN), both of which directly interact with the sarco-endoplasmic 
reticulum Ca2+ adenosine triphosphatase (SERCA) in the sarcoplasmic reticulum (SR) 
membrane to regulate Ca2+ pump activity.46,47 After an electrical stimulus of the 
myocyte plasma membrane, Ca2+ is released from the SR allowing Ca2+ to bind to 
the myofilament protein troponin C, which then switches on the contractile 
machinery. For relaxation to occur [Ca2+]i must decline, allowing Ca
2+ to dissociate 
from troponin. Ca2+ is pumped back into the SR by the SERCA.48 Skeletal muscle MLN 
forms a single-pass transmembrane alpha helix that binds to SERCA in the SR 
membrane and regulates calcium handling. MLN ablation in mice significantly 
increased Ca2+ handling and improved exercise performance, showing that MLN is 
the predominant inhibitor of SERCA pump activity in adult skeletal muscle.45 Very 
recently, that same group discovered a putative muscle-specific lncRNA that 
encodes a peptide of 34 amino acids and that they named dwarf open reading 
frame (DWORF).49 DWORF is robustly expressed in heart tissue, but DWORF mRNA 
was downregulated in dilated hearts of calcineurin transgenic mice. DWORF was 
found to enhance SR Ca2+ uptake and myocyte contractility displacing the inhibitory 
peptides PLN, SLN, and MLN from SERCA. Peak systolic Ca2+ transient amplitude 
and SR Ca2+ load were significantly increased in myocytes from DWORF 
overexpression mice. The pacing-induced Ca2+ transient decay rate was significantly 
enhanced in myocytes aMHC-DWORF transgenic mice, indicating increased SERCA 
activity in muscle cells overexpressing DWORF. In contrast, slow skeletal muscle 
lacking DWORF showed delayed Ca2+ clearance and relaxation and decreased 
activity of SERCA.49  
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The reason why these micropeptides were missed earlier is that it is very difficult to 
identify functional short ORFs in RNA transcripts. As bioinformatics tools improve, 
more micropeptides will most likely be found and characterized.  
 
 
Therapeutic potential of targeting lncRNAs 
 
Our understanding of lncRNA biology is still in an elementary stage and much more 
experimental work is needed. As described in Chapter 1, lncRNAs can exert different 
functions. They can regulate expression of genes located in close proximity (cis-
acting) or target distant transcriptional activators or repressors (trans-acting).50 
LncRNAs can act as molecular decoys and ‘sponge’ protein factors or competing 
endogenous RNAs (ceRNAs) for miR target sites.51 Third, lncRNAs can act as 
molecular guides by directing ribonucleoprotein complexes to specific chromatin 
targets.52  
 
In addition to miRs, lncRNAs also have demonstrated to play crucial roles during 
cardiac embryogenesis (summarized in Chapter 2) and heart failure (Chapter 6) and 
in the development of heart failure, as their expression levels were found to be 
dysregulated in cardiac disease (summarized in Chapter 2). Expectedly, researchers 
are developing ways to correct the abnormal expression levels of these particular 
lncRNAs. Functional natural antisense transcripts (NATs) typically originate opposite 
the sense strand of many protein-coding genes, often overlapping in part with 
mRNA, promoter and regulatory regions.53 Similar to miR antisense 
oligonucleotides, single-stranded oligonucleotides can be synthesized to strand-
specifically block the interaction of the NAT with the corresponding sense strand 
gene mRNA, causing transcriptional de-repression of the gene. Brain-derived 
neurotrophic factor (BDNF) is normally repressed by a conserved noncoding 
antisense RNA transcript, BDNF-AS. Inhibition of this transcript was achieved by 
single-stranded, 16-nucleotide gapmers consisting of three LNA-modified DNA bases 
at each of the ends with ten unmodified DNA bases in the middle, allowing for 
RNaseH cleavage. This approach resulted in upregulated BDNF mRNA, altered 
chromatin marks at the BDNF locus, increased protein levels and induced neuronal 
outgrowth and differentiation both in vitro and in vivo.54 Similar to miR antisense 
oligonucleotides, it is important to introduce chemical modifications to promote 
metabolic stability and minimizing the length of the oligonucleotide to aid cellular 
uptake, while maintaining selectivity to minimize off-target activities.  
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Inhibition of lncRNA function by antisense oligonucleotides will face similar 
challenges as antisense miR oligonucleotides do (Chapter 3). Toxicity and off-target 
effects and delivery issues still have to be addressed. On the other hand, lncRNAs do 
open up some possibilities for strategies that are not applicable to protein targets. 
Targeting a specific lncRNA could upregulate an endogenous gene in a natural way. 
Inhibiting lncRNAs that regulate the expression of haploinsufficient genes could 
increase activity of the functional copy and result in normal functioning. Whereas 
miRs are translational repressors targeting mRNAs, lncRNAs primarily regulate 
chromatin in order to inhibit transcription. Furthermore, in contrast to miRs that 
can target hundreds of different mRNAs, cis-acting lncRNAs are gene-locus-specific. 
There are probably thousands of unexplored lncRNAs, whereas fewer miR species 
exist and those have been more comprehensively investigated. LncRNAs have been 
reported to show relatively low expression compared to mRNAs. If lncRNAs are 
indeed transcriptional repressors, this could indicate that a small number of lncRNA 
molecules is sufficient to demonstrate efficacy, creating a potential advantage of 
targeting lncRNAs at a lower dose than the standard oligonucleotides used for 
mRNA and miR knockdown.  
 
Classifying lncRNAs into diverse functional classes will capacitate the design of 
therapeutics that possess a certain mode of action, such as the transcriptional 
derepression shown by antisense lncRNA oligonucleotides. Further functional 
genomic studies are required to establish the roles of lncRNAs. Large-scale 
inhibition and overexpression approaches in proper cell models, with subsequent 
detailed in vitro and in vivo characterization of selected functional candidates will 
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Cardiovascular diseases (CVDs) are the number one cause of hospitalization and 
death worldwide. Different CVDs include aneurysms, angina, arrhythmias, 
stroke, coronary artery disease (or CHD), myocardial infarction, valve problems 
(stenosis, regurgitation), hypertension, pulmonary heart disease, 
cardiomyopathy, and congestive heart failure.  According to the most recent 
health statistics of the World Health Organization (WHO), an estimated number 
of 17.3 million people died from CVDs in 2008 of which 6.2 million were due to 
stroke and 7.3 million were due to coronary artery disease. More than 80% of 
the deaths occur in low- and middle-income countries, affection women and 
men in equal proportion.* In Europe, CVDs account for over 4 million deaths 
each year, with coronary heart disease (CHD) and stroke being the main forms. 
Almost half (47%) of all deaths are from CVD (52% of deaths in women and 42% 
of deaths in men). Just under half of all deaths from CVD in both men and 
women are from CHD, with stroke accounting for nearly a third of deaths in 
women and a quarter of deaths in men.**  
 
While current pharmacological treatment strategies (e.g. β-blockers and ACE-
inhibitors) have shown effectiveness in prolonging survival of heart failure 
patients, the prognosis of affected individuals remains poor and new 
therapeutic approaches for treatment of this devastating disease are still 
necessary. Besides the devastating effects on the quality of life of those patients 
(social burden), life-long treatment is expensive and increases the economic 
burden on society that comes with high healthcare costs.  
 
Many risk factors are associated with CVD. Obesity1, plasma triglyceride level2, 
physical inactivity3, elevated serum cholesterol level4, cigarette smoking5, 
hypertension6, diabetes and glucose intolerance7 are all primary risk factors for 
CVD. Metabolic syndrome is a cluster of metabolic conditions that can lead to 
CVD, including hypertension, abnormal cholesterol, insulin resistance, and 
obesity. Total blood volume and cardiac output correlate positively and 
proportionately with the degree of excess body weight, because of the high 
metabolic activity of excessive fat. The increased filling pressure and volume in 
obese patients often leads to development left ventricular eccentric 
hypertrophy and chamber dilation.8 Body mass index in obese patients was also 
reported to correlate with other structural abnormalities such as left ventricular 
mass and wall thickness, and concentric remodeling.9 Although some studies 
reported evidence of eccentric LV hypertrophy in obese patients8,10,11, other 
studies of obese subjects found a predominance of concentric hypertrophy12,13.  
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In this thesis we describe specific non-coding RNA species, long non-coding 
RNAs (lncRNAs) and microRNAs (miRs) that are involved in cardiac disease. The 
focus on RNA biology opens new avenues to improve our understanding of 
inter-cellular and inter-organic communication, increases our repertoire of 
available clinically useful biomarkers and innovative new medication for 
relevant human medical conditions.  
 
The scientific results published in this thesis are particularly interesting for 
fellow researchers and pharmaceutical companies, since there is still a dire need 
for pharmaceutical treatment approaches. Here we identified miRs that are 
specifically involved in eccentric hypertrophy. The majority of current research 
on miRs in HF focuses on concentric hypertrophy and heart failure and it is still 
not clear what triggers the heart to activate pathways leading to eccentric 
remodeling. Further investigation of our described candidates can lead to 
identification of specific target molecules causing eccentric remodeling, and 
targeting these molecules could provide better-tailored therapy for patients. In 
this case our miRs would be used as tools to identify the mRNA targets that 
exert the effects.  
 
Valorization of this kind of research can be the translation into patents, spin-off 
companies and licenses. When a therapeutic target is identified, the next step is 
to design a chemical or biological molecule that can target it. Efficacy, drug 
metabolism, pharmacokinetics and safety all have to be addressed in the pre-
clinical phase. Drug metabolism and pharmacokinetics will be addressed further 
during clinical trial phases. Plenty of tests have to be completed before a 
therapeutic molecule can enter the clinical trial phases. For example, metabolism 
and clearance are tested by assessing stability in hepatocytes, human 
cytochrome P (CYP) isoforms involved and reactive intermediate formation. CYPs 
are the major enzymes involved in drug metabolism, accounting for about 75% 
of the total metabolism.14 Regarding tissue distribution, exposure in efficacy in 
target tissue and major organs should be assessed, and plasma protein binding. 
To use our candidate miRs for therapeutic purposes, the hurdle that one miR can 
target dozens of mRNAs throughout the body has to be overcome. One way of 
circumventing targeting healthy organs is making the delivery of the miR 
modulator tissue-specific. Other important aspects to be addressed are human 
pharmacokinetics prediction and human dose prediction. Toxicology includes 
target assessment (physiological function, potential side effects, tissue 
distribution, cross-species comparison), genetic toxicity screening, and toleration 
studies.*** All these and other issues have to be addressed before a drug can 
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proceed into phase I trials. It is evident that it still will take some time before 
those miRs are used as therapeutical targets in the clinic. This thesis aimed to 
provide a solid starting point for what miRs to pursue in the quest for molecular 
therapeutics for eccentric cardiac remodeling. Furthermore, we discussed the 
therapeutic potential of antisense oligonucleotides against miRs (Chapter 3) and 
briefly touched the subject of using lncRNAs as potential therapeutic targets 





* World Health Organization, June 2014 
** European Cardiovascular Disease Statistics 2012, June 2014 
***FDA Guidelines Guidance for Industry: Preclinical Assessment of Investigational Cellular and Gene 
Therapy Products, January 2016 
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